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LIM-domain-binding protein 1 (Ldb1) and the LIM-Homeodomain factor (LIM-HD) Islet-1 (Isl-1) share a
robust functional relationship in directing differentiation of developmental progenitor populations.
However, their mechanistic role in terminally differentiated cells is uncharacterized. In the developing
endocrine pancreas, conditional ablation of either Isl-1 in the pancreatic epithelium or Ldb1 in the Pax6+
pancreatic endocrine progenitors suspended pancreatic endocrine differentiation. In light of their
functional requirement in the developing endocrine pancreas, both factors remain ubiquitously enriched in
the distinct, terminally differentiated endocrine cell-types that comprise the adult endocrine pancreas. To
determine the requirement for Ldb1 and Isl-1 in the mature pancreatic β-cell, I combined physiological
characterization of inducible, β-cell-specific loss-of-function mice with high-throughput cistromic and
transcriptomic analyses. Ldb1 and Isl-1 were required for maintaining the glucose homeostatic role of the
mature β-cell as well as the terminally differentiated status of the β-cell. Consistent with the established
mechanistic relationship between Ldb1 and Isl-1 in progenitor populations, Ldb1 and Isl-1 were coenriched throughout the β-cell genome. Comparison of our islet- and insulinoma-based cistromic data
sets with the glucagonoma Isl-1 cistrome revealed differential enrichment of Isl-1 between the
immortalized murine α- and β-cell lines; this differential enrichment may underlie the distinct terminal
identities of α- and β-cells. Contextualized through the broader role of Ldb1-mediated complexes in
directing cell fate decisions, my findings in the mature β-cell indicate that Ldb1-mediated complexes are
likely responsible for directing and maintaining the terminal differentiation status of all pancreatic
endocrine cell types.
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ABSTRACT
LDB1‐MEDIATED COMPLEXES: A TRANSCRIPTIONAL PARADIGM THAT
ESTABLISHES AND MAINTAINS PANCREATIC ENDOCRINE CELL INDENTITY
Benjamin N. Ediger
Doris A. Stoffers
LIM‐domain‐binding protein 1 (Ldb1) and the LIM‐Homeodomain factor (LIM‐HD) Islet‐1 (Isl‐1)
share a robust functional relationship in directing differentiation of developmental progenitor
populations. However, their mechanistic role in terminally differentiated cells is uncharacterized. In
the developing endocrine pancreas, conditional ablation of either Isl1 in the pancreatic epithelium or
Ldb1 in the Pax6+ pancreatic endocrine progenitors suspended pancreatic endocrine differentiation.
In light of their functional requirement in the developing endocrine pancreas, both factors remain
ubiquitously enriched in the distinct, terminally differentiated endocrine cell‐types that comprise the
adult endocrine pancreas. To determine the requirement for Ldb1 and Isl‐1 in the mature pancreatic
β‐cell, I combined physiological characterization of inducible, β‐cell‐specific loss‐of‐function mice
with high‐throughput cistromic and transcriptomic analyses. Ldb1 and Isl‐1 were required for
maintaining the glucose homeostatic role of the mature β‐cell as well as the terminally differentiated
status of the β‐cell. Consistent with the established mechanistic relationship between Ldb1 and Isl‐1
in progenitor populations, Ldb1 and Isl‐1 were co‐enriched throughout the β‐cell genome.
Comparison of our islet‐ and insulinoma‐based cistromic data sets with the glucagonoma Isl‐1
cistrome revealed differential enrichment of Isl‐1 between the immortalized murine α‐ and β‐cell
lines; this differential enrichment may underlie the distinct terminal identities of α‐ and β‐cells.
Contextualized through the broader role of Ldb1‐mediated complexes in directing cell fate decisions,
my findings in the mature β‐cell indicate that Ldb1‐mediated complexes are likely responsible for
directing and maintaining the terminal differentiation status of all pancreatic endocrine cell types.
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CHAPTER 1
Diabetes dilemmas and progenitor factor paradigms.
INTRODUCTION
We are currently in a period of profound medical advancement where arduous scientific
investigation is collectively informing the development of effective, novel therapeutics. While it is
important to appreciate the almost miraculous steps that have been made on multiple biomedical
frontiers, it is also fair to assert our ideal therapeutic goals have yet to be fully realized. Given the
current pipeline where laboratory research drives clinical progress, the distance between the status
quo and the ideal treatment delineates the gaps in our scientific understanding. Focusing on the
efforts combating the diabetes pandemic, our progress with generating functional, transplantable
pancreatic β‐cells in vitro consummately illustrates this point. The successful generation of insulin‐
producing cells esteems the progress made by scientific investigators utilizing reductionist,
hypothesis‐driven approaches to unravel β‐cell biology. However, deviations from the ideal
therapeutic result such as the poor differentiation efficiency, minimal glucose‐stimulated insulin
response, abundance of polyhormonal cells, etc. simultaneously remind us there are mysteries still to
be solved.
One such unknown is the biology directing pancreatic endocrine cell fate determination and
maintenance following pancreatic endocrine progenitor specification. The transcription factors
NeuroD1, Islet‐1, Rfx6, and Insm1 are expressed shortly after Neurog3‐mediated endocrine‐
progenitor specification and remain ubiquitously expressed in the multiple functionally distinct cell‐
types of the mature endocrine pancreas. Individual ablation of these factors halts pancreatic
endocrine maturation, and recent studies have demonstrated that NeuroD1 and Rfx6 are required for
maintaining the functional capacity of terminally differentiated β‐cells. Therefore, does this group of
pancreatic pan‐endocrine transcription factors function to establish the general endocrine identity of
all the cell‐types that populate the mature endocrine pancreas? Or, do these transcription factors
have cell‐type‐specific roles that act to differentiate and maintain the distinct pancreatic endocrine

1

cell‐fates? With respect to these two questions, a intriguing target of investigation is Islet‐1 (Isl‐1). In
contrast to NeuroD1, Rfx6, and Insm1, the functional role for Isl‐1 is well characterized in directing
the terminal differentiation of progenitor populations in multiple biological. Isl‐1 directs cell fate via
a functional relationship with the co‐adaptor protein Ldb1. Intriguingly, Ldb1, while not a DNA‐
binding transcription factor, shares many of the same qualities of a pancreatic pan‐endocrine
transcription factor. Ldb1 is ubiquitously expressed in the pancreatic endocrine compartment,
required for pancreatic endocrine progenitor differentiation, and expressed in all terminally
differentiated pancreatic endocrine cell types.
In Chapter I, I review the function of the pancreas, how the gross etiology of diabetes
perturbs this function, and the current transplantation options for diabetics (Part I). I also review
how our increasing understanding of pancreatic developmental biology has informed efforts to
generate insulin‐producing cells from pluripotent stem cell (Part II). I then introduce the key
functional paradigms that have been established for Ldb1 (Part III) and Isl‐1 (Part IV). Finally, the
collective functional understanding of both Isl‐1 and Ldb1 in the developing and mature endocrine
pancreas is presented (Part V).
PART I. THE PANCREAS AND THE GROSS BIOLOGY OF DIABETES
A. Basic anatomy and function of the murine pancreas.
The mammalian pancreas is a critical component of organism energy homeostasis. It is a
compound organ consisting of separate but juxtaposed exocrine and endocrine glands. The mature
exocrine gland is comprised of acinar cells that synthesize and secrete over 20 different zymogenic
enzymes (DNases, proteinases, lipases, etc.) that are critical for gastrointestinal nutrient digestion
(Stanger and Hebrok 2013). Anatomically, the acinar cells are clustered at the terminal ends of a
branching epithelial system that drains the secreted zymogens to the duodenum via the bile duct
(Slack 1995). The epithelial ductal cells that comprise the drainage system also secrete bicarbonates
and mucins that aid in gastrointestinal digestion (Slack 1995).
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The pancreatic endocrine gland accounts for approximately 2% of the total pancreatic tissue
and is a collection of multicellular aggregates termed islets of Langerhans or islets (Collombat, et al.
2010). The islets are dispersed in a seemingly random pattern throughout the entirety of the
pancreas and are composed of a five terminally‐differentiated cells types that are identified by the
hormone they synthesize and secrete: α‐cells (glucagon), β‐cells (insulin), δ‐cells (somatostatin), PP‐
cells (pancreatic polypeptide) and ε‐cells (ghrelin). The islets are highly vascularized, affording the
endocrine tissue precision detection of nascent metabolites and signaling molecules within the
plasma and providing a direct means of hormone delivery to peripheral tissue (Lammert, et al. 2003;
Slack 1995). In addition to being highly vascularized, islets are significantly innervated – an
anatomical feature that establishes islets as crucial nodes linking the central nervous system to
peripheral tissue energy homeostasis (Rodriguez‐Diaz and Caicedo 2014).
With respect to organism energy homeostasis, the insulin and glucagon hormones function
in opposition to regulate glucose metabolism (Lund, et al. 2014; Rutter, et al. 2015). In the fed state
(hyperglycemia), high levels of glucose stimulate β‐cells to secrete insulin, a hormone that
predominantly signals glucose uptake, storage, and metabolism in the liver and peripheral tissue
(Rutter, et al. 2015). In the fasted state (hypoglycemia), α‐cells secrete glucagon to promote
glycogenolysis, gluconeogenesis, and lipolysis (Lund, et al. 2014). Both the δ‐ and PP‐cells function to
regulate other hormones and exocrine enzyme secretion (Adrian, et al. 1978; Hermansen and
Schwartz 1979; Roncoroni, et al. 1983). The δ‐cells may function in a paracrine manner to calibrate
the physiological opposition between β‐cells and α‐cells (Hauge‐Evans, et al. 2009; Zhang, et al.
2014). The physiological role of the ghrelin‐producing ε‐cells in the mature organism is unclear
(Heller, et al. 2005; Vignjevic, et al. 2012; Wierup, et al. 2002); in fact, the number of ε‐cells decreases
precipitously in the human postnatal endocrine pancreas (Wierup, et al. 2002). The average murine
islet is 75% β‐cells and 20% α‐cells (Brissova, et al. 2005); the other mature endocrine cells types (δ,
ε, and PP) approximately account for the remaining 5% of cells (Brissova, et al. 2005). Murine islets
display a stereotypic morphology where the core is primarily populated by β‐cells and the remaining
endocrine cell types exist on the periphery of the islet (Pan and Wright 2011).
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B. The gross etiology of the predominant presentations of diabetes.
The endocrine pancreas is most commonly associated with diabetes, a family of metabolic
disorders primarily characterized by different forms of β‐cell dysfunction. Broadly, diabetes is
clinically defined in three categories: type 1, monogenic, and type 2. Type 1 diabetics, during
childhood, experience near complete autoimmune depletion of their β‐cell mass (van Belle, et al.
2011). Eventually, patients require exogenous insulin administration due to the significant extent of
autoimmune β‐cell depletion. While inflammation from viral infection and genetic predispositions
are implicated in the etiology of type 1 diabetes, a universal trigger that initiates the autoimmune
response against the β‐cells has not been identified (van Belle, et al. 2011). The monogenic forms of
diabetes result in genetic β‐cell dysfunction (Mastracci and Sussel 2013; Pajvani and Accili 2015b).
Monogenic diabetes results from autosomal dominant mutations where disease presentation occurs
prior to 25 years‐of‐age (Fajans, et al. 2001). The monogenic disorders are categorized with respect
to the mutated gene, thus, reflecting the collection of autosomal dominant mutation associated with
any individual gene. For instance, there are mutations in factors important for mature β‐cell function,
e.g. GCK (MODY2) (Froguel, et al. 1992)and INS (MODY10) (Edghill, et al. 2008; Molven, et al. 2008),
or transcription factors required for mature β‐cell function, e.g. PDX1 (MODY4) (Stoffers, et al. 1997a;
Stoffers, et al. 1997b) and NEUROD1 (MODY6) (Malecki, et al. 1999).
Type 2 diabetes is a polygenic disease characterized by progressive exhaustion of the β‐cell
population due to chronic, untenable functional demand (Mastracci and Sussel 2013; Nolan and
Prentki 2008; Pajvani and Accili 2015b). Unlike type 1 and monogenic diabetes, environmental
factors namely a patient’s lifestyle play a central role in the etiology of type 2 diabetes (Donath and
Shoelson 2011). Chronic caloric overconsumption places a high functional demand on the β‐cell
(Nolan and Prentki 2008). Remarkably, normal physiologic processes can compensate, to a point
(Pajvani and Accili 2015b; Weir and Bonner‐Weir 2004). In response to chronic hyperglycemia, β‐
cells become hyper‐functional, hypertrophic, and hyperplastic (Weir and Bonner‐Weir 2004).
However, if functional demand exceeds the capacity of this compensatory response, the β‐cells
become dysfunctional, most likely as a result of oxidative and stress and high protein synthesis
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triggering the unfolded protein and endoplasmic reticulum stress responses (Nolan and Prentki
2008; Prentki and Nolan 2006). At this point, β‐cells are believed to become apoptotic and/or, as
recent mouse study suggests, the mature β‐cell population functionally senesces through a
dedifferentiation process (Talchai, et al. 2012).
Individuals may be genetically predisposed to develop type 2 diabetes, but the penetrance of
this genetic predisposition is contextualized through the lens of the patient’s lifestyle (Kahn, et al.
2009). Moreover, the pathophysiological etiology of type 2 diabetes involves multiple organs and
systems (Nolan, et al. 2015). On one hand, that increases the chances for genetic predispositions that
contribute to the disease, but, on the other, it provides researchers and clinicians with more potential
therapeutic targets, e.g. Metformin reducing hepatic glucose production (Dunn and Peters 1995),
Rosiglitizone sensitizing peripheral tissue to insulin (Richter, et al. 2007), and Canagliflozin inhibiting
the subtype 2 sodium‐glucose transport protein in the kidney (Katsi, et al. 2013). Nonetheless,
current drug interventions can have unwanted side effects and high financial costs (ADA 2012;
Nissen and Wolski 2007).
If frank diabetes is left unmanaged, chronic hyperglycemia results in a host of undesirable
complications ranging from nephropathy, blindness, ulcers, amputations, and/or cardiovascular
diseases (O'Connell, et al. 2013). For patients with frank diabetes, disease management is a constant
and painful process of monitoring plasma glucose levels and insulin injections. Fortunately,
improvements in insulin pump technology have made significant strides towards a precise,
automated disease management device (Schaepelynck, et al. 2011). Nonetheless, the average life
expectancy of a type 1 diabetic is reduced compared to that of an average healthy individual
(Cameron and Wherrett 2015). For pre‐diabetic patients and those not dependent on exogenous
insulin, a variety of therapeutics aimed at improving the function of β‐cells (Sulfonylurea and
Exenatide) and peripheral tissue (listed above) are available to aid in preventing and reversing
progression to frank diabetes (Ashcroft 1996; Nielsen, et al. 2004). Nonetheless, clinical
management, as it stands right now, is unwieldy for the patient and costly to the taxpayer (ADA
2012). Alarming statistics from the CDC track a multi‐decade increase in the proportions of United
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States citizens that are clinically obese and those that are type 2 diabetic (Beckles and Chou 2013).
This trend is not unique to the United States of America; the global incidence of type 2 diabetes is on
the rise (Guariguata, et al. 2014; Scully 2012).
C. Current transplant therapies for diabetics.
In the case of type 1 diabetes, whole pancreas transplants can successfully provide patients
with normoglycemia (Frank, et al. 2004). The current 1‐year and 5‐year survival percentages for
whole pancreas transplants are 82% and 58%, respectively (Gruessner and Gruessner 2013). Despite
the effectiveness of a successful transplant, it is a complicated surgical procedure that exposes
patients to significant risks and requires lifetime immunosuppression therapy. With that in mind, the
procedure is reserved for patients with severe brittle diabetes or those already undergoing a kidney
transplant. In contrast, islet transplants provide an option that does not require major surgery,
however, patients must still undergo immunosuppression therapy. Islets are normally transplanted
into the hepatic portal vein where they subsequently migrate to and engraft in the liver (Cogger and
Nostro 2014). The first successful transplant that resulted in brief insulin independence was
reported in 1990 (Scharp, et al. 1990). In 2000, the Edmonton islet transplant protocol by reducing
alloimmune reactivity and improving islet survival extended patient insulin independence to
approximately a year (Shapiro, et al. 2000). While insulin independence is transient following islet
transplants, the residual islet function in transplant patients improved diabetic symptoms and
protected them from severe hypoglycemic episodes (Shapiro, et al. 2000). In the intervening 15
years, improved immunomodularity techniques have extended the insulin independence period to 5
years (Bellin, et al. 2012). Nonetheless, patients still require immunosuppression therapy. To protect
transplanted islets from immune system detection, efforts to engineer microencapsulation devices
that function as artificial immune‐privileged sites are underway (Scharp and Marchetti 2014).
Despite the noticeable progress, current therapies rely on cadaveric donor material, a very rare
commodity. With the significant scarcity of donor islets, even alternative sources such as porcine
islets have been pursued in combination with encapsulation techniques (Neufeld, et al. 2013;
O'Connell, et al. 2013). To reduce cross‐species immune responses, progress has been made towards
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genetically engineering humanized pigs where the galactosyltransferase xenoantigen gene (GalT) has
been ablated or the human complement regulatory proteins (CD46, CD55, and CD59) have been
added (Mendicino, et al. 2011; Thompson, et al. 2011).
PART II. DEVELOPMENTAL BIOLOGY INFORMING IN VITRO β‐CELL GENERATION
A. Absence of an adult pancreatic endocrine stem‐cell population.
To improve current transplant therapies, significant investment has been made in
understanding the biology of diabetes and the endocrine pancreas. Initially, there was hope that an
endocrine pancreas adult stem‐cell population could be used to generate β‐cells in vitro. Studies
demonstrated that normal β‐cells were long‐lived and their rare turnover was diminished with age
(Cnop, et al. 2009; Perl, et al. 2010). One interpretation of these characteristics was that a rare stem
cell population in the endocrine pancreas was responsible for replacing a robust, slowly depleted β‐
cell population. However, lineage‐tracing studies have since demonstrated that, under normal
physiological conditions, postnatal β‐cells are derived from pre‐existing β‐cells (Dor, et al. 2004).
Given the body of evidence against a β‐cell stem cell population, significant effort has now been
directed at in vitro genesis of functional β‐cells. These efforts have been accelerated thanks to the
identification of human embryonic stem cells (hESCs) and, more recently, researchers successfully
using a set of four transcription factors to essentially reset human fibroblast cells into induced
pluripotent stem cells (iPSCs) (Takahashi, et al. 2007; Thomson, et al. 1998). Subsequently, the
collective understanding of pancreas organogenesis has crucially informed the development of
directed differentiation protocols designed to generate in vitro β‐cells. These directed differentiation
protocols attempt to recapitulate, in a step‐wise fashion, the key developmental signals that drive the
distinct stages of endocrine pancreas organogenesis (Pagliuca and Melton 2013). Most protocols
involve the following four stages: 1) definitive endoderm, 2) pancreatic progenitors, 3) endocrine
progenitors, and 4) hormone‐producing cells.
B. Biology informing PSC‐derived definitive endoderm and pancreatic progenitors.
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In directed‐differentiation protocols, the definitive endoderm (DE) stage approximately
equates to the cells that compose the endoderm germ layer at the gut tube stage of embryogenesis. In
the developing embryo, there are two distinct areas of the foregut endoderm that are the ontogenic
origin of the cells comprising the mature pancreas (Slack 1995). These two areas are positioned
contralaterally on gut tube along the dorsal‐ventral axis. Like the rest the anterior‐posterior (AP)
patterning of gut tube, these pre‐pancreatic areas are specified in response to posteriorizing
morphogen gradients of Fibroblast Growth Factor 4 (FGF4), Wnt, and retinoic acid (RA) that are
generated by the overlying mesodermal tissues (Dessimoz, et al. 2006; McLin, et al. 2007; Wells and
Melton 2000). The collective effect of these extrinsic signals is subsequently reinforced cell
autonomously via region‐specific transcription factors. The expression of the transcription factors
Pdx1 and Ptf1a specifies the two areas of foregut endoderm that form the dorsal and ventral
pancreatic anlages (Kawaguchi, et al. 2002; Krapp, et al. 1998; Offield, et al. 1996). Following the
foregut specification, at embryonic day 9.5 (E9.5), the dorsal foregut endoderm thickens and
envaginates to initiate the development of the dorsal pancreatic anlagen (Wessells and Cohen 1967).
Shortly thereafter at E10.5, thickening and envagination of the ventral foregut endoderm indicates
budding of the anlagen that forms ventral pancreatic and common bile duct (Offield, et al. 1996;
Spooner, et al. 1970). As the gut tube begins to coil at E11.5, the dorsal and ventral pancreatic anlages
are brought into proximity and fuse into one organ by E12.5 (Spooner, et al. 1970).
Notably, the dorsal and ventral pancreatic anlages are formed in response to distinct sets of
signaling cues due to their spatial arrangement (Pan and Wright 2011). The dorsal foregut endoderm
is juxtaposed against the notochord until E8.5, whereas, the ventral foregut endoderm contacts with
the cardiac mesoderm and septum transversum mesenchyme (Slack 1995). Broadly, the pre‐
pancreatic ventral foregut is established by instructive cues (BMP, RA, Activin) from the lateral plate
mesoderm (Kumar, et al. 2003). In contrast, activin‐βB and FGF2 signaling from the notochord is
permissive for the specification of the dorsal prepancreatic foregut (Hebrok, et al. 1998), most likely
functioning via repression of Sonic Hedgehog (Shh). Illustrating that distinct mechanisms specify the
respective pancreatic buds, germ‐line knockouts of the RA synthesizing enzyme (RALDH2) and the
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transcription factor Islet1 result in dorsal pancreatic bud agenesis with little effect on ventral bud
(Ahlgren, et al. 1997; Martin, et al. 2005; Molotkov, et al. 2005).
Similar to in vivo mouse development, directing hESCs and iPSCs to the definitive endoderm
status relies heavily on manipulating WNT and NODAL signaling (D'Amour, et al. 2005). As described
above, both of these signaling pathways are important for early pancreas morphogenesis. Wnt
signaling is essential for the anterior‐posterior patterning of the foregut endoderm and Activin β2, a
Nodal activator, is important for repressing Shh expression in the dorsal foregut endoderm. Echoing
ventral pancreas bud development, hESCs and iPSCs that have reached the definitive endoderm are
capable of adopting either a hepatic or pancreatic fate (Abdelalim and Emara 2015; Jung, et al. 1999).
To prevent hepatic fate and ensure a higher efficiency of generating pancreatic progenitors, FGF
receptor and BMP antagonists are commonly used at this stage (Mfopou, et al. 2010). Like the cells
composing dorsal and ventral pancreatic buds, PSC‐derived pancreatic progenitors are identified by
the expression of PDX1. PDX1 expression is induced by the protein kinase C activator Indolactam V
and enhanced by RA and the BMP inhibitor dorsomorphin (Chen, et al. 2009; Kunisada, et al. 2011).
+

C. Biology informing NEUROG3 endocrine progenitors.
During pancreas organogenesis, two waves of endocrine cells are produced. Between E9.5
and E12.5, the first‐wave of endocrine cells, a small population of glucagon+ cells that may also briefly
express insulin, appear in the dorsal and ventral buds (Herrera 2000; Pictet, et al. 1972). Little is
known about the purpose of these endocrine cells, but lineage‐tracing studies indicate some portion
of them persist in the mature endocrine pancreas (Gu, et al. 2002). However, the majority of
endocrine progenitors are specified after E13.5 during a period of increased cellular differentiation
in developing pancreas. This second‐wave of endocrine progenitors are specified, delaminate from
pancreatic epithelium, and subsequently coalesce into the islets that are interspersed throughout the
mature organ (Pan and Wright 2011). It is unequivocal that Neurogenin3 (Neurog3) expression is
necessary and sufficient for specifying endocrine fate in the developing pancreatic epithelium
(Gradwohl, et al. 2000; Schwitzgebel, et al. 2000). Moreover, all pancreatic endocrine cells (both the
first and second waves) can be traced back to a Neurog3+ precursor (Gu, et al. 2002). Not
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surprisingly, the ‘endocrine progenitor’ cell in PSC directed‐differentiation protocols is identified by
expression of NEUROG3 (Abdelalim and Emara 2015).
In vivo, the second wave of endocrine progenitors arises from a ductal/endocrine bipotent
progenitor population localized in the trunks of the pancreatic epithelium (Solar, et al. 2009). In a
seemingly stochastic process, Neurog3 expression is activated at a relatively low level (Neurog3LO) in
a subset of the bipotent progenitors by a network of transcription factors: Sox9, Hnf1β, Hnf3β, Hnf6,
and Pdx1 (Lee, et al. 2001; Lynn, et al. 2007; Oliver‐Krasinski and Stoffers 2008; Wang, et al. 2009b).
However, the Neurog3LO cells are only endocrine biased and require a subsequent up‐regulation of
Neurog3 expression to become committed, Neurog3HI pancreatic endocrine progenitors (Wang, et al.
2009b). It is unclear whether the transition from Neurog3Lo to Neurog3HI occurs spontaneously or
following an asymmetric cell division. Either way, Neurog3HI cells immediately activate Notch
signaling to presumably suppress Neurog3 expression in neighbor cells (Jensen, et al. 2000).
Likewise, directed differentiation protocols utilize NOTCH inhibitors to increase the yield of
NEUROG3+ endocrine progenitors from pancreatic progenitor stage (Abdelalim and Emara 2015).
While all the terminally differentiated pancreatic endocrine cell types derive from Neurog3HI
endocrine progenitors, an individual, endocrine‐committed, Neurog3HI progenitor appears to be
unipotent and postmitotic (Desgraz and Herrera 2009). Unfortunately, it is still unclear when the
mature endocrine cell identities are specified in the Neurog3HI endocrine progenitors. One study
suggests a temporal component affects when the different endocrine cell‐types are specified. By
driving Neurog3 expression via the Pdx1 promoter in Neurog3 knockout mice, researchers noted that
the endocrine cells types were generated at different times relative to each other (Johansson, et al.
2007). The α‐cells appeared as early as E8.5; β‐ and PP‐cells at E11.5 and E12.5, respectively; and, at
E14.5, δ‐cells appeared and β‐cells were being generated in higher proportions. While that model
system was contrived, the results refute the null hypothesis that all pancreatic endocrine cell types
arise stochastically, albeit in varying proportions.
D. Cell autonomous transcriptional programs direct the differentiation of hormone‐producing cells.
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While it is unclear how mature endocrine cell‐fate is determined following endocrine
specification, careful genetic manipulation using mouse models have identified key transcription
factors that are required for enforcing the differentiation processes downstream of the Neurog3HI
endocrine progenitor status. Since many of these factors are expressed in a cell‐type specific manner,
they function as proxy identifiers of the mono‐hormonal cell types in the mature endocrine pancreas
and the final stages of PSC direct‐differentiation protocols. These transcription factors can be broadly
grouped into three categories: 1) factors that are universally required for continued differentiation;
2) factors required specifically for the differentiation of an individual lineage; and 3) factors, usually
specific to a lineage, that reinforce cell‐type function but have minimal developmental requirements
(Pan and Wright 2011). Examples of the first class of factors are NeuroD1, Insulinoma‐associated
antigen 1 (Insm1), Regulatory X‐box binding 6 (Rfx6), and Islet‐1 (Isl‐1). These factors appear to be
direct targets of Neurog3 (Gradwohl, et al. 2000; Huang, et al. 2000; Mellitzer, et al. 2006; Soyer, et al.
2009), and they remain expressed in the terminally differentiated cells that populate the adult
endocrine pancreas. Individual loss‐of‐function studies of these factors resulted in developmental
arrest of the endocrine progenitors (Du, et al. 2009; Gierl, et al. 2006; Mellitzer, et al. 2006; Smith, et
al. 2010; Soyer, et al. 2009).
Pax4 and Arx are ideal examples of the second class of transcription factors. Pancreata from
Pax4 null mice lack β‐cells and δ‐cells while α‐cells and ε‐cell numbers are significantly increased
(Prado, et al. 2004). Mice with Arx mutations displayed the reciprocal phenotype with an increase in
the β‐cells and δ‐cells seemingly at the expense of α‐cells (Collombat, et al. 2003). In fact,
misexpressing Pax4 in terminally differentiated α‐cells induces an α‐cell to β‐cell conversion
(Collombat, et al. 2009); again, the reciprocal result is observed when Arx is misexpressed in
terminally differentiated β‐cells (Collombat, et al. 2007). These factors are mutually antagonistic, but
are clearly required for the respective terminal differentiation of the α‐ and β‐cell lineages. Nkx2.2, a
possible partner of Pax4 (Prado, et al. 2004), and Pdx1 can also be grouped in this second class.
However, conditional ablation of Pdx1 in specified β‐cells appears is required for survival, and the
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concomitant expansion the α‐ and δ‐cell populations is due to a non‐cell autonomous compensatory
proliferation response (Gannon, et al. 2008).
The third class of transcription factors is less defined. The ideal examples are the bZIP
MafA/B factors in the β‐cell. In mature β‐cells MafA is required for direct regulation of a significant
number of genes vital for mature β‐cell physiological function and ontogenetic identity such as
insulin, Slc2a2, and Pdx1 (Aramata, et al. 2005; Zhao, et al. 2005). Notably, during late β‐cell
differentiation, the cells transition from a MafB+ state to a MafA+ state through an intermediate
MafB+, MafA+ state (Artner, et al. 2010; Nishimura, et al. 2006). While MafA is required for mature β‐
cell function, it has no role in pancreatic endocrine development (Zhang, et al. 2005). Alternatively,
MafB is required differentiation and maturation of both α‐cells and β‐cells (Artner, et al. 2007). Foxa2
may be another factor that falls under this category. Foxa2 is required for the differentiation of α‐
cells but only the final maturation and function of β‐cells (Gao, et al. 2010; Gao, et al. 2007; Lee, et al.
2005).
As could be expected, the above classification system does not perfectly fit every factor, e.g.
Pdx1 and Nkx6.1/2. For instance, Nkx6.1 and Nkx6.2 double null mice have reduced numbers of
Neurog3+ progenitors, however, the loss of endocrine progenitors only results in reduced α‐cells and
β‐cell populations (Henseleit, et al. 2005). Moreover, recent studies employing inducible
recombination technology demonstrated that the pan‐endocrine factors NueroD1 and Rfx6 each are
required for regulating the functional capacity of mature β‐cells (Gu, et al. 2010; Piccand, et al. 2014).
As a whole, these transcription factor studies provide a rough mechanism for the differentiation
events that occur post Neurog3‐mediated endocrine specification. Additionally, they also highlight
that activation of hormone expression is not equivalent with full functionality and that even the
hormone‐producing endocrine cells exhibit plasticity in response to targeted genetic manipulation.
E. Complications with generating functional, hormone‐producing β‐cells.
The first hESC‐derived, insulin+ cells generated by a directed differentiation protocol were
reported in 2006 (D'Amour, et al. 2006). In this success and subsequent attempts, the insulin+ cells
generated in vitro from either hESCs or hiPSCs expressed a panel of transcriptional factors (PDX1,
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MAFA, NKX6.1, NEUROD, ISL‐1) and functional proteins (INS and GLUT2) synonymous with β‐cell
identity. But, the hESC‐derived, insulin+ cells did not respond to glucose, an observation similar to
what is seen in immature human β‐cells (Basford, et al. 2011). The cells were also polyhormonal, co‐
expressing glucagon and/or somatostatin (Basford, et al. 2011; Nostro, et al. 2011), an observation
drawing parallels to the population of polyhormonal endocrine cells identified in the human fetus
during the first trimester (Jeon, et al. 2009; Riedel, et al. 2011). A study utilized an Insulin‐driven GFP
to enrich hESC‐derived, insulin+ cells with FACS to then transplant the cells into NOD‐SCID mice
(Basford, et al. 2011; Micallef, et al. 2011). Following transplantation, the sorted cells became insulin‐,
glucagon+ and were unable to rescue the diabetic mice. Consistent with the other observations
indicating these hormone‐producing cells are immature, high‐throughput expression analysis of
sorted, hESC‐derived, insulin+ cells yielded a transcriptome closely matching immature human β‐
cells (Hrvatin, et al. 2014). Intriguingly, there has been more success with transplanting the hESC‐
derived cells at the pancreatic progenitor stage. When highly enriched populations of hESC‐derived
pancreatic progenitors are transplanted into immune‐compromised mice, they were capable of
generating islet‐like structures containing monohormonal cells (Kroon, et al. 2008).
Immunohistochemical analysis identified all pancreatic cells types (acinar, ductal, endocrine)
populating these grafts, an observation that is consistent with the expected pluripotency of hESC‐
derived pancreatic progenitors. Most importantly, the hESC‐derived pancreatic progenitor
transplants were functional and capable of ameliorating hyperglycemia in STZ‐treated mice (Rezania,
et al. 2012).
Considering the difference in results between transplanting hESC‐derived pancreatic
progenitors and the insulin+ cells, there are elements in the current directed‐differentiation protocols
that are not faithfully recapitulating in vivo development. Nonetheless, the hESC‐derived pancreatic
progenitors studies provided clear evidence that cells at the pancreatic progenitor stage are capable
of yielding functional insulin‐producing cells. Through large screening efforts, two groups have
improved there differentiation protocols and can now generate insulin+ cells from hESCs and hiPSCs,
respectively, that display an in vitro insulin response to static glucose‐levels and ameliorates
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hyperglycemic mice approximately 12x to 4x faster than transplanting pancreatic progenitors
(Pagliuca, et al. 2014; Rezania, et al. 2014). Given the amazing strides taken towards developing
functional β‐cells in vitro, these recent successes are encouraging. Nonetheless, clear concerns
remain to be addressed. With hESCs and hiPSC therapies, the threat of teratomas may never be
eliminated, making encapsulation a de facto element of future therapeutic efforts. Moreover the
efficiency of these recently published differentiation protocols are low must be improved to provide
a patient insulin independence following transplantation. It is estimated a successful transplant
would necessitate 300,000 islet equivalents (IEQs) for human insulin independence; with the 20‐
50% differentiation efficiencies of the latest methods, 300,000 IEQs would translate into
300,000,000 cells per patient (Cogger and Nostro 2014). To improve the differentiation efficiencies
of these protocols, fully elucidating the principal remaining mysteries of pancreas organogenesis will
be essential.
F. Logical implications concerning the role of pancreatic pan‐endocrine transcription factors.
One area of pancreas organogenesis, when starting my dissertation, that had not been
significantly addressed was the role pan‐endocrine transcription factors played in the developing
and mature endocrine pancreas. As already introduced, there are number of transcription factors
(NeuroD1, Insm1, Rfx6, and Isl‐1) that are activated in all of the endocrine progenitors presumably
by Neurog3 (Gradwohl, et al. 2000; Huang, et al. 2000; Mellitzer, et al. 2006; Soyer, et al. 2009).
Moreover, each factor is required for the terminal differentiation of the majority, if not all, of the
pancreatic endocrine cell‐types (Du, et al. 2009; Gierl, et al. 2006; Mellitzer, et al. 2006; Smith, et al.
2010; Soyer, et al. 2009). In addition to being required for the terminal differentiation of the
endocrine pancreas, these factors remain expressed in all cell types that comprise the mature
endocrine pancreas. Considering the résumé of a pancreatic pan‐endocrine factor, any given pan‐
endocrine factor must either have the same function in all the distinct terminally differentiated cell‐
types within the endocrine pancreas, or some mechanism must exist to distinguish its cell‐type‐
specific function. Among these four factors, Isl‐1 is unique in regards to this hypothesis. Unlike the
other factors, it has a well‐characterized role in directing and maintaining cell‐fate decisions in
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progenitor populations throughout the developing embryo and it is a well‐established functional
cofactor of Ldb1 (Cho, et al. 2014; Hunter and Rhodes 2005; Jurata, et al. 1998). Ldb1, like Isl‐1, is
enriched in a developing and mature pancreas in a pan‐endocrine fashion (Hunter, et al. 2013).
Moreover, similar to Isl‐1 and the other three pan‐endocrine factors, ablating Ldb1 in the endocrine
progenitors halts pancreatic endocrine differentiation(Hunter, et al. 2013).
PART III. LIM‐DOMAIN‐BINDING PROTEIN 1: A FACILITATOR OF PROGENITOR DIFFERENTIATION
A. LIM‐domain‐binding proteins and proteins containing tandem LIM‐domains.
LIM‐domain‐binding (Ldb) proteins also referred to as Nuclear LIM Interactors (NLI) or Cofactor of
LIM (CLIM) proteins have no inherent DNA‐binding or enzymatic activity (Figure 1A) (Curtiss and
Heilig 1998; Jurata, et al. 1998; Matthews and Visvader 2003). Ldb factors were first identified
through an expression overlay screen using the LIM Only 2 (LMO2) protein as a probe (Jurata, et al.
1996). This and subsequent studies demonstrated that Ldb factors bind tandem LIM‐domains with
high affinity (Agulnick, et al. 1996; Bach, et al. 1997; Jurata, et al. 1996). LIM is an acronym of the first
three proteins identified containing the eponymous domain: the Caenorhabditis elegans LIM‐
Homeodomain (LIM‐HD) protein lin‐11 that regulates the asymmetric cell division of secondary
vulval blast cells (Freyd, et al. 1990); the vertebrate LIM‐HD protein Isl‐1 that bound to the rat ins1
enhancer probe (Karlsson, et al. 1990); and another C. elegans LIM‐HD factor, mec‐3, that is essential
for the differentiation of touch receptor neurons (Way and Chalfie 1988). A LIM‐domain is a 55
amino acid sequence that forms two contiguous Zn2+‐finger structural motifs (Perez‐Alvarado, et al.
1994). More detailed structural analysis of a LIM‐domain utilizing nuclear magnetic residence
revealed a series of anti‐parallel f sheets with a hydrophobic core that coordinated two Zn2+
molecules tetrahedrally (Perez‐Alvarado, et al. 1994). Even though LIM‐domains are similar in
structure to GATA‐1‐type zinc fingers, there is no evidence that LIM‐domains bind DNA (Curtiss and
Heilig 1998; Jurata, et al. 1998). Instead, LIM‐domains mediate protein‐protein interactions.

15

:]"

@9':;+;).-'!"#$&17*.+$A.+3.+6'>*-?1)''
!"

T'6D";JJ-SA$C-*"
Q-.$A*"

\<
F'6AS'J"

/L3"L*('%$SC-*"
Q-.$A*"

!"#$%&

:"

/012"E:

A9':;+;).-'!"#$%17;1317*.+'>*-?1)''
!"
/L32"

/L35"

/L3"L*('%$SC-*"
Q-.$A*"

X-.'-0-.$A*"

89':;+;).-'!"#$<+2='>*-?1)''
!"

:"

/0
L*('

4*6W"A*"LJ6'(<2"AJ-D-%.J+-%(F-6-&J"

:"
/L32"

/L35"

Figure 1. The key functional domains of the LIMDomainBinding, LIMHomeodomain, LIM
Only factors. A. Schematic of a generic LIM‐domain‐binding (Ldb) factor depicting the relative
position of the Self Association Domain (green), the conserved α‐helices (orange) required for
nuclear migration and recruiting P‐TEFb and Fog1, and theQAJ($6"!"#<'6'.'*("
LIM Interaction Domain (purple). B.
Schematic of a generic LIM‐Homeodomain factor depicting the relative position of the tandem LIM‐
Domains (red) and Homeodomain (black). The LIM Interacting Domain exclusively contained within
Islet‐1 isoforms and orthologs is depicted in light purple. C. Schematic of a generic LIM‐Only factor
depicting the relative position of the !
tandem LIM‐Domains (red). A‐C. “N” indicates the amino‐
"
/012"
terminus and “C” indicates
the carboxy‐terminus.
B‐C. The individual LIM domains are enumerated in
#$
the standard manner with respect to their proximity to the amino terminus. The individual
schematics, individual functional domains, and the exact positions of the functional domains within
/LQ" to scale.
the schematics are not depicted

;]"

K]"

++"

789+75$"

/345"
"
#$62

!"
:"

#$%&'(")'*'"

:;!!#)<!9<=<>);#;?"
7<1-@<);#;"1AB$%C('".-CD"

,%-.-('%"

7S(-0'%."
16
T-.$CS"
3-(-%"
!'I%-*J"
:%$*A$6"

<U/L3":-0'V"0%AP'J"
JI1(WB'"D$('"
<TW*'%&W"OA(F"
B%-*'I%$6"1X/X"D$S(-%J"

The superclass of LIM‐domain‐containing proteins is currently divided into 14 subclasses
based on a variety of parameters including cellular localization (nuclear or cytoplasmic), catalytic
activity, actin association, number of LIM domains, and the presence of additional functional domains
(Kadrmas and Beckerle 2004). Despite the variety of LIM‐containing proteins, Ldb proteins interact
exclusively with the tandem LIM‐domain structures present in the nuclear LMO and LIM‐HD protein
subclasses (Figure IB‐C) (Breen, et al. 1998). These two subclasses are distinct in that they contain a
single set of sequential, closely spaced LIM domains. Ldb proteins interact with the tandem LIM
domains through their LIM interacting domain (LdbLID) (Figure 1A) (Jurata and Gill 1997). While the
cytoplasmic LIM‐Kinase proteins also contain a single set of tandem LIM domains, these factors are
not bound by Ldb proteins due to specific hydrophobic residues within the LdbLID that disrupt
binding (Deane, et al. 2003a). Another important functional domain within Ldb proteins is the self‐
association domain (Ldb1SAD) also referred to as the dimerization domain (DD) (Figure 1A) (Jurata
and Gill 1997). As the domain’s name indicates, Ldb proteins self‐dimerize via the LdbSAD. The
capacity of Ldb factors to simultaneously self‐associate and interact with either LIM‐HD or LMO
proteins facilitates the aggregation of multimeric transcription factor complexes.
In mice there are two Ldb protein isoforms: Ldb1 and Ldb2. Murine Ldb1 is encoded on
chromosome 19 and is made up of 10 exons encompassing 4 kilobases (kb) (Yamashita, et al. 1998),
and the human clones of Ldb1 and Ldb2 were identified in the late 1990's (Drechsler, et al. 1999;
Semina, et al. 1998; Ueki, et al. 1999). While it has been generally accepted that Ldb self‐association
is limited to homodimerization, the possibility of Ldb trimers or higher multimers has not been
rigorously disproven. Interestingly, biochemical analysis would support that the mouse protein
isoforms Ldb1 and Ldb2 form trimers and octamers, respectively (Cross, et al. 2010).
B. Ldb, LIM‐HD, and LMO function in the Drosophila
A requirement and mechanistic role for the Ldb factor was first characterized in the context
of Drosophila melanogaster wing development (Figure 2A). The Drosophila ortholog of Ldb1, Chip,
was identified as an enhancer‐facilitator of the cut locus, a cis‐regulatory element controlling, among
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other things, wing margins (Morcillo, et al. 1997). The disrupted wing development phenotype
observed in Chip mutants was similar to a dorsal wing development phenotype observed in
Drosophila that were mutant for apterous, the gene including the LIM‐HD protein ortholog of mouse
and human Lhx2 (Figure 2B‐C) (Cohen, et al. 1992). Surprisingly, under‐ and over‐expression of Chip
both resulted in dorsal wing agenesis (Figure 2D) (Fernandez‐Funez, et al. 1998). However,
simultaneous over‐expression of both apterous and Chip resulted in no phenotype (Figure 2E)
(Rincon‐Limas, et al. 2000). Collectively these results indicated a functional interaction between Chip
and apterous that was sensitive to the relative levels of each factor. In support of a functional
interaction between Chip and apterous, removing the ChipLID resulted in a mutant phenotype (Figure
2F) (van Meyel, et al. 1999). Unexpectedly, removing the ChipSAD also yielded flies with wing agenesis
(Figure 2G). To incorporate the functional requirement for both the ChipLID and ChipSAD into a
mechanism sensitive to the relative levels of Chip and apterous, a tetrameric complex composed of
two Chip, apterous dimers was proposed (Figure 2A) (van Meyel, et al. 1999). In validation of this
proposed complex, a chimeric protein consisting of the apterousHD and the ChipLID rescued the wing
development phenotype in apterous mutants (Milan and Cohen 1999). A final layer of this
mechanism was introduced when ectopic expression of the Drosophila LMO ortholog Beadex also
resulted in a mutant phenotype (Milan and Cohen 1999; Milan, et al. 1998). Presumably, Beadex
over‐expression disrupted the formation of the functional tetrameric complex. Demonstrating a
conserved functional role in Drosophila development, the Chip, apterous mechanism was also
required for appropriate interneuron development (Lundgren, et al. 1995; Shoresh, et al. 1998; van
Meyel, et al. 2000).
C. Ldb1 plays a critical role in numerous developmental contexts.
Ldb1 is crucial for mouse embryogenesis. In mice, germ‐line Ldb1 knockout embryos were
not viable and ceased development between E9.5‐E10 (Mukhopadhyay, et al. 2003). At E8.5 the Ldb1
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knockout embryos displayed anterior truncation, absence of heart formation, and loss of foregut
indentation. Closer inspection of the embryos revealed significant developmental defects. The most
anterior region of the embryo terminated in a convoluted neural plate and lacked rostral structures
anterior of the otic vesicles. Likewise, there was disrupted hindbrain and anterior midbrain
development. The somites existed in many rows that were fused medially; there were two neural
grooves but defective longitudinal expansion of the neural epithelium; and trunk duplication was
also often observed. The development of extraembryonic tissue was also impaired. The yolk sac
failed to expand around the fetus and the allantois failed to form or, when present, lost contact with
the amnion and failed to contact to the chorion. Blood islands failed to form and there was no
evidence of any hematopoietic development. Similarly, the primordial germ cells failed to form.
Developmental arrest was accredited to the apoptotic mesenchymal cells. The equivalent knockout
study in zebrafish demonstrating an equally severe developmental phenotype (Becker, et al. 2002).
Interestingly, unpublished communications from the group that characterized the germ‐line Ldb1
knockout claim the germ‐line Ldb2 knockout mice presented no gross phenotypic defects.
D. The SCL‐complex, an example of Ldb‐mediated LMO complexes.
In mice, Ldb factors, like in flies, function as coadaptors. Currently, two major functional
paradigms for Ldb factors have been characterized. These paradigms are grossly distinguished based
on whether the Ldb factor directly interacts with a LMO or LIM‐HD factor (Figure 2‐4). The SCL‐
complex, a multimeric transcription factor complex that directs hematopoiesis and erythropoiesis
(Love, et al. 2013), exemplifies the LMO paradigm (Figure 3). The name of the complex refers to Stem
Cell Leukemia (SCL) protein also known as T‐cell Acute Leukemia protein 1 (Tal1), a hematopoietic‐
specific bHLH factor that is incorporated into the Ldb1‐mediated complex (Begley, et al. 1989). The
canonical version of the pentameric SCL‐complex consists of Gata1 and Tal1 bridged by Lmo2 (Figure
3A) (Osada, et al. 1995). Additionally, Tal1, a member of the tissue‐specific Class B bHLH factors,
heterodimerizes with either E12 or E47, members of the ubiquitously expressed Class A bHLH
factors (Hsu, et al. 1994). The core transcription factors of the SCL‐complex recognize and
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Figure 3. The pentameric SCLcomplex mediates promoterenhancer looping. Adapted from
Love, et al. 2013. A. Schematic representing the five components of the SCL‐complex. The
components are Ldb1 (blue) with LIM‐Interacting Domain (LID) and Self Association Domain (SAD)
labeled, LMO2 (red), Gata1 (green) with amino‐terminus (N) and carboxy‐terminus (C) labeled, Tal1
(brown), and E47 or E2a (orange). The DNA is represented by the black double helix to indicate
which components of the SCL‐complex bind DNA. The SCL‐complex consensus E‐box‐GATA bipartite
motif is indicated below the DNA. B. Schematic of SCL‐complexes mediating promoter‐enhancer
looping between a distal cis‐element and the promoter of generic target gene (gray) through Ldb1
self‐association.
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bind a bipartite E‐box‐GATA consensus sequence (Figure 3A) (Wadman, et al. 1997). With the aid of
the bipartite consensus sequence, EMSA and IPs identified that Ldb1 was also incorporated into SCL‐
complex by interacting with LMO2 (Visvader, et al. 1997; Wadman, et al. 1997).
A rudimentary functional requirement for Ldb1 in erythropoiesis was demonstrated when
forced over‐expression of Ldb1 prevented differentiation of G1ER proerythroblast cells, an erythroid‐
committed, Gata1‐null cell‐line that can be induced to differentiate by exogenous Gata1 (Visvader, et
al. 1997). A similar result was achieved in the murine erythroleukemia (MEL) cells by exogenous
expression of Ldb1 or a dimerization‐defective Ldb1 (Xu, et al. 2003). Alternatively, enhanced Ldb1
expression enhanced erythroid differentiation in factor‐dependent cell progenitor (FDCP)‐mix cells
or in mouse, bone‐marrow‐derived, Sca+, Lin‐ cells (Hansson, et al. 2007). While collectively these
over‐expression studies failed to generate a consensus on the functional role of Ldb1 in
erythropoiesis, they did indicate that the SCL‐complex, like the Chip, apterous complex, was
functionally sensitive to the relative levels of its components.
Broadly, the SCL‐complex serves as a scaffold for recruiting mediators of transcription
regulation. The role for the SCL‐complex as a scaffold was convincingly demonstrated by two liquid
chromatography‐mass spectrometry/mass spectrometry (LC‐MS/MS) studies that employed in vivo
biotinylation pull‐downs in MEL cells; one study biotinylated Ldb1 and the other biotinylated TAL1
(Goardon, et al. 2006; Meier, et al. 2006). For instance, the SCL‐complex recruits the MTG/ETO co‐
repressor family members ETO2 and MTGR1 that can subsequently recruit repressive factors such as
NCor, Sin3A and HDACs. In addition to establishing the SCL‐complex as a protein scaffold, these
studies also demonstrated the sheer variety of nascent Ldb1‐incorporating complexes that exist in
MEL cells. As the MEL cells differentiated, the overall profile of these nascent complexes changed,
indicating that the formation of these nascent complexes is dynamically connected to differentiation.
For instance, incorporation of Cdk9, Eto2, and Mtgr1 decline when MEL cells differentiate.
Presumably, exclusion of Cdk9 correlates with the erythrocyte progenitors exiting the cell cycle and
the absence of Eto2/Mtgr1 correlates with increased transcriptional activation at certain loci.
Combining high‐throughput cistromic and transcriptomic analyses has also helped elucidate
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the functional dynamics of these nascent Ldb1‐incorporating complexes (Soler, et al. 2010). The
pentameric SCL‐complex is predominantly enriched in proximity to genes that are activated during
erythropoiesis. In contrast, enrichment of Gata1 in the absence of the other SCL‐complex components
was associated with genes that are repressed during erythropoiesis; these Gata1‐only sites are also
depleted of E‐box motifs. Intriguingly, the species of Gata factor that is incorporated into the SCL
complex either maintains the hematopoietic state or activates erythropoiesis. This mechanism has
been coined the ‘Gata‐switch’ (Bresnick, et al. 2010). A Gata2‐containing SCL‐complex, is enriched in
HSCs and functions to maintain stem‐cell populations, whereas, incorporation of Gata1 at the
expense of Gata2 promotes erythropoiesis. Intriguingly, these two versions of the SCL‐complex bind
indistinguishable consensus sequences (Li, et al. 2010a), suggesting that the distinct SCL‐complexes
recruit distinct co‐regulators. For instance, ETO2 is co‐enriched with the hematopoietic Gata2‐
containing SCL‐complex, whereas, ETO2 enrichment is negatively correlated with both
erythropoiesis and Gata1 occupancy. Similarly, meta‐analysis of a Klf1 ChIP‐Seq and Ldb1 ChIP‐Seq
using unfractionated bone‐marrow, demonstrated that the majority of Klf1 enrichment overlaps with
enrichment of the erythropoietic Gata1‐containing SCL‐complex (Li, et al. 2013), highlighting a
relationship between the three factors considered master regulators of erythropoiesis: Tal1, Gata1,
and Klf1.
E. Ldb1‐mediated chromatin nuclear‐localization and looping.
Given that Ldb factors do not bind DNA nor do they have any catalytic activity, it was
originally unclear what specific role Ldb1 played in the SCL‐complex. Studies investigating the
transcription of the β‐globin locus, have revealed that Ldb1, through its Ldb1SAD, mediates promoter‐
enhancer looping (Figure 3B) (Song, et al. 2007). In both mice and humans the β‐globin locus consists
of 4 and 5 genes, respectively, that encode different isoforms of the hemoglobin subunit (Kim and
Dean 2012). As the animal develops, the nascent erythrocyte populations express different β‐globin
genes. In humans, expression progresses from the most embryonic ε isoform to the fetal Gγ and Aγ
isoforms to the adult δ and β isoforms, this temporal expression pattern matches how the individual
genes are physically arranged 5’ to 3’ on the chromosome. An important component of the regulatory
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mechanism is an upstream locus control region (LCR) that is essential for the proper expression of
the genes within the β‐globin locus (Tolhuis, et al. 2002). In differentiating erythrocytes, the SCL‐
complex plays an important role and is enriched at cis‐regulatory elements within the LCR and the β‐
globin locus (Song, et al. 2007). For proper temporal expression of the correct β‐globin isoform, it is
essential that the LCR and the β‐globin locus are brought into close spatial proximity via chromatin
looping. The self‐dimerization function of Ldb1 is essential for this chromatin looping. Truncated
versions of Ldb1 lacking either the Ldb1SAD or Ldb1LID function as dominant negatives to β‐globin
expression by disrupting chromatin looping between the β‐globin locus and the LCR (Song, et al.
2007). Conversely, fusing the full length Ldb1SAD to LMO2 is sufficient to rescue Ldb1‐depleted MEL
cells. Ldb1 is also required for optimal recruitment of positive elongation factor b (P‐TEFb), the
complex containing cyclin T1 and cyclin‐dependent kinase 9, as well as the migration of the β‐globin
locus from the periphery of the nucleus to areas of higher transcription (Song, et al. 2010). Both of
these functional roles are linked to conserved α‐helices within the Ldb1SAD (Figure 1B) that are
dispensable for self‐dimerization but required for appropriate recruitment of Fog1, SWI/SNF, and
components of the nucleosome remodeling complex (NuRD) (Krivega, et al. 2014). Taken together
these recent findings regarding Ldb1 at the β‐globin locus, indicate distinct function roles for Ldb1 in
mediating chromatin looping and transcriptional elongation that must either work simultaneously or
in close succession.
F. Biochemical investigation of Ldb1, LMO containing complexes.
The proposed mechanism by which Ldb aggregates multimeric complexes to direct distinct
transcriptional programs requires the coordination of protein‐protein interactions and tight
regulation of component stoichiometric levels at both the transcriptional and post‐translational
levels. The validity of these putative Ldb‐mediated complexes has been significantly bolstered by
detailed biochemical analysis that has largely been produced from the lab of Jacqueline Matthews.
Their work has validated many of the fundamental conclusions regarding the role of Ldb factors in
aggregating multimeric transcriptional complexes. Notably, these biochemical investigation into the
protein‐protein interactions between Ldb1 and tandem LIM‐domain containing proteins has largely
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relied on extrapolating observations from engineered proteins where the Ldb1LID was conjugated to
a LIM‐domain via a flexible linker (Jeffries, et al. 2006). This has been necessary because 1)
synthesizing full length proteins at the volume required for the analytical techniques was impractical
and 2) polypeptides representing the functional domains, e.g. LIMs and LID, would aggregate and
became insoluble (Deane, et al. 2001). The flexible linker strategy circumvented these technical
obstacles while only nominally stabilizing the intramolecular interactions (Jeffries, et al. 2006).
This technique was first used to interrogate the binding interaction between the Ldb1LID and
the first LIM domains (Figure IC) within LMO2 LIM1 and LMO4 LIM1 (Deane, et al. 2001). Nuclear
magnetic resonance (NMR) analysis revealed that the native, unbound Ldb1LID is unstructured and
upon binding with a LMOLIM1 takes on an extended conformation that makes coordinated
hydrophobic and electrostatic interactions with the LMOLIM1 (Deane, et al. 2003a), an observation
that is common for domains that mediate protein‐protein interactions. Subsequently, cyystallization
of a chimeric protein conjugating both LIM domains from LMO4 to the Ldb1LID provided increased
insight into the molecular interaction of these domains (Deane, et al. 2003b; Deane, et al. 2004).
When interacting with the LMO4LIM1/2, the unstructured Ldb1LID assumed an extended structure that
could be more accurately characterized as a tandem β‐zipper. The LMO4LIM1 played the dominant
role in the interaction, and binding of the weaker LMO4LIM2 stabilized the complex. Surprisingly, the
interaction between Ldb1LID and LMO4LIM1/2 was resilient to individual point mutations at seemingly
key residues, highlighting the capacity for Ldb1LID to bind diverse LMO and LIM‐HD proteins.
Conversely, the tandem LIM domains of the related LIM Kinase (LIMK) family of proteins lack critical
hydrophobic residues that are conserved in the LIM domains of LMO and LIM‐HD proteins; the
absence of these residues is what is predicted to inhibit Ldb proteins from interacting with LIMK
proteins.
Looking at the whole SCL‐complex, biochemical modeling of the Tal1:LMO2 interaction
identified a crucial residue in LMO2 located between the LIM domains that provides the necessary
rotational flexibility of LIM domains to avoid steric hindrances that would otherwise disrupt LMO2
and Tal1 binding (El Omari, et al. 2011; El Omari, et al. 2010). Biochemistry and computer modeling
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were combined to generate estimated binding kinetics for the various components of the complex
(Ryan, et al. 2008). From an energetics perspective, the SCL‐complex was highly stable and DNA
containing an E‐box site provided little additional stability. This would suggest that SCL‐recruitment
to DNA is not dependent on E‐box recognition and would agree with other studies implicating that
the GATA factor is predominantly responsible for recruiting the SCL‐complex to loci containing
bipartite motifs (Love, et al. 2013). While it appears the E‐box factors are not necessary for recruiting
the SCL‐complex to DNA, the class A E‐box factor within the SCL‐complex is integral in recruiting co‐
repressive elements like Eto2 and mSin3A. Whereas, the incorporated GATA factor has a role in
recruiting either Fog1 or coactivators like p300 (El Omari, et al. 2013).
G. Ldb‐mediated LIM‐HD complexes direct motor neuron fate.
Alternatively to directly interacting with LMO proteins, Ldb factors also directly bind LIM‐
HD factors. In vertebrates, motor neuron sub‐populations can be identified by the LIM‐HD species
they express, this is referred to as the ‘LIM‐code’ (Alaynick, et al. 2011). While the LIM‐code aids in
identifying motor neuron populations, the LIM‐code also represents an intricate Ldb1‐mediated
mechanism that directs the terminal differentiation of the somatic motor neurons (Figure 4). Genetic
manipulation of the LIM‐code can significantly impact motor neuron differentiation, cell‐body
localization, and axon guidance (Liang, et al. 2011). The functional role for these complexes in motor
neuron differentiation was initially demonstrated through chick embryo electroporation
experiments that targeted the juxtaposed ventral neural tube Vp2 and pMN progenitor populations
that yield the V2 interneurons and motor neurons, respectively (Figure 4). In response to Shh signal
emanating from the neural tube floor plate, a distinct set of transcription factors specify the
respective progenitor domains and activate the proneural factors (Diez del Corral and Storey 2001).
Isl‐1 and Lhx3 drive differentiation of the motor neurons, whereas, V2 interneuron differentiation
only requires Lhx3 (Figure 4) (Tanabe, et al. 1998). A seminal study utilizing chicken embryos
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Figure 4. Multimeric Ldb1mediated LIMHD complexes drive motor neuron differentiation.
The fate of the juxtaposed Vp2 and pMN progenitors (green circle) are driven by Ldb1‐mediated
complexes. Ldb1 (dark blue) and Lhx3 (orange) drive V2 interneuron (V2) fate (blue circle) through
a tetrameric complex. Ldb1, Lhx3, and Isl‐1/2 (green) drive motor neuron (MN) fate (yellow circle)
through a hexameric complex. LMO4 (red) functions to buffer the relative stoichiometric levels of
Ldb1 and LIM‐HD components. DNA double helix (black) provided to demonstrate how the
multimeric complexes interact with the chromatin.
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While the chick electroporation study was seminal in demonstrating that combinatoric, Ldb‐
mediated LIM‐HD complexes function to direct cell fate, the findings regarding the structural
organization of the Ldb1‐mediated complexes were slightly over‐interpreted. Notably, the proposed
symmetry of the postulated tetrameric and hexameric LIM‐HD complexes are largely based on the
interpretation of co‐immunoprecipitations performed with in vitro generated proteins or
reticulocyte lysates (Jurata, et al. 1998; Thaler, et al. 2002). While these experiments demonstrated
that the proposed symmetrical complexes are feasible, they have also instilled certain assumptions
that have not been rigorously examined. One assumption is that Ldb factors exclusively self‐associate
in homodimers. Another assumption is that the composition of the Ldb, LIM‐HD complexes is always
symmetric, e.g. LIM‐HD:Ldb:Ldb:LIM‐HD. A third assumption is that these complexes do not mediate
chromatin looping; instead, all the DNA‐binding domains within the complex bind cis‐elements in
close proximity to each other. Again, while there may be biological truth to these presumptions, they
have not been proven to be exclusively correct.
Two follow‐up studies from the group that published the original chicken embryo findings
provide an example of how the above assumptions have colored future investigations. The more
recent of the two studies demonstrated that step‐wise reductions in aggregate levels of Isl‐1 and its
protein isoform Isl‐2 elicited a dose‐dependent effect on V2 interneuron and motor neuron fate in
favor of the former at the expense of the latter (Song, et al. 2009). In the same study, the authors also
identified that exogenous Lmo4 represses motor neuron fate via sequestering Ldb1. They concluded
that nascent Lmo4 buffers against the formation of a functional complex when complex component
expression levels are low (Figure 4). Notably, this study was performed after the group had already
argued that the proneural bHLH factors, the set of factors that specify and drive pan‐neuronal
function, synergized with the hexameric Ldb1, Isl‐1, Lhx3 complex to enhance motor neuron gene
expression (Lee and Pfaff 2003). To investigate the mechanistic relationship between Ldb1‐mediated
hexamer and proneural factors, the authors engineered a unique λ‐Isl‐1HD‐Lhx3HD fusion protein,
where the self‐binding domain of the λ repressor protein would allow Ldb1‐independent association
of the fusion protein. Co‐electroporating embryos with both the λ‐Isl‐1HD‐Lhx3HD fusion protein and
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the proneural bHLH factor NeuroM increased motor neuron specification above electroporating the
fusion protein alone. However, the λ‐Isl‐1HD‐Lhx3HD fusion protein was never as effective at
enhancing motor neuron specification as the native Ldb1‐mediated complex. Collectively, this study
indicated a requirement for Ldb1 in maximizing the synergistic relationship between NeuroM and
the hexameric LIM‐HD complex.
While both studies provided significant insights into the role of LIM‐HD complexes, their
respective conclusions seem limited in comparison to contemporary studies of the SCL‐complex.
Given the interaction between LMO, bHLH, and Ldb1 factors is key to the SCL‐complex paradigm,
neither of the above studies attempted to connect any of these elements to their findings. Instead, the
conclusion of the more recent of the two studies strongly reflects the Chip, apterous mechanism in
Drosophila. In contrast, more recent studies have begun to reveal a more dynamic Ldb1‐mediated
mechanism involved in neuronal specification. A 2009 study demonstrated that an SCL‐complex that
incorporated LMO4 instead of LMO2 directed V2 interneuron subtype specification (Joshi, et al.
2009). This novel SCL‐complex was demonstrated to direct the inhibitory, GABAergic V2b fate over
the excitatory, glutamatergic V2a fate. Furthermore, the Ldb1, Isl‐1 complex has recently been
implicated in mediating chromatin looping in cardiomyocyte progenitors (Caputo, et al. 2015a).
Possibly, studies like these will pave the way for a reevaluation of the Ldb‐mediated LIM‐HD
functional model.
H. Biochemical investigation of Ldb1, LIM‐HD containing complexes.
Biochemical approaches have also been taken to elucidate the interactions between the LIM‐
HD factors Lhx3 and Isl‐1 and the Ldb1LID. While the overall molecular interaction between the
Ldb1LID and either the Lhx3LIM1/2 or Isl‐1 LIM1/2 were similar to that observed with the LMO2 or LMO4
LIM domains, the Ldb1LID and LIM‐HDLIM interactions were weaker (Matthews, et al. 2008). In fact,
the Isl‐1LIM1/2 had the weakest interaction with the Ldb1LID. Interestingly, yeast two‐hybrid analysis
identified a unique domain in both Isl‐1 and Isl‐2 that closely resembles the Ldb1LID (Figure 1B). Like
the Ldb1LID, these respective domains were capable of directly binding the tandem LIM domains of
Lhx3 and Lhx4 (Bhati, et al. 2008; Gadd, et al. 2011). Additionally, The Isl‐1LID mediates an
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intramolecular interaction with the Isl‐1LIM1/2 (Gadd, et al. 2012). This intramolecular reaction
prevents the Isl‐1HD from binding DNA, thus, disrupting the Isl‐1 intramolecular interaction appears
to be prerequisite for Isl‐1 DNA‐binding activity. Computer modeling of the relative likelihood of
multimeric LIM‐HD complex formation found that formation of the Ldb1:Lhx3 tetramer was
significantly more favorable than the Ldb1:Isl‐1:Lhx3 hexamer (Bhati, et al. 2008). The Ldb1:Isl‐
1:Lhx3 hexamer was only energetically favorable when both 1) Isl‐1 concentration was high and 2)
DNA sequences containing spaced homeobox elements were added to the computer modeling. This
analysis argues that, unlike the Scl‐complex, a DNA interaction is essential for the formation of the
hexameric LIM‐HD complexes.
Like the Ldb1LID, LMOLIM interactions, there appears to be a significant level of redundancy in
Ldb, LIM‐HD paradigm (Gadd, et al. 2011). The binding structures from the permutations of
interactions between the Isl‐1 LID and Isl‐2 LID and the Lhx3LIM1/2 and Lhx4 LIM1/2 are very similar, but
the individual amino acid residue interactions were marginally different. While the marginally
different residue interactions may serve to fine tune cell fate specification in a healthy system, the
high redundancy seems to also offer a level of protection against serious mutations. For instance, the
Y114C mutation in Lhx3, located in the LIM2 domain, is highly associated with combined pituitary
hormone deficiency, a congenital form of hypopituitarism (Bhati, et al. 2012). Structural analysis of
this mutant Lhx3 interacting with either the Ldb1LID or Isl‐1LID revealed that the mutant Lhx3LIM2 can
still coordinate zinc and interact with both LID domains. However, mutant interactions are
considerably less stable, presumably because the mutation disrupts the hydrophobic core of the
Lhx3LIM2 domain. While this mutation yields a significant pituitary phenotype, neuronal
differentiation is grossly normal because of Lhx4 redundancy.
I. Other notable biological contexts demonstrating unique Ldb1‐mediated biology.
In the mouse telencephalon, both transcriptional paradigms of Ldb1‐mediated complexes
are utilized to direct neuronal fate. Ablating Ldb1 with Cre driven by the Nkx2.1 promoter, a marker
for the neuronal‐lineages originating from the medial ganglionic eminence (MGE), resulted in the
absence of the cholinergic and GABAergic neuronal populations in the cortex (Zhao, et al. 2013).
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These results suggest an interaction between Ldb1 and Lhx8 in the cholinergic neurons and Lhx6 in
the GABAergic cortical neuronal populations. The model is consistent with previous observations
supporting an Ldb1, Isl‐1, Lhx8 hexamer directing the cerebellar cholinergic fate (Cho, et al. 2014).
There is also evidence indicating that Ldb1 forms complexes with the proneural bHLH factors in the
developing cortex (Asprer, et al. 2011). Namely a Lmo4, Neurog2, Ldb1 complex is implicated in
regulating neuronal induction in the developing cortex.
The pituitary gland, another ectoderm‐derived organ, represents a unique, poorly
understood biological context where multiple Ldb‐mediated transcriptional paradigms are
employed. In fact, a minimally investigated Ldb paradigm transcriptional paradigm was first
characterized in the developing gonadotropes. An early study investigating the role of Ldb1 in the
pituitary gland was one of the first to demonstrate that paired‐like homeodomain proteins may also
be incorporated in Ldb‐mediated complexes (Bach, et al. 1997). This study demonstrated that the
pituitary‐enriched factors Ldb1, Lhx3, and Pitx1 formed a complex in vitro, and expression of all
three factors significantly enhanced signal from a Cga promoter reporter assay, the gene encoding
the gonadotrope‐specific factor Chorionic Gonadotropin Subunit Alpha. Studies using the murine
pituitary tumor cells LβT2 and the human gonadotrope αT3‐1 cells also identified a Ldb1, Lhx2
complex that regulated the Cga promoter (Susa, et al. 2006). Without any significant follow‐up
studies, it is hard to reconcile how Ldb1, Lhx2, Lhx3, and Pitx1 may functionally interact in the
developing gonadotropes.
A recent study focusing on another pituitary cell type, the corticotrope, provides a good
example of the experimentation necessary to begin to address questions surrounding the role for
Ldb1 in gonadotrope development. Through a combination of ChIP‐Seq and a method very similar to
chromatin conformation capture (3C), the authors demonstrated that Ldb1 mediates chromatin
looping in murine pituitary AtT20 cells (Zhang, et al. 2015), reflecting the well‐characterized
functional role of Ldb1 as part of the SCL‐complex. Similar to the SCL‐complex, an Ldb1‐mediated
complex containing the bHLH protein Ascl1 is necessary to enhance or repress target genes in the
AtT20 cells and the repressive or activating function of this complex was dictated by recruited
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cofactors. The Ldb1‐mediated complexes in the AtT20 cells acted repressively via increased
promoter pausing that was in part a result of recruiting the NURD complex. Presumably, this putative
Ldb1‐mediated complex requires an LMO factor, but that connection to the SCL‐complex paradigm
was not investigated.
PART IV. ISLET‐1: A DRIVER OF POST‐MITOTIC PROGENITOR FATE
A. The LIM‐HD protein Islet‐1.
As reviewed above, an important paradigm in Ldb1‐mediated transcriptional regulation is
nucleating multimeric LIM‐HD complexes. The LIM‐HD protein Isl‐1 is a unique component of this
transcriptional paradigm. Unlike most LIM‐HD factors, Isl‐1 and its protein isoform Isl‐2 contain a
domain similar in structure and function to the Ldb1LID (Bhati, et al. 2008). It is thought that the Isl‐
1/2LID facilitates the insertion of Isl‐1 or Isl‐2 into nascent Ldb1:LIM‐HD dimers to form Ldb1:Isl‐
1/2:LIM‐HD trimers (Bhati, et al. 2008). Despite biochemical analysis suggesting that the trimers are
less energetically favorable than the dimers, the dimers and trimers hypothetically direct distinct
transcriptional programs that have been shown to mediate cell‐fate decisions, drive progenitor
maturation, and/or maintain functional qualities of terminally differentiated cells. Germ‐line
knockout of Isl1 results in a pleiotropic phenotype that fails to develop past E9.5, indicating a
requirement for Isl‐1 in a broad range of developing tissues (Ahlgren, et al. 1997). Not surprisingly,
the Isl1 and Ldb1 germ‐line knockout phenotypes have many similarities, an observation that
reflects the functional relationship of the two proteins. In general, Isl‐1 should be considered a
developmental factor. While its expression may be retained in multiple terminally differentiated
cells, Isl‐1 expression is almost exclusively activated in developmental contexts. Isl‐1 is generally
activated in post‐mitotic progenitors that originate from the ectoderm and endoderm (Figure 2).
However, that delineation is not as clear with mesodermally‐derived progenitors that express Isl‐1
(Figure 5). Highlighted below are key biological contexts where distinct elements of Isl‐1 biology
have been characterized.
B. Isl‐1 and its role in motor neuron specification and maturation.
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Isl‐1 expression is required for the specification of all and the maturation of most motor
neurons. Motor neurons are cholinergic, efferent neurons that control muscle movement (Pfaff, et al.
1996). Motor neuron cell bodies are located in the spinal cord and their axons project to innervate
muscle fibers (Bonanomi and Pfaff 2010). Motor neurons can be broadly divided into three groups:
somatic motor neurons that innervate skeletal muscle and control locomotion; visceral motor
neurons that innervate cardiac muscle and smooth muscle; and cranial motor neurons, a term
encompassing the branchiomotor and visceral motor neurons located in the midbrain, hindbrain, and
cervical spinal cord that innervate the face and neck. Motor neurons are arranged along the rostral‐
caudal axis in longitudinal arrays known as motor columns. The median motor column (MMC) spans
across the entire rostral‐caudal axis and innervates the axial muscle groups. Lateral motor columns
(LMC) span both the brachial and lumbar levels of the spinal cord and innervate the respective limb
muscle groups. The LMCs are further subdivided into lateral (lLMC) and medial (mLMC) columns
that respectively innervate the dorsal and ventral muscle groups. Within the thoracic level of the
spinal cord, the hypaxial motor column innervates the body wall muscles. Also within the thoracic
spinal level is the preganglionic motor column that innervates the sympathetic ganglia. The
specification of the cell types that make up this complex anatomical structure is highly linked to Isl‐1
function in conjunction with Ldb1 and other LIM‐HD proteins (Alaynick, et al. 2011).
An Ldb1:Isl‐1:Lhx3 trimer directly activates and maintains the cholinergic properties that
functionally identify motor neurons (Cho, et al. 2014). This essential requirement for Isl‐1 in motor
neuron development has been effectively illustrated by recent attempts to generate motor neurons
from embryonic stem cell (ESC)‐derived embryoid bodies. In a recent study, the combination of an
inducible Isl‐1‐Lhx3 fusion protein and retinoic acid (RA) more effectively promoted motor neuron
fate from ESC‐derived embryoid bodies than the contemporary RA and Shh incubation protocol (Lee,
et al. 2012). While general motor neuron specification is dependent on the Ldb1:Isl‐1:Lhx3 trimer,
varying permutations of the Ldb1‐mediated, Isl‐1‐incorporating complex direct motor neuron
subtype differentiation. For instance, cranial motor neuron sub‐specification requires a Phox2a, Isl‐1,
Ldb1 complex (Mazzoni, et al. 2013) and down‐regulating Isl‐2 directs visceral over somatic motor
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Figure 5. Visual summary of select developmental biological contexts where Isl1 is required.
The developmental biological contexts are organized based on the germ layer from which they
originate: ectoderm (blue), mesoderm (red), and endoderm (purple). Within each ‘germ‐layer’,
related biological contexts are grouped by the term indicated in the first column. The main biological
contexts introduced in Chapter 1 are indicated in the second column. The key Isl‐1 biology observed
in each biological context is summarized in the text boxes.
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neuron fate (Thaler, et al. 2004). Similarly, alterations in Isl1 gene dosage can significantly effect
motor neuron specification and the maintenance of spinal motor neuron identity. In Isl1
hypomorphic mouse models, proper motor columns fail to form, axons innervating axial and
diaphragm muscles are missing, and cranial ganglia neurons fail to survive (Liang, et al. 2011).
Likewise, similar motor neuron phenotypes are observed when the levels of Onecut factors, direct
transcriptional regulators of Isl1, are genetically manipulated. In Onecut1/Onecut2 double‐knockout
mice, somatic motor neurons are converted to visceral motor neurons at the thoracic spinal level and
mLMCs are converted to lLMCs (Roy, et al. 2012). The increase of lLMCs at the expense of mLMCs
was also observed when microRNA‐9, a negative regulator of Onecut1 protein levels, was over‐
expressed in developing chick embryos (Luxenhofer, et al. 2014).
C. Isl‐1 and its role directing forebrain neuronal identity.
Isl‐1 is also essential for the differentiation of neuronal progenitor populations throughout
the developing central nervous system. Interestingly, Isl‐1 expression has yet to be detected in the
ventricular zones of the developing rodent forebrain. Like in the somatic neural tube (Alaynick, et al.
2011), Isl‐1 appears to be exclusively activated in post‐mitotic progenitor populations, and the
restriction of Isl‐1 expression to post mitotic‐cells is highly conserved evolutionarily (Moreno and
Gonzalez 2007; Moreno, et al. 2008; Sugahara, et al. 2011). In rodents, Isl‐1 expression is enriched in
the ventral subventricular zones, indicating that Isl‐1 expression is activated in neuronal progenitors
soon after exiting the ventricular zone (Mastick and Andrews 2001; Stenman, et al. 2003; Wang and
Liu 2001). In the developing forebrain, Isl‐1 is required for directing the fate of multiple functionally
distinct neuronal lineages. For instance, Isl‐1 directs the fate of the glutamatergic and cholinergic
neurons within the red and oculomotor nuclei within the mesencephalon (Nelander, et al. 2009). In
the mouse and zebrafish diencephalon, Isl‐1 directs the fate of the thalamic dopaminergic neurons
(Filippi, et al. 2012; Nakagawa and O'Leary 2001).
In the telencephalon, Isl‐1 is required for directing the fate of the post‐mitotic neuronal
progenitors that contribute to the striatum. The striatum is the largest nucleus of the basal ganglia
and is responsible for coordinating cognitive function with motor coordination (Graybiel 1990). The
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predominant cell‐type comprising the striatum is the GABAergic medium‐sized spiny neurons
(MSNs) that project to the substantia nigra (striatonigral) and globus pallidus (striatopalladal)
(Gerfen and Surmeier 2011). Developmentally, the MSNs originate from the Lateral Ganglionic
Eminence (LGE) (Deacon, et al. 1994). The cholinergic interneurons that also populate the striatum
originate from the Medial Ganglionic Eminence (MGE) (Olsson, et al. 1998), whereas, the
interneurons that originate from the LGE migrate to the olfactory bulb and amygdala (Stenman, et al.
2003). As seen in the somatic motor neurons, Isl‐1 is necessary for directing cholinergic interneuron
fate in the telencephalon and remains expressed in these terminally differentiated neurons (Cho, et
al. 2014; Fragkouli, et al. 2009). Cholinergic interneurons within the dorsal and ventral striatum,
nucleus basalis, caudate‐putamen, magnocellular preoptic area, and medial septum all express Isl‐1
(Elshatory and Gan 2008). Conditionally ablating Isl1 in the interneuron progenitors using Six6Cre,
effectively inhibited the maturation of the cholinergic interneurons in all the above locations
(Elshatory and Gan 2008). But, a Foxg1rTA; tetOCre strain that ablates Isl1 in the non‐cholinergic
neurons of the telencephalon demonstrated a functional requirement for Isl‐1 in the generating the
GABAergic striatonigral neurons (Ehrman, et al. 2013). In support of this finding, conditionally
ablating Isl1 in neuronal progenitors with the NestinCre strain resulted in an increase in the
striatopalladal neuron population at the expense of the striatonigral neurons, whereas, over‐
expression of Isl1 in the developing striatum had the reciprocal effect (Lu, et al. 2013). Taken
together, the assignment of the three striatal neuron fates depends on the expression pattern of Isl‐1.
Specifically, a post‐mitotic Lhx6+, Lhx7+ progenitor can either become GABAergic or cholinergic,
where the default fate appears to be GABAergic and activation of Isl‐1 followed by Lhx6 repression
leads to a cholinergic interneuron fate (Fragkouli, et al. 2009). Following Isl‐1 activation but prior to
permanent adoption of a cholinergic‐fate, there also appears to be a refractory period where
repression of Isl‐1 can restore GABAergic fate (Lopes, et al. 2012).
D. Isl‐1 and its role with POU‐domain factors in retinal development.
Isl‐1 is also essential for the differentiation of many sensory neuron populations including
the somatic sensory neurons (Sun, et al. 2008), the auditory and vestibular system (Huang, et al.
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2013), and the retina (Elshatory, et al. 2007). Within these varied biological contexts, the role of Isl‐1
is similar to that in the developing forebrain and motor neuron progenitor populations: directing the
terminal differentiation of mostly post‐mitotic progenitor populations. Among the different sensory
neuron populations where Isl‐1 is active, the retinal ganglion progenitors demonstrate a unique
mechanistic paradigm where Isl‐1 and the POU‐domain containing factor Pou4f2 (Brn3b) interact to
direct differentiation. Expression of the bHLH factor Atoh7 (Math5) in retinal progenitors cells is
essential for differentiation of retinal ganglion cell (Yang, et al. 2003). In mice null for Atoh7 in the
retinal progenitors, forced expression of both Isl1 and Pou4f2 in the retinal progenitors is sufficient
to direct a retinal ganglion cell fate (Wu, et al. 2015). At face value, these results were not surprising
because Isl‐1 is co‐expressed with Pou4f2 in the nascent, post‐mitotic retinal ganglion cells (Pan, et
al. 2008). Nonetheless, high‐throughput cistrome and transcriptome analysis have identified that
these two factors work synergistically at common targets (Mu, et al. 2008; Zhang, et al. 2013). Even
more recently, GST pull‐down assays demonstrated an interaction between these two factors that
required the region encompassing the Isl‐1LID and two regions within Pou4f2, the homeodomain and
a small region upstream of the POU domain (Li, et al. 2014). While a functional interaction between
Isl‐1 and POU‐domain containing factors has been more thoroughly investigated in the retinal
ganglion progenitors, evidence in other biological contexts suggests this mechanism may be more
widely implemented. In the development of the inner ear, evidence points towards Isl‐1 and Pou4f3
functionally interacting (Deng, et al. 2014a). Additionally, both ISL‐1 and POU4F1, BRN3A, are
expressed in the human glutamatergic and cholinergic neuronal progenitors within the respective
red and oculomotor nuclei (Nelander, et al. 2009).
E. Isl‐1 and its role in heart development.
Isl‐1 is a key factor regulating heart development. Global knockout of Isl1 in mice is
embryonic lethal in large part due to aberrant heart development (Ahlgren, et al. 1997). In fact, a role
for Isl‐1 in cardiogenesis is highly conserved throughout bilateral dueterostomes (Pandur, et al.
2012). In spite of evolutionary conservation, the developmental role for Isl‐1 in heart development
appears to be essentially the opposite of that in all the other Isl‐1 biological contexts. Instead of
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directing differentiation in post‐mitotic progenitors, Isl‐1 functions to maintain the proliferative
undifferentiated state of the mesenchymal progenitor population that contributes to the mature
heart structures. The cells that comprise the structures of the mature heart are incorporated into the
developing myocardium in two temporally distinct waves. Those that incorporate first from the
splanchnic mesoderm contribute to the majority of the left ventricle and small portions of each
atrium; these cells are referred to as the first heart field and may transiently express Isl‐1 (Ma, et al.
2008; Meilhac, et al. 2004). In contrast, the cells of the second heart field linger within the precardiac
mesoderm remaining undifferentiated and highly proliferative as they are gradually incorporated
into the developing organ (Meilhac, et al. 2004).
At E7.5, Isl1 is expressed in the anatomical location where heart progenitors arise, the
splanchnic mesoderm, in the stereotypical crescent pattern of the heart progenitors (Cai, et al. 2003).
However, Isl1 expression crescent is juxtaposed but does not overlap with a similarly shaped
crescent defined by atrial myosin light chain 2 (MLC2a) expression, a marker of myocardial fate. As
heart development proceeds, the Isl‐1+ crescent in the precardic mesoderm is maintained until all
cells have differentiated to the respective cardiomyocytes, endothelial cells and smooth muscles cells
that comprise the mature heart organ. Using an Isl1Cre/+ strain crossed with an inducible Rosa26LacZ
strain in parallel with a separate Isl1LacZ/+ strain the same group observed that the Isl‐1+ lineage
contributed to the outflow tract, right ventricle, majority of the atria, and a small portion of the left
ventricle (Sun, et al. 2007; Yang, et al. 2006). While Isl1 was not expressed in the differentiated,
MLC2a+ cardiomyocytes, those cells identified by Isl‐1 lineage tracing contributed almost exclusively
to the heart structures derived from the second heart field population. Subsequent studies have since
confirmed that Isl‐1 marks the second heart field population and is important for maintaining the
undifferentiated and proliferative state of that cell population (Ma, et al. 2008). Given that Isl‐1 is
required for maintaining the undifferentiated state of heart progenitors during embryogenesis, few
cells express Isl‐1 the mature organ. Excluding the neural crest‐derived parasympathetic neurons,
only the pacemaker cells and a scattered population of smooth muscle cells in the great arteries

38

retain Isl‐1 expression in mice (Weinberger, et al. 2012). In humans, however, a population of Isl‐1+
cardiac stem‐cells exists that diminishes rapidly with age (Mishra, et al. 2011).
Despite the distinctly unique role Isl‐1 plays in heart development compared to other
progenitor populations, little is know about its transcriptional role in the progenitors. Even though
the LIM‐HD, Ldb1 paradigm has been largely absent in this field, there is still evidence that the some
iteration of known Ldb‐mediated complexes may be involved with Isl‐1 transcriptional
transactivation in the heart progenitors. For instance, GATA, Ebox and Isl‐1 motifs are located within
the promoter region of Mefc2, a direct Isl‐1 target gene that encodes one of the earliest factors
promoting cardiomyocyte differentiation (Dodou, et al. 2004). Similarly, Isl‐1, Gata4, and Tbx20
appear to work synergistically to activate Fgf10 expression, a driver of anterior heart field structures,
in progenitors contributing to the cardiac outflow tract (Golzio, et al. 2012). Notably, a recent study
has demonstrated that cardiomyocte differentiation depends on promoter‐enhancer looping
mediated by an Ldb1, Isl‐1 complex (Caputo, et al. 2015a). This is the first evidence demonstrating
that Ldb1 is required for promoter enhancer looping in the context of the LIM‐HD transcriptional
paradigm.
PART V. CURRENT UNDERSTANDING OF LDB1 AND ISL‐1 IN THE DEVELOPING AND MATURE PANCREAS
A. Isl‐1 and its role in pancreatic development across species.
Isl‐1 is critical for the development of both the exocrine and endocrine components of the
pancreas. At E9 in mice, Isl‐1 protein is first detected in both the pancreatic epithelium and the
surrounding lateral mesenchymal cells (Ahlgren, et al. 1997). The Isl‐1+ cells in the pancreatic
epithelium at this point identify the first wave of endocrine cells. In germ‐line Isl1 knockout mice,
the first wave of endocrine cells is absent and there is agenesis of the dorsal pancreatic bud.
However, the latter observation appears to reflect an extra‐pancreatic role for Isl‐1 in the lateral
pancreatic mesenchyme. Consistent with this hypothesis, dorsal pancreatic anlagen agenesis is
rescued in the explant cultures using wildtype mesenchyme. While amylase+ cells were observed in
these Isl1 knockout explant cultures, no insulin+, glucagon+, nor somatostatin+ cells were detected.
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This argues that expression of Isl‐1 in the pancreatic epithelium is required for pan‐endocrine
differentiation.
A direct requirement for Isl‐1 in pancreatic endocrine differentiation was further supported
by characterization of a mouse model that conditionally ablated Isl1 in the pancreatic epithelium
using the Pdx1Cre strain (Du, et al. 2009). While Pax6+ endocrine progenitors persisted and
delaminated to form islet structures, expression of the endocrine hormones was undetectable with
the exception of ghrelin. However, the population of ghrelin+ cells in the mutant mice was
comparable to control animals at both E15.5 and E18.5, indicating the Isl1 endocrine progenitors
were not being shunted to a ε‐cell fate. Additionally, the retained Pax6+ hormone‐negative population
in the mutant mice exhibited reduced proliferative capacity and slightly increased apoptosis.
Postnatal mutant animals failed to thrive past three weeks‐of‐age and those animals that persisted to
three weeks‐of‐age were hyperglycemic. The respective β‐cells and α‐cell maturation factors MafA
and Arx were both decreased in E15.5 mutant pancreata. ChIP combined with reporter assays has
subsequently demonstrated that Isl‐1 directly regulates MafA through the cis‐element Region 3 and
Arx through the cis‐element Re1 (3rd Intron, ~5.6kb downstream of the TSS) and Re2 (~23.6kb
downstream of the TSS) (Liu, et al. 2011; Raum, et al. 2006).
Epistatically, Isl1 expression is activated downstream of the Neurog3 (Gradwohl, et al.
2000). Therefore, these two murine studies indicate Isl‐1 is essential for directing the terminal
differentiation of the primary pancreatic endocrine cells types. Importantly, ISL‐1 expression is also
detected in the human fetal pancreas. The expression of ISL1 significantly increases between 8 and
21 weeks‐of‐gestation, with a significant increase in expression occurring between 14 and 16 weeks‐
of‐gestation (Lyttle, et al. 2008). The timing of expression would suggest that ISL‐1 is downstream of
NEUROG3. Additionally, ISL‐1 colocalizes with NEUROD1, NKX2.2 and PAX6 during the 8‐21 week
period, suggesting that similar transcriptional networks regulate both human and mouse pancreatic
endocrine development (Lyttle, et al. 2008). Nonetheless, it is unclear whether Isl‐1 plays a direct
role in specifying distinct pancreatic endocrine cell‐fates in either rodents or humans because it is
universally expressed in the endocrine progenitors.
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B. Insights into the functional role of Isl‐1 in the mature β‐cells.
Given the role of Isl‐1 in pancreatic endocrine development, it is interesting to observe that
it remains expressed in the mature islets of mice (Thor, et al. 1991). Investigating the role for Isl‐1 in
a cell‐type‐specific manner within the pancreas has been hampered by the need for effective
inducible loss‐of‐function mouse models. In spite of this, some crucial insights have been gained.
Focusing on β‐cell biology, one hypothesis is that Isl‐1 is directly involved in regulating the
proliferation and survival of β‐cells, a reasonable line of thought given the observations made
regarding postnatal islets in the pancreatic epithelial Isl1 loss‐of‐function model (Du, et al. 2009).
Work using isolated rat islets has provided debatable support to this hypothesis. Transducing
isolated rat islets with an Isl1 over‐expressing vector increased the amount of islet cells outside of
the G1 phase of the cell cycle; the reciprocal observation was seen when rat islets were transduced
with siRNA targeting Isl1 (Guo, et al. 2011). To argue that Isl‐1 is directly regulating proliferation,
the group demonstrated Isl‐1 was enriched at homeobox elements proximal to the TSS of Myc and
Ccnd1, genes encoding the key proliferative factors c‐Myc and CyclinD1. Despite their results, it is
debatable what physiological relevance can be extrapolated from an immortalized cell line with
regards to proliferation. Equally, it is unclear how the in vitro islet phenotypes reflect in vivo
physiology.
In contrast to the rat islet study, a transgenic mouse modestly over‐expressing Isl1 using the
Pdx1 promoter (Pdx1PBIsl1myc) did not detect any increased proliferation of β‐cells (Liu, et al.
2012). Instead, islets isolated from this mouse had increased glucose‐stimulated insulin secretion
compared to controls. Neither Myc nor Ccnd1 were differentially expressed in microarray analysis of
islets from these transgenic mice. Reconciling the results of these two studies is difficult due to the
disparate techniques employed and the relationship between β‐cell function and proliferation
(Prentki and Nolan 2006). Arguably, the transgenic mouse model is the stronger study. However, the
transgenic mouse study has its limitations including 1) the Pdx1 promoter probably drives
expression in δ‐cells (Guz, et al. 1995), 2) the myc‐tag could compromise Isl‐1 functionality, and 3)
interpreting how over‐expression studies with LIM‐HD affect Ldb‐mediated complex formation is
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difficult.
Resolving these discrepancies has been complicated by studies correlating Isl1 expression
with various models of islet dysfunction. For instance, the male Zucker diabetic fatty rat, a model of
non‐insulin dependent diabetes mellitus, stereotypically progresses from a pre‐diabetic state to a
diabetic state (Tokuyama, et al. 1995). In isolated islets from these rats, Isl1 expression is
significantly reduced compared to age‐matched controls at the pre‐diabetic state, where the islets
were reported to secrete more insulin in response to glucose. In the diabetic state, Isl1 expression
was reduced even more and islets at this stage were unresponsive to glucose. In a transgenic mouse
model of Prader‐Willi syndrome (TgPWS), islets are dysfunctional (reduced insulin secretion) and
apoptotic, however, Isl1 expression was increased (Stefan, et al. 2011). Similarly, Isl1 expression
was increased in the islets of Akita mice, a pseudo‐model of type 1 diabetes, where dysfunctional
insulin folding leads to hyperglycemia (Guo, et al. 2011). Lastly, STZ treatment has also been shown
to reduce Isl1 expression in isolated mouse islets (Tonne, et al. 2013). Taken together these results
would suggest that the functional role for Isl‐1 is probably dynamic and context dependent.
Nonetheless, two recent studies coming from the same group have demonstrated a clear
functional role for Isl‐1 as a key intrinsic mediator of extrinsic leptin and kisspeptin signaling on β‐
cells (Chen, et al. 2013; Chen, et al. 2014a). While the negative effect of leptin signaling on β‐cell
insulin synthesis is known, this group demonstrated in mice that leptin signaling reduced Isl‐1
expression. Using an inducible whole animal Isl1 loss‐of‐function model (Isl1mERCremER/F), they
demonstrated that Isl1 depleted islets were refractory to leptin‐mediated insulin reduction. Using
the mouse insulinoma NIT cells, they identified that phospho‐Stat3 negatively regulates Isl1 at a
Stat3 binding site ~1200bp upstream of the TSS. Their more recent study demonstrates that
kisspeptin signaling through the G protein‐coupled receptor 54 negatively regulates both insulin and
Isl‐1 in the NIT cells and the mouse pancreas. Like with leptin, Isl1 depleted islets were refractory to
kisspeptin‐mediated insulin reduction. In further support of Isl‐1 mediating a functional role in
mature β‐cells. Microarray analysis of young islets from 1.5‐month‐old mice compared to old islets
isolated from 14‐ to 19‐month‐old mice revealed distinct transcriptional differences. Isl1 was among
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the ten most down‐regulated transcripts in the aged‐mice (Rankin and Kushner 2010). This finding is
important because aging also correlates with decreased β‐cell functional capacity (Rankin and
Kushner 2010). Despite these findings, the total requirement for Isl‐1 in the mature β‐cell is still
poorly defined.
C. Putative and more established direct transcription targets of Isl‐1.
Isl‐1 has been implicated in regulating a number of genes important to pancreatic endocrine
function. In fact, Isl‐1 was first identified in a screen for factors that bound to a probe containing 4
copies of the region 199bp to 252bp upstream of the rat ins1 TSS (Karlsson, et al. 1990). Notably, the
same probe that was used to originally identify Isl‐1 also pulled down Lmx1a, another LIM‐HD factor
(German, et al. 1992). Lmx1a was also able to generate signal in rat insulin reporter assays
performed in BHK21 cells while Isl‐1 elicited no signal. Further support for Isl‐1 directly regulating
Ins expression has predominantly relied on EMSAs and insulin promoter reporter assays in a variety
of relevant and non‐relevant cell types. Isl‐1 dependent reporter signal has been observed in NIH3T3
cells transfected with a human insulin reporter (hinspluc); in HEK293T, HeLA, and RIN m5F cells
transfected with pFOXLUC; in HEK293T cells transfected with RIP1LUC and pGLhINS; in HepG2
cells transfected with pRINSGFP; and in both HEK293 and NIT cells transfected with pGL3.0
containing the ‐410bp rat insulin region (Ando, et al. 2003; Eeckhoute, et al. 2006; German, et al.
1992; Lin, et al. 2012; Peng, et al. 2005; Zhang, et al. 2009). The only Isl‐1 ChIP that has been
performed has been in HeLA cells transfected with a tagged FLAGIsl1 and the pFOXLUC (Eeckhoute,
et al. 2006). With respect to this assortment of reporter assays, it is unclear whether these
experiments 1) demonstrate that Isl‐1 directly regulates insulin or 2) reconfirm LIM‐HD factors bind
homeobox elements and the region proximal to the insulin enhancer happens to contain a few.
Isl‐1 has also been implicated in directly regulating proglucagon, somatostatin, and islet
amyloid polypeptide (IAPP). Similar to the insulin enhancer screens described above, a proximal
proglucagon promoter probe also bound Isl‐1. CAT reporter assays in InR1‐G9 cells identified three
putative functional homeobox sites between 36 and 95bp upstream of the proglucagon TSS (Wang
and Drucker 1995). Isl‐1 also has been shown to interact with the region 137 to 156bp upstream of

43

the human IAPP TSS using EMSA and reporter assays in InR1‐G9 cells (Wang and Drucker 1996).
With respect to somatostatin, DNase protection assays using crude nuclear extracts of the pancreatic
tumor Tu6 cells demonstrated that Isl‐1 is capable of binding a region 79‐105bp region upstream of
the TSS (Leonard, et al. 1992). A putative homeobox site in that upstream region was necessary for
CAT reporter signal in Tu6 cells. Finally, a role for Isl‐1 in regulating expression of the gene encoding
the Kir6.2 ATP‐sensitive potassium channel, Kcnj11, was implicated in studies of immature rat
enterocytes (Hashimoto, et al. 2005). Exogenous expression of both Pdx1 and Isl1 enabled immature
rat enterocytes to produce and release insulin. Kir6.2, a critical component of the insulin secretion
mechanism, is activated in these cells, but Pdx1 expression was not sufficient to activate Kcnj11
expression. Evidence establishing a more direct role for Isl‐1 directly regulating Kcnj11 was not
explored. Like with insulin expression, the above studies tenuously indicate Isl‐1 may be involved in
directly regulating the expression of these genes.
However, follow‐up investigations with improved techniques need to be performed to
convincingly demonstrate the true direct regulatory targets of Isl1. For instance, ChIP in
combination with mouse models and reporter assays has provided strong evidence that Isl‐1 directly
regulates MafA and Arx (Du, et al. 2009; Liu, et al. 2011). The fact that Isl‐1 directly activates MafA, a
β‐cell maturation factor, and Arx, an α‐cell specification factor, is an intriguing aspect of the potential
requirement for Isl‐1 in the endocrine pancreas. This finding certainly implies that a more intricate
mechanism is at play in the endocrine progenitors. Unfortunately, very little is known regarding what
initially drives the endocrine progenitors towards a distinct mature endocrine cell type.
D. Isl‐1 and putative binding partners in the endocrine pancreas.
Unlike most of the other biological contexts introduced in Parts III and IV, there has been
few attempts to connect the role for Isl‐1 in the endocrine pancreas to the Ldb‐mediated LIM‐HD
factor transcriptional paradigm introduced in Part III. In spite of this, some studies have identified
potential novel binding partners for Isl‐1 in β‐cells. For instance, an interaction was observed
between Isl‐1 and HNF4α2 via respective GST pull‐downs and co‐immunoprecipitatons in HEK 293T
and RIN m5F cells (Eeckhoute, et al. 2006). Protein truncations experiments revealed that the LIM
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and HD domains of Isl‐1 and the AF‐2 module and F‐domains of HNF4α2 were required for optimum
GST pull‐down. Isl‐1 and HNF4α2 were able to synergistically activate proximal enhancer reporters
for Hnf1α, Pparα, and rat Ins1 in cotransfected HeLa and RIN m5F cells. Similarly, co‐
immunoprecipitation using co‐transfected HEK 293T cells demonstrated a putative physical
interaction between Isl‐1 and the pan‐endocrine bHLH factor NeuroD1 (Peng, et al. 2005; Zhang, et
al. 2009). Exogenous expression of Isl‐1 and NeuroD1 was able to synergistically activate insulin
reporters in HEK 293T cells. Furthermore, the Isl‐1 LIM domains and the NeuroD1 bHLH domain
were required for the putative physical interaction. However, an endogenous Isl‐1, NeuroD1
interaction was not observed in βTC3 cells (Hunter, et al. 2013). Despite these conflicting results
from the two groups, a synergistic Isl‐1, NeuroD1 interaction is tantalizing considering the
synergistic relationship between the proneural bHLH factors and the Ldb1, Isl‐1, Lhx3 trimers in
motor neuron differentiation (Lee and Pfaff 2003).
E. Evidence for a functional Ldb1, Isl‐1 complex in the developing pancreas.
Our knowledge regarding the role of Ldb1 in the mouse pancreas has primarily been
established one study (Hunter, et al. 2013). As early as E10.5, Ldb1 is expressed ubiquitously in the
budding pancreatic anlages. At this time point, Ldb1 is notably expressed in all first wave endocrine
cells and all Isl‐1+ cells. As development proceeds, strong expression of Ldb1 remains in all cells of
the islets and the ducts, whereas, acinar expression is still detectable but noticeably reduced.
To specifically determine the requirement for Ldb1 in the endocrine precursor cells, Ldb1L/L; Pax6
Cre mice were generated to. Similar to removing Isl1 in the pancreatic epithelium, ablating Ldb1 in
the pancreatic endocrine progenitors severely compromised the formation of the pancreatic
endocrine compartment. Unlike the previous Isl‐1 study where only the mono‐hormonal ghrelin
population was unaffected, both the pancreatic polypeptide and ghrelin populations were unaffected
in the Ldb1L/L; Pax6Cre mice. As expected, the Ldb1L/L; Pax6Cre mice were hyperglycemic by P18.
Excitingly, both MafA and Arx were significantly down‐regulated in the Ldb1L/L; Pax6Cre mice. They
also demonstrated that Glp1r, Slc2a2, and G6pc2 were down‐regulated in the E18.5 Ldb1L/L; Pax6Cre
mice. To determine whether Ldb1 was enriched at any of these down‐regulated genes, ChIP assays
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were performed. In αTC6 cells, Ldb1 was enriched in the Arx locus at both previously described sites
of Isl‐1 enrichment. Likewise, Ldb1 was enriched at MafA Region 3 in βTC3 cells. Further ChIP
analysis in βTC3 cells identified Isl‐1 and Ldb1 enrichment proximal to the Glp1r TSS. As for Slc2a2,
one upstream area and one downstream area of enrichment were identified. Both Isl‐1 and Ldb1
occupied these novel regulatory elements. Lastly, endogenous Isl‐1 co‐immunoprecipitated with
endogenous Ldb1 and vice versa in βTC3 cells. Whereas, neither endogenous Isl‐1 nor Ldb1 co‐
immunoprecipitated with endogenous Pdx1, NeuroD1, Hnf1α, MafA, or Pax6. While this final
experiment did not reveal any novel Isl‐1 or Ldb1 binding partners, it successfully demonstrated that
Isl‐1 and Ldb1 are robust binding partners in a cell type relevant to β‐cell biology and are most likely
directly interacting in the developing pancreatic endocrine cells.

Closing remarks‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
Given the similar developmental requirements for Isl‐1 and Ldb1 and their functional relationship in
directing terminal differentiation of pancreatic endocrine progenitor populations, the continued
expression of these two factors in the mature endocrine pancreas suggests a requirement in
maintaining the functional properties of the terminally differentiated endocrine cell types. If both of
these factors are required, the functional role established for Ldb1 in other biological contexts would
strongly implicate Ldb1 in directing a dynamic transcriptional mechanism in the endocrine pancreas.
In the remaining document, I utilized targeted, inducible loss‐of‐function mouse models in
combination with high‐throughput cistrome and transcriptrome analysis to interrogate the
functional requirement for Isl‐1 (Chapter 2) and Ldb1 (Chapter 3) specifically in the mature murine
pancreatic β‐cell. The results of my findings are discussed in Chapter 4.
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CHAPTER 2

Islet‐1 is essential for pancreatic β‐cell function
Sections of this chapter have been adapted from the following manuscript: “Islet‐1 is essential for
pancreatic β‐cell function” Benjamin N. Ediger, Aiping Du, Jingxuan Liu, Chad S. Hunter, Erik R. Walp,
Jonathan Schug, Klaus H. Kaestner, Roland Stein, Doris A. Stoffers, and Catherine Lee May. Diabetes. 2014
(Dec); 63(12): 4206‐17.
SUMMARY
Isl-1 is essential for the survival and ensuing differentiation of pancreatic endocrine progenitors. Isl-1
remains expressed in all adult pancreatic endocrine lineages; however, its specific function in the postnatal
pancreas is unclear. Here we determine whether Isl-1 plays a distinct role in the postnatal β-cell by
performing physiological and morphometric analyses of a tamoxifen-inducible, β-cell-specific Isl-1 loss of
function mouse: Isl-1L/L; Pdx1-CreERTm. Ablating Isl-1 in postnatal β-cells reduced glucose tolerance
without significantly reducing β-cell mass or increasing β-cell apoptosis. Rather, islets from Isl-1L/L; Pdx1CreERTm mice showed impaired insulin secretion. To identify direct targets of Isl-1, we integrated highthroughput gene expression and Isl-1 chromatin occupancy using islets from Isl-1L/L; Pdx1-CreERTm mice
and βTC3 insulinoma cells, respectively. Ablating Isl-1 significantly affected the β-cell transcriptome,
including known targets Insulin and MafA as well as novel targets Pdx1 and Slc2a2. Using ChIP-Seq and
luciferase reporter assays we found that Isl-1 directly occupies functional regulatory elements of Pdx1 and
Slc2a2. Thus, Isl-1 is essential for postnatal β-cell function, directly regulates Pdx1 and Slc2a2, and has a
mature β-cell cistrome distinct from that of pancreatic endocrine progenitors.
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INTRODUCTION
Compromised pancreatic β-cell function is a critical factor underlying the onset of diabetes
mellitus (Weir and Bonner-Weir 2004). β-cell functional capacity is regulated by extrinsic signaling
pathways and an intrinsic network of transcription factors (Melloul, et al. 2002; Prentki and Nolan 2006). It
is established that β-cell-specific transcription factors like MafA and Pdx1 are essential components of this
intrinsic transcriptional network (Ahlgren, et al. 1998; Artner, et al. 2010; Babu, et al. 2007; Hang and
Stein 2011). It is less clear how pan‐endocrine transcription factors like Islet‐1 (Isl‐1) affect postnatal
β‐cell function. These factors are expressed in all postnatal pancreatic endocrine cell types, suggesting roles
in general endocrine function, cell-type-specific physiology, or both. The majority of in vivo studies
investigating pan-endocrine transcription factors have conditionally ablated their respective genes prior to
maturation of the pancreatic endocrine compartment (Ashery-Padan, et al. 2004; Du, et al. 2009; Gierl, et
al. 2006; Smith, et al. 2010). As a result, it remains unclear whether these factors have unique functional
roles in the endocrine cell types of the postnatal pancreas. To this point, a recent study demonstrated that
the pan-endocrine factor NeuroD1 is necessary for maintaining functional maturity of mouse β-cells (Gu, et
al. 2010). Given these findings, Isl‐1 and other pan‐endocrine transcription factors may have
functional roles in the postnatal β‐cell distinct from their well‐established developmental roles.
Isl-1 is a Lin11 Isl-11 Mec-3 (LIM)-Homeodomain factor that is essential for the genesis of the
dorsal pancreatic bud at E9.5, survival of Pax6+ endocrine progenitors at E13.5, and the ensuing maturation
of α-, β-, δ-, and pancreatic polypeptide (PP)-cells (Ahlgren, et al. 1997; Du, et al. 2009). Isl-1 was
identified as an insulin enhancer binding protein (Karlsson, et al. 1990) and subsequently shown to directly
interact with NeuroD1 to promote insulin expression (Zhang, et al. 2009). While Isl-1 expression is
conserved in a variety of adult neuroendocrine cell-types (Thor, et al. 1991), many of the identified Isl-1
target genes are associated with pancreatic endocrine function including IAPP, Sst, Gcg, and Kcnj11/Kir6.2
(Du, et al. 2009; Hashimoto, et al. 2005; Hunter, et al. 2013; Leonard, et al. 1992; Wang and Drucker
1995). In adult mouse β-cells, Isl-1 was identified as a key downstream target of Leptin-induced Janus
Kinase (JAK) Signal Transducer and Activator of Transcription 3 (STAT3) signaling (Chen, et al. 2013).
Recently, a transgenic mouse with islet‐specific over‐expression of Isl1 displayed improved β-cell
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function (Liu, et al. 2012). Interest in the mechanisms whereby Isl-1 regulates postnatal β-cell function is
further raised by Type 2 diabetes mellitus (T2DM) linkage and genome-wide association studies that
identified genetic markers in the chromosomal region encompassing the ISL-1 locus (Ehm, et al. 2000;
Shimomura, et al. 2000; Wiltshire, et al. 2001; Yokoi, et al. 2006).
Despite genetic links to T2DM in humans and evidence that Isl-1 regulates key genes associated
with pancreatic function, the in vivo requirement for Isl-1 in postnatal β-cell function has not been
thoroughly investigated. Here, we derived an inducible, β-cell-specific, Isl-1 loss of function mouse. By
combining microarray analysis of Isl-1 deficient islets with Isl-1 ChIP-Seq of βTC3 mouse insulinoma
cells, we constructed the transcriptional network controlled by Isl-1 and identified novel gene targets
directly regulated by Isl-1 in postnatal β-cells.
MATERIALS AND METHODS
Animal models‐
The Isl1L/L and Pdx1CreERTm mouse lines have been previously described (Gu, et al. 2002;
Sun, et al. 2008). Mice were maintained on a mixed C57BL/6; CD1; and Sv129 background. The
morning after birth was considered P0.5. Analysis was restricted to female mice. Tamoxifen (Tm,
Sigma, T5648) at 50µg per gram of mouse bodyweight was administered to 8‐week‐old mice via
three intraperitoneal injections at 24‐hour intervals. Tm was dissolved in 90% Sunflower Seed Oil
(Veh) (v/v), 10% Ethanol (v/v). Unless otherwise stated, analysis of Tm‐treated animals was
performed 2 days after the third injection. The Children’s Hospital of Philadelphia Institutional Use
and Care Committees approved all animal studies.
Immunohistochemical and immunofluorescence analyses‐
Pancreata were dissected; fixed in 4% paraformaldehyde (pH 7.0) for 6h at 25°C; and
embedded in paraffin or Optimal Cutting Temperature (OCT) Compound (Tissue‐Tek, 4583). Sections
were blocked using CAS‐Block (Invitrogen, 008120) and primary antibodies were applied overnight
at 4°C. Primary and secondary antisera information is provided in Table 1 and 2 respectively. For
immunofluorescence, Vectashield mounting medium with DAPI (Vector, H‐1200) was used to
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counter‐stain nuclei and FITC tyramide signal amplification (Perkins‐Elmer NEL741001KT) was used
for Isl‐1 detection. For immunohistochemistry, signal was detected using VECTASTAIN Elite ABC Kit
(Standard) (Vector, PK‐6100) and Peroxidase Substrate Kit DAB (Vector, SK‐4100). Staining was
visualized using a Leica DM6000 B microscope and images were captured using the Leica LAS AF
software and Leica DFC300 FX digital camera.
To quantify staining, slides were digitally scanned using an Aperio Scanscope CS2 or
Metamorph and analyzed using ImageScope software. Isl‐1 ablation efficiency for a hormone+
population was calculated as the percentage of Isl‐1+ nuclei hormone+ cells per total hormone+ cells
using Indica Labs image analysis algorithms. β‐cell mass was calculated by averaging the percentage
of insulin stained tissue area over three sections that were taken at 100µm levels. The fraction of
positive area was then multiplied by the wet mass of the dissected pancreas measured at tissue
harvest. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed as
described (Soleimanpour, et al. 2010) on three sections taken at 40µm taken from pancreata that
were harvested 14 days after the first Tm‐injection. These sections were then co‐stained for insulin.
TUNEL+, insulin+ cells were counted manually and normalized to the number of total β‐cells. The
number of total β‐cells was determined by counting the Nkx6.1+ nuclei on an adjacent section.
RNA isolation, cDNA synthesis, quantitative qPCR, and Microarray‐
Total RNA was extracted from pancreatic islets isolated by the standard Collagenase P
(Roche, 11 213 873 001) protocol (Gupta, et al. 2005) or whole pancreata. Total RNA preparation
and cDNA synthesis were performed as described (Liu, et al. 2012). Quantitative PCR (qPCR)
reactions were performed using SYBR Green JumpStart Taq ReadyMix (Sigma, S4438) and a
Stratagene Mx3005P qPCR system. Fold enrichment of mRNA message was calculated by normalizing
to a reference gene. (See Table 3 for qPCR primers). Control and mutant isolated islet total RNA
extractions were matched for pancreatic endocrine purity as described (Lantz, et al. 2004).
Microarray analysis was performed by the University of Pennsylvania’s Diabetes Research Center
Functional Genomics Core. RNA was labeled with the Agilent Low Input kit and hybridized, using a
dye‐switch design, to the Agilent 4x44k Whole Genome Mouse array. Arrays were hybridized
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overnight and scanned using the Agilent Array Scanner. Data was normalized using
normalizeBetweenArrays from the Limma package followed by SAMR to identify differentially
expressed genes.
Western Blot Analysis‐
Western blots were performed as described (Liu, et al. 2011) using isolated islet whole‐cell
lysates. Pdx1 (Santa Cruz, Pdx1 sc‐14664, 1:200) and α‐Tubulin (Sigma Aldrich, T5168, 1:3000)
antisera were used.
Glucose and Hormone Assays‐
Plasma glucose and insulin were measured as described (Liu, et al. 2012). Random‐fed
plasma glucose was assessed between 10:00 and 11:00AM. Glucose tolerance and glucose‐stimulated
plasma insulin levels were assessed as described (Du, et al. 2009). Isolated islet glucose‐stimulated
insulin secretion (GSIS) was assessed via static incubations using 20‐50 islets of similar size as
described (Liu, et al. 2012). Values for islet insulin content and secretion were normalized to the total
number of islets per incubation. Values for relative islet insulin secretion reflect islet insulin
secretion normalized to islet insulin content. Mouse insulin concentration was determined by ELISA
(Mercodia, 10‐1247). Pancreatic insulin content were measured as described (Du, et al. 2009).
Chromatin Immunoprecipitation (ChIP) and ChIP‐Seq‐
βTC3 insulinoma cells were grown in monolayer (~4x106 cells) or mouse islets were
isolated from CD1 mice. ChIP assays were performed as described (Liu, et al. 2011). Normal mouse
IgG (Santa Cruz, SC2025) and anti‐Isl‐1 (Hybridoma Bank UI, 39.4D5‐C) were used to
immunoprecipitate sheared chromatin. Enrichment was determined using qPCR. Values are
presented as fold enrichment over normal mouse IgG. To account for background, values were
normalized to enrichment at the Pepck locus, which is not bound by Isl‐1. For ChIP primers see Table
3. Whole‐genome ChIP‐Seq analysis was performed using anti‐Isl‐1 (Hybridoma Bank UI, 39.4D5‐C)
to immunoprecipitate.
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Antigen

Raised In

Glucagon

Guinea Pig
(IgG)

Dilution

Embedding

1 to 3000

OCT/Paraffin

Glucagon

Rabbit

1 to 3000

OCT/Paraffin

Glut2

Rabbit

1 to 500

OCT/Paraffin

Insulin

Guinea Pig

1 to 1000

OCT/Paraffin

Insulin

Mouse

1 to 1000

OCT/Paraffin

Isl-1/2 HD

Mouse (IgG)

3-5µg/ml

OCT/Paraffin

Isl-1 HD

Mouse (IgG)

3-5µg/ml

OCT/Paraffin

MafA

Mouse (IgG)

1 to 1000

OCT/Paraffin

Nkx6.1
Somatostatin
(D20)

Mouse (IgG)

1 to 50

OCT/Paraffin

Goat (IgG)

1:250

Paraffin

Table 1. Primary antisera and use conditions.
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Antigen Retrival
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
pressure cooker
Citrate Buffer pH 6.0;
pressure cooker
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
microwave
Citrate Buffer pH 6.0;
microwave

Source
Millipore (4031-01F)
Biodesign (D10221R)
Chemicon (AB1342)
Abcam (AB7842)
ThermoScientific (MS1378)
Hybridoma Bank UI
(39.4D5-S)
Hybridoma Bank UI
(40.2D6-S)
Bethyl (A300-611A)
Hybridoma Bank UI
(F55A12-C)
Santa Cruz (SC-7819)

Raised against

Raised in

Conjugate

Dilution

Source

Mouse IgG

Horse

Biotin

1 to 100

Vector Laboratories (BA-2001)

Guinea Pig IgG

Goat

Biotin

1 to 200

Guinea Pig IgG

Donkey

Cy3

1 to 500

Guinea Pig IgG

Donkey

Cy2

1 to 500

Rabbit IgG

Donkey

Cy3

1 to 500

Vector Laboratories (BA-7000)
Jackson ImmunoResearch (706 165
148)
Jackson ImmunoResearch (706 485
148)
Jackson ImmunoResearch (711 165
152)

Rabbit IgG

Goat

Alexa Fluor 488

1 to 100

Life Technologies (A11008)

Table 2. Secondary antisera and use conditions.
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Name

Forward Primer (5' to 3')

Actin

GCA AGT GCT TCT AGG CGG AC

Reverse Primer (5' to 3')
AAG AAA GGG TGT AAA ACG CAG
C

Use

Hprt

GGC CAG ACT TTG TTG GAT TTG

TGC GCT CAT CTT AGG CTT TGT

qPCR

Amylase

CTT GTG GCA ATG ACT GGG TCT

GCT GAC CAT TGA CCA CAT TCC

qPCR

qPCR

Pc2

AGG CAG CTG GCG TGT TTG

GAA GCT GGT TCC GCT TGG A

qPCR

Insulin1

AGG ACC CAC AAG TGG AAC AAC

GTG CAG CAC TGA TCC ACA ATG

qPCR

Islet-1 (Exon4)

GCG CTC ATG AAG GAG CAA CTA

TGA TGC TGC GTT TCT TGT CC

qPCR

MafA

GAG GAG GTC ATC CGA CTG AAA

GCA CTT CTC GCT CTC CAG AAT

qPCR

Pdx1

CTT AAC CTA GGC GTC GCA CAA

GAA GCT CAG GGC TGT TTT TCC

qPCR

Slc2a2

CCA GCG AAG AGG AAG AAC AC

qPCR

PEPCK

GCA ACT GGG TCT GCA ATT TT
CAA CAG GCA GGG TCA AAG TTT
AG

AGG CCT CAG GCC CCT CTA T

ChIP-qPCR

Pdx1 Area I

TGC CTG CAA AAC CAC TAA GA

GAG GTA CCC TGC CTC CTC TC

ChIP-qPCR

Pdx1 Area II

ATG AAG CGT CGA GAT GGA AG

CAC CCC AGG ATG TTT GCT TA

ChIP-qPCR

Pdx1 Area III

CCG AGG AGA TAG CAT CGA GT

ATC TCT ACA GGC CTG CCT CA

ChIP-qPCR

Pdx1 Area IV

TGC CTC AGT GCC CTT TAC TC

CTA AGA GTG CTC TGG GCT CTG

ChIP-qPCR

Table 3. qPCR Primers.
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Pdx1 Enhancer

HBE Enumeration

dsDNA Oligonucleotide*

Area I

1

TATCAGGACGTCCTGCTAATAAAAGACT

Area I

2

ACTGTCCACAGTATAATTGGTTTACAG

Area I

3

TCTTGCCTAATGGCTGGGTATCTCAGA

Area I

4

GTATCACCCATAATGGATTTAGCCACCT

Area I

5

TATGTAACCATTAGCCAAATCAAAAG

Area II

1

GTGAGAATTTATTTATTTGTTTCCTGTGAAAA

Area II

2

GCAAAAATATTAAATGGGAATAAAT

Area II

3

AATGCATGCAATTAGACCAGAAGTGCTAA

Area II

4

TAGGTAGATTATCTGTGAGGGTCAACA

Area IV

1

CGTTTTTTTCTATTAAGAATGATTTTTTG

Area IV

2

GAATTAAGTGGAATTAGCTAACAAATTATATA

Area IV

3

GCATTAAGGTCCTCGTTAATGGTCC

Area IV

4

TTATTGCCTGCCTTTAATTGTACTTAT

Table 4. EMSA dsDNA oligonucleotides. Red nucleotides indicate a putative homeobox element.

55

RESULTS
L/L

A. Isl‐1 ; Pdx1‐CreER
tamoxifen.

Tm

mice exhibit a baseline level of postnatal Isl‐1 ablation prior to administering

To determine the functional requirement for Isl‐1 in the postnatal β‐cell we derived an
inducible, β‐cell‐specific, Isl1 loss of function mouse model (Isl1L/L; Pdx1CreERTm). Due to a recent
report demonstrating minimal Tamoxifen (Tm)‐independent recombination of the Rosa26 locus in
Pdx1CreERTm transgenic mice (Liu, et al. 2010), we assessed baseline Isl‐1 protein and transcript
levels before administering Tm to 8‐week‐old female Isl1L/L; Pdx1CreERTm mice, hereon notated as
Isl1L/L; Pdx1CreERTm(No Tm). Isl‐1 immunohistochemistry in 8‐week‐old Isl1L/L; Pdx1CreERTm(No Tm)
animals revealed pancreatic islets with multiple Isl‐1‐ nuclei (Figure 6A‐B). When quantified, Isl1L/L;
Pdx1CreERTm(No Tm) mice had a 20% decrease in Isl‐1+ nuclei compared to controls (Figure 6C). Using
qPCR, we determined that the relative Isl1 mRNA transcript was reduced by approximately 38% in
islets isolated from Isl1L/L; Pdx1CreERTm(No Tm) animals; however ,this difference was not statistically
significant (Figure 6D).
Despite a reduction in Isl‐1+ β‐cells, gross pancreatic morphology, islet distribution and
insulin staining were indistinguishable between 8‐week‐old Isl1L/L; Pdx1CreERTm(No Tm) animals and
controls (Figure 6E‐F and data not shown). Importantly, β‐cell mass in 8‐week‐old Isl1L/L; Pdx1
CreERTm(No Tm) pancreata, as reflected by insulin+ staining, was equivalent to that of age‐matched
controls (Figure 6G). Despite maintaining normal β‐cell mass, 8‐week‐old Isl1L/L; Pdx1CreERTm(No Tm)
animals displayed reduced first‐phase insulin secretion in response to acute glucose challenge
(Figure 6H). In 4‐week‐old Isl1L/L; Pdx1CreERTm(No Tm) animals we also observed a moderate
impairment of in vivo GSIS that was associated with mild glucose intolerance (Figure 7A‐B).
Intriguingly, 8‐week‐old Tm‐treated Isl1L/+; Pdx1CreERTm mice did not display glucose tolerance
defects (Figure 7C), suggesting that Isl‐1 is haplosufficient in the β‐cell and any pathophysiological
defects reflect complete Isl1 ablation in the β‐cell. Together, these control experiments demonstrate
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Figure 6. Partial ablation of Isl1 in Isl1L/L; Pdx1CreERTm animals prior to Tmadministration
impairs response to acute glucose challenge. A‐B: Isl‐1 immunohistochemistry of 8‐week‐old
female islets (20x). In B, the dotted line highlights major, contiguous areas of Isl‐1 paucity. C:
Quantification of Islet‐1+ nuclei per pancreatic endocrine area in 8‐week‐old females ± SEM (n=5 per
genotype; p =0.00627). D: Isl1 mRNA levels relative to Actin transcript using total RNA extracts from
8‐week‐old female isolated islets ± SEM (n=5 per genotype). E‐F: Insulin immunohistochemistry of 8‐
week‐old female islets (20x). G: Insulin+ mass of 8‐week‐old females ± SEM (n=5 per genotype). H:
Plasma insulin levels of 8‐week‐old females after intraperitoneal (IP) glucose bolus following a 16‐
hour fast ± SEM (Isl1L/L(no Tm) n=4; Isl1L/L; Pdx1CreERTm(no Tm) n=6). C‐D, G‐H: black bars = Isl1L/L(no
L/L; Pdx1CreERTm
Tm) animals and white bars = Isl1
(no Tm) animals. Values for C‐D, and G are presented
as percent of the Isl1L/L(no Tm) animals. Analysis with two‐way Student’s t‐test: ** = p < 0.01. Analysis
with repeated measures, two‐way ANOVA with Bonferroni post‐test: †† = P < 0.01.
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Figure 7. Minor glucose homeostasis defects in 4weekold Isl1L/L; Pdx1CreERTm(no Tm) animals
but not 8weekold Isl1L/+; Pdx1CreERTmIP(Tm) animals. A: Plasma insulin levels from 4‐week‐old
females without Tm pulse‐chase responding to acute intraperitoneal (IP) glucose bolus after 16‐hour
fast ± SEM (Isl1L/L(no Tm) n=5 and Isl1L/L; Pdx1CreERTm(no Tm) n=6). Black bars = Isl1L/L(no Tm) and
white bars = Isl1L/L; Pdx1CreERTm(no Tm). B: i) Intraperitoneal (IP) glucose tolerance test performed
after 16‐hour fast on 4‐week‐old females ± SEM (Isl1L/L(no Tm) n=5 and Isl1L/L; Pdx1CreERTm(no Tm)
n=6). Solid line = Isl1L/L(no Tm) and dashed line = Isl1L/L; Pdx1CreERTm(no Tm). ii) Integrated area under
intraperitoneal glucose tolerance test curves as percent of Isl1L/L(no Tm) animals ± SEM, p = 0.0278.
Black bars = Isl1L/L(no Tm) and white bars = Isl1L/L; Pdx1CreERTm(no Tm). C: Intraperitoneal (IP) glucose
tolerance test performed after 16‐hour fast on 8‐week‐old females that had received Tm pulse‐chase.
Values are presented as ± SEM (Isl1L/LIP(Tm) n=7 and Isl1L/+; Pdx1CreERTmIP(Tm) n=8. Solid line = Isl
1L/L IP(Tm) and dashed line = Isl1L/+; Pdx1CreERTmIP(Tm). Analysis with two‐way Students’s t‐test: * p <
0.05. Analysis with repeated measures, two‐way ANOVA with Bonferroni post‐test: † = P <0.05, †† = P
< 0.01, and ††† = P < 0.001.
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that the Pdx1CreERTm strain directs limited, Tm‐independent recombination of Isl1 as early as 4
weeks‐of‐age.
Isl‐1 is required for the differentiation and maturation of pancreatic endocrine precursors
(Du, et al. 2009). Conditionally ablating Isl‐1 in the pancreatic epithelium at E13.5 results in mice that
are born without a mature endocrine compartment, are hyperglycemic by P7, and die between 3 and
8 weeks‐of‐age (Du, et al. 2009). Significant Tm‐independent recombination of the Isl1 locus during
embryogenesis could confound analysis of postnatal animals. However, insulin+, Isl‐1‐ cells were
rarely detected by co‐immunofluorescence at P0.5 in pancreata from Isl1L/L(No Tm) or Isl1L/L; Pdx1
CreERTm(No Tm) animals (Figure 8A‐B). We also determined that the level of pancreatic Isl1 transcript
at P0.5 was indistinguishable between Isl1L/L(No Tm) and Isl1L/L; Pdx1CreERTm(No Tm) animals (Figure
8C). At P5, Isl1L/L; Pdx1CreERTm(No Tm) mice displayed normal random‐fed plasma glucose, their
endocrine compartment was present, and gross pancreatic morphology and intra‐islet hormone
distribution appeared normal (Figure 8D‐F). Furthermore, Isl1L/L; Pdx1CreERTm(No Tm) animals
showed no signs of morbidity (data not shown). These observations contrast with previously
characterized mouse models that ablate Isl1 in the developing pancreas (Ahlgren, et al. 1997; Du, et
al. 2009). Altogether, Isl1L/L; Pdx1CreERTm(No Tm) animals have no evidence of significant Tm‐
independent recombination during pancreas development.
B. Ablating Isl‐1 in β‐cells impairs glucose tolerance and insulin secretion without impacting β‐cell mass.
To maximally ablate Isl‐1 in adult β‐cells, we administered Tm to 8‐week‐old Isl1L/L; Pdx1
CreERTm and control Isl1L/L animals, respectively notated Isl1L/L; Pdx1CreERTmIP(Tm) and Isl1L/L IP(Tm)
(Figure 9A). The 5‐day pulse‐chase recombined most remaining β‐cell Isl1 alleles. Isl1 mRNA
expression in islets isolated from Isl1L/L; Pdx1CreERTmIP(Tm) animals was consistently reduced to
approximately 24% of Isl1L/L IP(Tm) levels (Figure 9B). A similar result was observed with Isl‐1
immunostaining; almost all insulin+ cells lacked Isl‐1 expression (Figure 9C‐E). The majority of the
remaining Isl‐1+ nuclei were located at the periphery of the islet where non‐β‐cell endocrine cell
types (i.e. α, δ, ε, and PP‐cells) are typically located in mouse islets (Figure 9C‐F). Accordingly, Isl‐1
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Figure 8. Isl1L/L; Pdx1CreERTm animals are grossly normal birth and do not display Tm
independent recombination of Isl1. A‐B: Insulin (), Isl‐1(‘), and DAPI (‘‘), and merged (‘‘‘)
visualized by coimmunofluorescence in P0.5 pancreata (40x). White arrowheads indicate insulin+,
Isl‐1‐ cells. C: Isl1 mRNA expression relative to Actin using whole RNA extracts from P0.5 whole
pancreata. Values presented as percent of Isl1L/L(no Tm) animals ± SEM (Isl1L/L(no Tm) n=3 and Isl1L/L;
Pdx1CreERTm(no Tm) n=3). D: Random‐fed plasma glucose at P5.0 ± SEM (Isl1L/L(no Tm) n=3 and Isl1L/L;
Pdx1CreERTm(no Tm) n=4). E‐F: Insulin (Ins) and glucagon (Gcg) visualized by coimmunofluorescence
in P5 female pancreata (20x). G‐H: Pancreatic islet coimmunofluorescence for Isl‐1, glucagon (Gcg),
and DAPI at 20x of from female animals after completing tamoxifen induction protocol. C and D:
Black bars = Isl1L/L(no Tm), black and white bars = Isl1L/+; Pdx1CreERTm(no Tm), and white bars = Isl1L/L;
Pdx1CreERTm(no Tm). D: Cohorts contained both male and females.
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was not ablated in α‐ cells; however, Isl‐1 was ablated in a significant percentage of δ‐cells (Figure
9C‐E and 8G‐H), paralleling Pdx1 expression in adult δ‐cells (Guz, et al. 1995).
When compared to Isl1L/LIP(Tm) animals, Isl1L/L; Pdx1CreERTmIP(Tm) mice had increased
random‐fed plasma glucose levels but maintained equivalent random‐fed insulin levels (Figure 9F‐
G). Following fasting, Isl1L/L; Pdx1CreERTmIP(Tm) mice displayed a robust glucose intolerance
phenotype and impaired GSIS response (Figure 9H‐I). In agreement with our findings in the postnatal
Isl1L/L; Pdx1CreERTm(No Tm) animals (Figure 6 and 7), the vehicle‐treated Isl1L/L; Pdx1CreERTmIP(Veh)
animals also displayed a moderate but significant glucose tolerance phenotype (Figure 9H). Within
only five days, maximally ablating Isl1 noticeably exacerbated the Isl1L/L; Pdx1CreERTmIP(Veh) glucose
intolerance and GSIS phenotypes. Unlike 8‐week‐old Isl1L/L;Pdx1CreERTm(No Tm) animals (Figure 6H),
both the first and second phases of the GSIS response were significantly reduced in Isl1L/L; Pdx1
CreERTm IP(Tm) mice (Figure 9I).
Isl‐1 has been implicated as a survival factor in developing cell populations including
pancreatic endocrine progenitors (Du, et al. 2009; Pfaff, et al. 1996; Shi, et al. 2009). A substantial and
rapid reduction in β‐cell mass could account for the physiological defects observed in the Isl1L/L;
Pdx1CreERTm IP(Tm) animals; however, there was no difference in the number of insulin+, TUNEL+ cells
between Isl1L/L; Pdx1CreERTmIP(Tm) and Isl1L/LIP(Tm) animals (Figure 10A‐C) and β‐cell mass was not
significantly reduced (Figure 10D). Taken together, these analyses demonstrate that the glucose
homeostasis defects in Isl1L/L; Pdx1CreERTmIP(Tm) mice are not due to a significant increase in β‐cell
apoptosis or a substantial reduction in β‐cell mass.
We observed a 25% reduction in total pancreatic insulin content in Isl1L/L; Pdx1CreERTmIP(Tm) mice
(Figure 10E). Since Isl‐1 has been demonstrated to regulate Insulin transcription (Karlsson, et al.
1990; Zhang, et al. 2009), we quantified the level of total Insulin mRNA in isolated islets and observed
a 75% reduction in Isl1L/L; Pdx1CreERTmIP(Tm) animals (Figure 10F). Reduced pancreatic insulin
content and islet insulin transcripts without increased apoptosis prompted us to investigate the
functional capacity of islets. To directly evaluate islet function, we isolated islets from Isl1L/L; Pdx1
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Figure 9. Maximal ablation of Isl1 in the adult animal impairs insulin secretion. A: The Tm‐
administration schedule for 8‐weeks‐old female animals. Three sequential intraperitoneal injections
of Tm (50µg per g of mouse bodyweight) or vehicle (SFSO) were administered at 24‐hour intervals
followed by a 2‐day chase. B: Isl1 mRNA expression relative to Actin using total RNA extracts from
isolated islets as percent of Isl1L/LIP(Tm) animals ± SEM (Isl1L/LIP(Tm) n=4 and Isl1L/L; Pdx1
CreERTmIP(Tm) n=4; p = 0.027). C‐D: Coimmunofluorescence for Insulin (Ins), Somatostatin (Sst), Isl‐1,
and DAPI at 20x. D: White arrowheads indicate Isl‐1‐, somatostatin+ cells and white arrows indicate
residual Isl‐1+, insulin+ cells. E: Isl‐1 ablation efficiency in glucagon+ (Gcg+), somatostatin+ (Sst+), and
insulin+ (Ins+) cell populations ± SEM (n=4 per genotype). F: Random‐fed plasma glucose ± SEM (Isl
1L/LIP(Tm) n=5 and Isl1L/L; Pdx1CreERTmIP(Tm) n=8; p = 0.0006 G: Random‐fed plasma insulin ± SEM
(n=8 per genotype). H: i) Intraperitoneal (IP) glucose tolerance test performed after 16‐hour fast.
Solid line with crosshairs = Isl1L/LIP(Tm), dashed line with crosshairs = Isl1L/L; Pdx1CreERTmIP(Tm), and
dash lined with open diamonds = Isl1L/L; Pdx1CreERTmIP(Veh). Values are presented as ± SEM (Isl
1L/LIP(Tm) n=12, Isl1L/L; Pdx1CreERTmIP(Tm) n=10, and Isl1L/L; Pdx1CreERTmIP(Veh) n=7). ii) Integrated
area under IPGTT curves as percent of Isl1L/LIP(Tm) ± SEM. I: Plasma insulin levels in response to acute
intraperitoneal glucose bolus after 16‐hour fast ± SEM (Isl1L/LIP(Tm) n=10 and Isl1L/L; Pdx1
CreERTmIP(Tm) n=8). B, E‐I: black bars = Isl1L/LIP(Tm), black and white bars = Isl1L/L; Pdx1CreERTmIP(Veh),
and white bars = Isl1L/L; Pdx1CreERTmIP(Tm). Analysis with two‐way Student’s t‐test: * = p < 0.05. *** =
p < 0.001Analysis with one‐way ANOVA and Tukey post‐test: # = P <0.05, ### = P <0.001. Analysis
with repeated measures, two‐way ANOVA and Bonferroni post‐test: † = P < 0.05, †† = P < 0.01, ††† = P <
0.001, †††† = P < 0.0001, and NS = No Significance.
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CreERTmIP(Tm) and Isl1L/LIP(Tm) animals and performed static incubation assays with basal and
stimulatory glucose concentrations (2.5mM and 16.0mM). In response to 16.0mM glucose, islets from
Isl1L/L; Pdx1CreERTmIP(Tm) animals secreted less insulin than islets isolated from Isl1L/LIP(Tm) animals
(Figure 10G). However, the insulin content per islet was also significantly depleted in Isl1L/L; Pdx1
CreERTmIP(Tm) animals (Figure 10H). When we normalized islet secretion to islet content, the relative
insulin secretion rate of Isl1L/LIP(Tm) and Isl1L/L; Pdx1CreERTmIP(Tm) islets was similar at both 2.5mM
and 16.0mM glucose (Figure 10I). Overall, our data demonstrate that ablating Isl‐1 in the adult β‐cell
impairs glucose homeostasis and compromises β‐cell insulin secretion primarily as a result of
reduced insulin synthesis.
C. The Isl‐1 cistrome of the mature β‐cell is distinct from that of the developing pancreatic epithelium.
To assess the gene expression changes occurring in Isl‐1 deficient β‐cells, a microarray was
performed using RNA isolated from Isl1L/L; Pdx1CreERTmIP(Tm) and Isl1L/LIP(Tm) islets. This analysis
yielded 714 genes whose expression was significantly altered (Figure 11A, 12A). We used Ingenuity
Systems software to perform gene ontology analysis of this data set. Not surprisingly, genes involved
in ‘glucose tolerance’ and ‘quantity of insulin in the blood’ were significantly enriched among affected
genes (Figure 11B). Interestingly, gene ontology categories associated with aspects of
neuroendocrine function were also distinguished through this analysis, including genes regulating
hormone concentration, intracellular molecular transport, and secretion of molecules (Figure 11B).
To determine if any of these differentially expressed genes were direct targets of Isl‐1 in the mature
β‐cell, we performed Isl‐1 ChIP‐Seq using chromatin extracted from mouse βTC3 insulinoma cells
(βTC3 cells). Meta‐analysis was performed using the microarray and ChIP‐Seq data sets to determine
putative targets of Isl‐1 transcriptional regulation (Figure 11A and 12A). From this analysis, we
identified MafA, a known regulatory target of Isl‐1 (Du, et al. 2009), as well as Slc2a2, the gene
encoding the glucose transporter (Glut2) essential for rodent β‐cell GSIS. We confirmed down‐
regulation of MafA and Slc2a2 at both the transcript and protein levels in islets isolated from Isl1L/L;
Pdx1CreERTmIP(Tm) animals (Figure 11C‐G).
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Figure 10. Ablation of Isl1 reduces pancreatic insulin content but does not increase βcell
apoptosis. A‐B: TUNEL, insulin, and DAPI shown by coimmunofluorescence (40x). TUNEL assays
were performed on pancreatic sections from animals 14 days after first Tm injection. White arrows
point to TUNEL+, insulin+ cells and the white arrowhead points to a TUNEL+; insulin‐ cell. C: Insulin+,
TUNEL+ cells as a percentage of total Nkx6.1+ β‐cells ± SEM (n=4 per genotype). D: Quantification of
insulin+ mass ± SEM (Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1CreERTmIP(Tm) n=8). E: Quantification of
pancreatic insulin content ± SEM (Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1CreERTmIP(Tm) n=8, p = 0.0482). F:
Quantification of insulin mRNA expression relative to Hprt using total RNA extracts from isolated
islets ± SEM (Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1CreERTmIP(Tm) n=8; p = 5.57x10‐3). G: Static incubation
of isolated islets in glucose at 2.5mM and 16.0mM ± SEM (Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1
CreERTmIP(Tm) n=8). Insulin secretion was normalized to islet number. H: Insulin content of islets used
in static incubations ± SEM (Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1CreERTmIP(Tm) n=8; p=0.014). I: Relative
islet insulin secretion where islet insulin secretion was normalized to islet insulin content ±
SEM.Values for D and F are presented as percent of Isl1L/LIP(Tm) animals. C‐I: Black bars = Isl1L/LIP(Tm)
and white bars = Isl1L/L; Pdx1CreERTmIP(Tm). Analysis with two‐way Student’s t‐test: * = p < 0.05, ** =
p < 0.01. Analysis with two‐way ANOVA and Bonferroni post‐test: † = P < 0.05.
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Gene network analysis of our microarray data set utilizing Ingenuity Systems software
yielded a de novo network containing factors essential for β‐cell function (Figure 11H). This gene
network included both MafA and Slc2a2. Pdx1 appeared in this network and was also identified in the
ChIP‐Seq. Intriguingly, Pdx1 was not differentially regulated when Isl1 was conditionally ablated
from the mouse pancreatic epithelium at E13.5 (Du, et al. 2009). In Isl1L/L; Pdx1CreERTmIP(Tm)
animals, however, Pdx1 was by this time significantly down‐regulated at both the transcript and
protein levels (Figure 13A‐B) to a degree commensurate with the pathophysiological reductions in
Pdx1 protein previously described in heterozygous Pdx1 loss of function mutants (Sachdeva, et al.
2009). The cis‐regulatory regions (Areas I, II, III, and IV) for Pdx1 have been well characterized
(Figure 13C) (Gerrish, et al. 2000; Gerrish, et al. 2004). Statistical analysis of the Isl‐1 βTC3 ChIP‐Seq
identified 3 peaks that corresponded to Pdx1 Areas I, II, and, IV (Figure 13C). To confirm the peak‐
calling analysis, we performed Isl‐1 ChIP followed by qPCR using chromatin extracted from βTC3
cells (Figure 13D) and from CD1 mouse islets (Figure 13E).
To determine if Isl‐1 binds to putative Homeodomain Binding Elements (HBEs) (i.e.
TAAT/ATTA‐containing regions) within Pdx1 Areas I, II, and, IV, we performed EMSAs using myc‐
tagged Isl‐1 incubated with a 32P‐radiolabeled MafA‐Region‐3 (Reg3) probe (Figure 13F).
Competition assays were performed using unlabeled oligonucleotide probes representing the
putative Isl‐1 sites within Pdx1 Areas I, II, and, IV. At least one competitor from each tested Pdx1
enhancer successfully reduced Isl‐1 binding to MafA‐Reg3. To determine if the HBEs within the
bound competitors were required for Pdx1 expression, we performed luciferase reporter assays in
βTC3 cells. Vectors containing the wildtype sequences of Pdx1 Areas I, II, or, IV elicited significant
signal above the empty vector (Figure 13G). From the oligonucleotide probes that successfully
competed with the MafA‐Reg3 probe, we selected one oligomer from each Pdx1 enhancer element:
Area I‐4, Area II‐3, and Area IV‐ 4. While we saw no change in signal when mutating HBE Area I‐4, we
did see a significant decrease in signal was found when either HBE Area II‐3 or Area IV‐4 was
mutated (Figure 13G). Lastly, we performed a luciferase reporter assay using the Pdx1‐Area II vector
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Figure 11. Ablating Isl1 significantly alters the pancreatic islet transcriptome. A: Exploded pie
chart representing genes identified by microarray with significant expression differences in Isl1L/L;
Pdx1CreERTmIP(Tm) animals. The red and green partitions represent genes that were, respectively, up‐
regulated and down‐regulated. Partitions outlined with the dashed line represent genes in 100kb
proximity to areas of Isl‐1 enrichment identified by the Isl‐1 βTC3 insulinoma ChIP‐Seq. Values are
presented as a percentage of all 714 significantly mis‐regulated genes identified in the microarray. B:
Selected biological processes that were enriched in gene ontology analysis of the microarray data set.
Values are presented as ‐log10(P value). C: MafA and Slc2a2 mRNA expression relative to Hprt ± SEM
(Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1CreERTmIP(Tm) n=8). Values are normalized by gene to the relative
expression in Isl1L/LIP(Tm) animals. Black bars = Isl1L/LIP(Tm) and white bars = Isl1L/L; Pdx1
CreERTmIP(Tm). Analysis with two‐way Student’s t‐test: * = p < 0.05. D‐E: Visualization of MafA using
immunohistochemistry (20x). F‐G: Visualization of Glut2 and Glucagon (Gcg) using
coimmunofluorescence (20x). H: De novo network generated from gene network analysis of Isl1L/L;
Pdx1CreERTm microarray dataset. Red and green highlights indicate statistically significant up‐ and
down‐regulation, respectively; intensity of highlight corresponds to fold change. White highlight
indicates factors that were not identified by the microarray. Solid arrows and dashed arrows
represent confirmed and suspected regulatory relationships, respectively.
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in HeLa cells. Exogenously over‐expressed Isl‐1 amplified wildtype Pdx1‐Area II vector reporter
activity (Figure 13H). Taken together,these experiments suggest that Isl‐1 directly regulates the adult
β‐cell expression of Pdx1 through at least Areas II and IV.
D. Isl‐1 directly regulates Slc2a2A through the downstream Re2 enhancer element.
Although previous work using βTC3 cells demonstrated that Isl‐1 was enriched at two
putative Slc2a2 cis‐regulatory elements (Re1 and Re2) (Figure 14A), Slc2a2 expression was unaltered
in Isl1L/L; Pdx1Cre mice, a model that ablated Isl1 in the pancreatic epithelium at E13.5 (Du, et al.
2009; Hunter, et al. 2013). Thus, Slc2a2 represents another key β‐cell gene that is putatively
regulated by Isl‐1 only in the mature β‐cell. To further determine whether Re1 and Re2 are involved
in mediating Slc2a2 expression, we used a luciferase reporter in βTC3 cells. Luciferase activity in
βTC3 cells was only observed using the reporter plasmid containing Re2. Furthermore, Isl‐1 over‐
expression was sufficient to increase the Re2‐containing vector reporter activity (Figure 14B). The
Slc2a2‐Re2 sequence is highly conserved when compared to rat and human genomes (Figure 14C).
Within Re2, five putative HBEs were identified (Figure 14C) and mutational analysis of Slc2a2‐Re2
sites 1, 2, and 5 reduced the reporter activity whereas similar treatment to site 4 enhanced activity
(Figure 14D). Overall, this analysis strongly supports the notion that Isl‐1 directly regulates Slc2a2
through cis‐regulatory elements in Slc2a2‐Re2.
Discussion
To determine the requirement for Isl‐1 in the postnatal β‐cell, we utilized a tamoxifen‐
inducible, β‐cell‐specific, loss of function mouse model. Ablating Isl‐1 in the postnatal β‐cell impaired
glucose tolerance and GSIS without affecting β‐cell survival. Moreover, loss of Isl‐1 compromised β‐
cell insulin secretion and altered the islet transcriptome. By combining microarray and ChIP‐Seq
analysis, we constructed a β‐cell transcriptional network for Isl‐1. Meta‐analysis of this network
identified new direct transcriptional targets of Isl‐1 including Slc2a2, the glucose transporter that
mediates a critical upstream step in mouse β‐cell glucose stimulated insulin secretion, and Pdx1, an
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Figure 12. Heatmap of isolated islet microarray replicates indicating putative Isl1 regulatory
targets identified in the βTC3 ChIPSeq. A: Microarray heatmap representing the fold‐change value
of gene expression comparing isolated islets from Isl1L/L; Pdx1CreERTmIP(Tm) animals to islets from
Isl1L/LIP(Tm) islets. Each column corresponds to biological replicates of purity matched total RNA
extractions. Red and green correspond to increased and decreased expression respectively. On the Y‐
axis are the gene names of potential Isl‐1 regulatory targets that were identified by consensus
regions between two ChIP‐Seq replicates.
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essential transcriptional regulator of postnatal β‐cell function. Remarkably, both Slc2a2 and Pdx1 are
regulated by Isl‐1 in the postnatal β‐cell but not in pancreatic endocrine progenitors.
This study also exposed a limitation of the Pdx1CreERTm line. When crossed to RosalacZ
mice, the Pdx1CreERTm line displayed negligible Tm‐independent recombination (Liu, et al. 2010). In
our Isl1L/L; Pdx1CreERTm mice, however, we encountered a significantly greater degree of Tm‐
independent Isl1 recombination. We demonstrated that this occurred postnatally and that our
analysis was not confounded by developmental deletion of Isl‐1. Notably, 8‐week‐old Isl1L/+; Pdx1
CreERTm(IP Tm) animals displayed no phenotype. Therefore, the phenotype in the Isl1L/L; Pdx1
CreERTm(No Tm) mice reflected the accumulation of β‐cells with two recombined Isl1 alleles. Overall,
increased surveillance for postnatal Tm‐independent recombination with appropriate controls is
warranted when employing the Pdx1CreERTm line.
Previous in vitro studies have identified that Isl‐1 regulates genes associated with pancreatic
endocrine function but have not provided definitive insights into the requirement for Isl‐1 in the
adult endocrine pancreas (Hashimoto, et al. 2005; Leonard, et al. 1992; Wang and Drucker 1995;
Wang and Drucker 1996). Following postnatal deletion of Isl‐1, we observed decreased β‐cell
function without increased apoptosis. In line with these observations, transgenic mice over‐
expressing Isl‐1 in the endocrine pancreas increased β‐cell function without enhanced β‐cell
proliferation (Liu, et al. 2012). Considering the established relationship between Isl‐1 and insulin
transcription (Chen, et al. 2013; Karlsson, et al. 1990; Zhang, et al. 2009), these in vivo findings
further demonstrate that Isl‐1 is essential for β‐cell functional capacity. Nonetheless, our findings are
at odds with the observation that over‐expression and knockdown of Isl1 in rat islets ex vivo
enhanced β‐cell proliferation and apoptosis, respectively (Guo, et al. 2011). We speculate that the
apoptosis/proliferation phenotypes observed in rat islets are secondary to Isl‐1 regulating β‐cell
function or that the insults of islet isolation and culture may have unveiled a prosurvival function of
Isl‐1 in β‐cells.
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Figure 13. Islet1 directly regulates Pdx1. A: i) Western blot for Pdx1 and α‐Tubulin using protein
lysates of isolated islets. ii) Quantification of Pdx1 normalized to α‐Tubulin ± SEM (n=3 per genotype;
p = 0.01222). B: Relative mRNA expression of Pdx1 to Hprt ± SEM (Isl1L/LIP(Tm) n=6 and Isl1L/L; Pdx1
CreERTmIP(Tm) n=8). Values are normalized to relative expression in Isl1L/L IP(Tm) animals. A ii) and B:
Black bars = Isl1L/LIP(Tm) and white bars = Isl1L/L; Pdx1CreERTmIP(Tm). C: A scaled schematic of the
Pdx1 genomic locus. The known Pdx1 regulatory domains Areas I, II, and, III are represented by white
boxes and Area IV by a black box. The Pdx1 transcription start site (TSS) is indicated by the arrow.
UCSC mouse genome browser of the Pdx1 genomic locus annotated with βTC3 chromatin Isl‐1 ChIP‐
Seq and Vertebrate Multiz Alignment in black; the Pdx1 TSS is underlined. Arrows highlight Isl‐1
enrichment at the four described Pdx1 regulatory elements. D: Isl‐1 ChIP using chromatin extracted
from βTC3 cells ± SEM (n=3). E: Isl‐1 ChIP using chromatin extracted from isolated islets (n=1).
Values in both D and E are presented as fold enrichment over Normal Mouse IgG after first
normalizing to the inactive Pepck locus. F: Electrophoretic mobility shift assay using recombinant
Myc‐tagged Isl‐1 protein. The Isl‐1 binding site at MafA‐Reg3 was used as the radiolabeled probe.
Control competition assays were performed with wildtype and mutated MafA‐Reg3 oligo probes.
Competition assays were also performed using oligonucleotide probes representing putative HBEs in
Pdx1‐Area I, II, and IV. Competitors were added at 100x free probe concentration. Supershifts using
both antibodies against Isl‐1 and Myc were observed. A protein:DNA complex was not observed in
the absence of recombinant Isl‐1‐Myc protein. Bold, italicized enumeration corresponds to selected
HBEs for mutational analysis. G: Luciferase assay for putative Isl‐1 HBEs in Pdx1 enhancers using
βTC3 cells. Values are normalized to empty pGL4.27 vector ± SEM (n=3). The black and white bar
represents empty vector. Vector inserts correspond to the selected HBEs in F. The black bars
represent wildtype sequences. The white bars represent mutational ablation of the putative HBE. H:
Luciferase assay for Pdx1 Area II in HeLa cells. Values are normalized to empty pGL4.27 vector ± SEM
(n=3). White and black bars represent cells transfected using pGL4.27 with and without the Pdx1
Area II insert, respectively. Analysis with two‐way Student’s t‐test: * = p < 0.05. Analysis with one‐
way ANOVA and Tukey post‐test: ### = P <0.001. Analysis with two‐way ANOVA and Bonferroni post‐
test: † = P <0.05, ††† P <0.001.
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Figure 14. Islet1 directly regulates Slc2a2. A: A schematic of the genomic Slc2a2 locus. White
boxes represent putative enhancer elements, Re1 and Re2. Re1 and Re2 are approximately 9kb
upstream and 39kb downstream of the Slc2a2 transcription start site (TSS), respectively. B:
Luciferase assay for putative Slc2a2 enhancer elements using βTC3 cells. Values are normalized to
empty pGL4.27 vector ± SEM (n=3). Black and white bars represent βTC3 cells with and without
over‐expression of Isl‐1‐Myc, respectively. C: Slc2a2‐Re2 sequence alignment for mouse, rat, and
human. Base pairs that differ from the mouse sequence are underlined. Putative HBEs are bolded and
italicized in the mouse sequence and bolded in both rat and human sequence. The five putative HBEs
are enumerated 1‐5. D: Luciferase assay for putative Isl‐1 binding sites in Slc2a2‐Re2 using βTC3
cells. Values are normalized to pGL4.27 vector containing wildtype (WT) Slc2a2‐Re2 ± SEM (n=3).
The black bar represents WT Slc2a2‐Re2. The white bars represent vectors containing Slc2a2‐Re2
with mutational ablation of the respective putative HBE. Analysis with one‐way ANOVA and Tukey
post‐test: ### = P < 0.001. Analysis with two‐way ANOVA and Bonferroni post‐test: †††† = P < 0.0001.
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It is becoming increasingly evident that specified β‐cells undergo a final period of maturation
before attaining complete physiological capacity (Pan and Wright 2011). Our findings suggest that
the requirement for Isl‐1 in postnatal versus developing β‐cells is distinct. While ablating Isl1 in
endocrine progenitors had no affect on fetal levels of Slc2a2 and Pdx1 (Du, et al. 2009; Hunter, et al.
2013), we demonstrate here that ablating Isl1 in postnatal β‐cells reduces expression of both genes.
Distinct roles for a transcription factor in developing versus postnatal β‐cells have been observed for
MafA and NeuroD1 (Artner, et al. 2010; Zhang, et al. 2005). Similarly, Arx is necessary for the
establishment of α‐cell fate during pancreas development, but is dispensable for maintaining α‐cell
fate even though its expression is maintained (Wilcox, et al. 2013). Determining what regulates these
shifts in transcriptional influence will be essential in defining immature versus mature pancreatic
endocrine cells.
Observing that Isl‐1 directly regulates MafA and Pdx1 in the postnatal β‐cells is also
noteworthy when considering the plasticity of the adult pancreatic endocrine compartment (Pan and
Wright 2011). Multiple studies have demonstrated that misexpression of MafA and Pdx1 is sufficient
to drive expression of β‐cell‐specific genes in non‐β‐cells (Hang and Stein 2011; Nomura, et al. 2006;
Zhou, et al. 2008). Isl‐1 also directly regulates Arx, a transcription factor necessary for directing α‐cell
fate (Liu, et al. 2011; Wilcox, et al. 2013). Since α‐, β‐, δ‐, and PP‐cells appear to arise from a common
progenitor pool (Pan and Wright 2011), ubiquitous expression of Isl‐1 in the adult endocrine
pancreas suggests that regulatory mechanisms exist to restrict Isl‐1 transcriptional targets among
the pancreatic endocrine lineages. It is well established that LIM‐HD transcription factors drive cell‐
fate decisions in progenitor populations by activating distinct expression profiles (Song, et al. 2009).
This is accomplished by LIM Domain Binding (Ldb) adaptor proteins nucleating combinatoric,
multimeric LIM‐HD complexes (Bhati, et al. 2008; Matthews and Visvader 2003). The building blocks
for this mechanism are still expressed in the adult endocrine pancreas. Ldb1, like Isl‐1, is
ubiquitously expressed in the adult endocrine pancreas, and other members of the LIM‐HD family of
transcription factors in addition to Isl‐1 are enriched in islets as well, including Lhx1 and Mnx1/Hb9
(Harrison, et al. 1999; Hunter, et al. 2013). The epigenetic landscapes of the pancreatic endocrine
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cell‐types may also play role in restricting Isl‐1 regulatory targets. For instance, Dnmt1‐mediated
DNA methylation is required to maintain β‐cell identity in part by repressing Arx transcription
(Dhawan, et al. 2011). Similarly, mapping histone epigenetic modifications has identified variable
enrichment of activating and repressive marks at cell‐type‐specific genes between human α‐ and β‐
cells (Bramswig, et al. 2013). Moving forward, it will be of great interest to determine which of these
mechanisms contribute to directing the Isl‐1 cistrome in the distinct endocrine lineages that populate
the adult pancreas.
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CHAPTER 3
Ldb1 is required for maintaining mature βcell identity through a robust functional
relationship with established developmental partner Isl1.
SUMMARY
The distinct functional paradigms for the LIM‐domain‐binding protein 1 (Ldb1) in progenitor and
stem‐cell populations throughout the developing organism are critical to embryogenesis. However,
Ldb1 has no inherent DNA‐binding capacity nor enzymatic activity. Instead, through self‐association
and binding the tandem LIM‐domains contained exclusively in the nuclear LIM‐Homeodomain (LIM‐
HD) and LIM‐Only (LMO) families of factors, Ldb1 nucleates multimeric transcription factor
complexes that drive developmental decisions. Mechanistically, these Ldb1‐mediated complexes are
crucial transcriptional scaffolds that can direct promoter‐enhancer looping as well as the nuclear
localization of chromatin. To date the role for Ldb1 has been almost exclusively investigated in the
context of progenitor or stem‐cell populations. We demonstrate, for the first time, the requirement
for Ldb1 in a terminally differentiated cell type, the pancreatic β‐cell, and simultaneously interrogate
a functional relationship with one of its most established partners the LIM‐HD factor Islet‐1 (Isl‐1).
Through the parallel physiological, transcriptional, and cistromic analysis of Ldb1 and Isl‐1 in the
mature β‐cell we demonstrate that Ldb1‐medated complexes are essential for maintaining mature β‐
cell function as well as the terminal differentiation status of the mature β‐cell. Ablating either Ldb1 or
Isl1 extinguished Ins1/2, MafA, and Pdx1 expression while increasing Neurog3 expression.
Furthermore, our high‐throughput cistromic analysis established Isl‐1 as the primary Ldb1 binding
partner in pancreatic islets. By comparing our islet‐based cistromic data with previously generated
Isl‐1 cistromes from βTC‐3 and αTC‐6 cells, we provide evidence indicating that an Ldb1, Isl‐1
complex functions more broadly in maintaining the terminally differentiated state of each endocrine
cell‐type comprising the mature pancreas.
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INTRODUCTION
The pancreatic β‐cell is unique in its ability to synthesize and secrete insulin, the hormone
required for directing peripheral tissue glucose uptake, storage, and metabolism. Diabetes is a
disease marked by either the autoimmune depletion of pancreatic β‐cells (Type 1 Diabetes) or the
functional exhaustion of the pancreatic β‐cells (Type 2 Diabetes) (Rutter, et al. 2015; van Belle, et al.
2011). Extensive investigation into the mechanisms that direct pancreatic β‐cell fate in the
developing mouse, has translated into significant strides in successfully differentiating human
induced pluripotent stem cells into functional, transplantable β‐cells (Cogger and Nostro 2014). A
well characterized component of pancreatic organogenesis is the transcription factor network that
dictates cell‐fate decisions as pancreas development progresses from the Pdx1+, Ptf1a+ pre‐patterned
foregut to the mature cell types the comprise the adult pancreatic exocrine and endocrine glands
(Pan and Wright 2011).
The pancreatic β‐cell is one of five mature endocrine cell types that populate the pancreatic
islet structures that are scattered throughout the adult pancreas (Ben‐Othman, et al. 2013). While all
five cell‐types arise from the same progenitor population (Gu, et al. 2010), activation of a handful of
cell‐type‐specific and semi‐specific transcription factors direct specification and the terminal
maturation processes of the respective endocrine cell types. With respect to murine β‐cell identity,
Pdx1 and Pax4 are critical for specifying β‐cell‐fate and factors such as FoxA2 and MafA reinforce the
functional maturation of the β‐cells (Gannon, et al. 2008; Gao, et al. 2010; Prado, et al. 2004; Zhang, et
al. 2005). In contrast to the cell‐type‐specific factors that direct pancreatic endocrine differentiation,
four key transcription factors are activated shortly after specification of the endocrine progenitor
and remain expressed in all the cell‐types that populate adult endocrine pancreas. The four pan‐
endocrine factors are the bHLH factor NeuroD1, the LIM‐Homeodomain (LIM‐HD) factor Islet‐1 (Isl‐
1), Insulinoma‐associated antigen 1 (Insm1), and Regulatory X‐box binding 6 (Rfx6) (Gradwohl, et al.
2000; Huang, et al. 2000; Mellitzer, et al. 2006; Soyer, et al. 2009). All four of these factors are
activated downstream of Neurogenin3 (Neurog3), the bHLH transcription factor that specifies
pancreatic endocrine fate, and individual loss of function studies for each factor results in arrested
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pancreatic endocrine development (Du, et al. 2009; Gierl, et al. 2006; Mellitzer, et al. 2006; Smith, et
al. 2010; Soyer, et al. 2009). Recently, inducible, β‐cell‐specific, loss‐of‐function mouse models have
demonstrated that NeuroD1, Isl‐1, and Rfx6 are all required for maintaining the functional maturity
of pancreatic β‐cells (Ediger, et al. 2014; Gu, et al. 2010; Piccand, et al. 2014).
LIM‐domain‐binding protein 1 (Ldb1) is another pan‐endocrine factor that is required for
the development of the pancreatic endocrine progenitors and remains enriched in all the mature cell‐
types that comprise the adult endocrine pancreas (Hunter, et al. 2013). Unlike the four pan‐
endocrine transcription factors mentioned above, Ldb1 has no inherent DNA‐binding activity (Jurata,
et al. 1998). Ldb1 also does not have any inherent enzymatic activity. Instead, Ldb1 interacts with
LIM‐HD or LIM‐only (LMO) factors through a LIM‐interaction domain (Ldb1LID) and self‐associates
into dimers through a self‐association domain (Ldb1SAD) (Agulnick, et al. 1996; Bach, et al. 1997;
Jurata and Gill 1997; Jurata, et al. 1996). Ldb1 plays a conserved role in directing cell‐fate decisions
predominant through two transcriptional paradigms that can be distinguished by whether Ldb1 is
directly interacting with a LIM‐HD or LMO factor (Love, et al. 2013; Matthews and Visvader 2003).
The LMO‐paradigm involves a pentameric complex where Ldb1 binds a LMO factor that is itself
bridging an E‐box heterodimer and a Gata factor (Osada, et al. 1995; Visvader, et al. 1997). This
transcriptional paradigm is implemented in hematopoiesis and erythropoiesis (Li, et al. 2010a; Li, et
al. 2010b). The LIM‐HD‐paradigm involves Ldb1 nucleating multimeric (tetrameric and hexameric)
LIM‐HD complexes to drive cell‐fate decisions and terminal maturation (Hunter and Rhodes 2005).
In determining V2 interneuron and somatic motor neuron fate, Ldb1‐mediated LIM‐HD complexes
drive V2 interneuron fate through a Lhx3:Ldb1:Ldb1:Lhx3 tetramer and motor neuron fate through
a Lhx3:Isl‐1:Ldb1:Ldb1:Isl‐1:Lhx3 hexamer (Thaler, et al. 2002).
Overall, the role for Ldb1 has been well characterized in development contexts, however, the
role for Ldb1 in mature terminally differentiated cell‐types, like the pancreatic β‐cell, has yet to be
investigated. While the functional requirement for Isl‐1 in mature β‐cells also implies Ldb1 is
important, other potential Ldb1 binding partners are also expressed in mature pancreatic islets
including the β‐cell‐specific LIM‐HD factor Mnx1 (Harrison, et al. 1999; Hunter, et al. 2013; Li, et al.
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1999). To determine the functional requirement for Ldb1 with respect to Isl‐1 in terminally
differentiated β‐cells we generated inducible, β‐cell‐specific loss‐function mice for each factor and
analyzed them in parallel. To determine the extent of the functional relationship between Ldb1 and
Isl‐1 in the mature β‐cell, we performed RNA‐Seq using enriched β‐cell populations from our
respective loss‐of‐function models and combined that data set with cistromic analysis of Ldb1 and
Isl‐1 in the primary mouse islets.
Collectively, Ldb1 was required for maintaining the mature identity of pancreatic β‐cells.
Upon ablating Ldb1 or Isl1, the expression of MafA and Pdx1 were reduced and simultaneously the
expression of Neurog3 was activated. Mechanistically, our high‐throughput analysis indicates that
Ldb1 and Isl‐1 function as a complex in both repressive and activating roles. Moreover, meta‐analysis
of the islet‐based ChIP‐Seqs with Isl‐1 ChIP‐Seqs performed in βTC‐3 and αTC‐6 cells, indicated that
the putative Ldb1, Isl‐1 complex is enriched at distinct cis‐regulatory elements between β‐cells and
α‐cells.
MATERIALS AND METHODS
Animal Models‐
For all experiments herein male mice were used and all genetic strains (Ldb1L, Isl1L, MIP
CreERTm, and Rosa26LsLeYFP) have been previous described (Srinivas, et al. 2001; Sun, et al. 2008;
Tamarina, et al. 2014; Wicksteed, et al. 2010; Zhao, et al. 2007). Mice were maintained on a mixed
SV/129, C57Bl/6 background. When the Ldb1L/L; MIPCreERTm, Rosa26LsLeYFP/ LsLeYFP; MIPCreERTm,
Ldb1L/L; Rosa26LsLeYFP/ LsLeYFP; MIPCreERTm, and Ldb1L/L were used in an experiment, Tamoxifen
(Sigma, T5648) was administered to them at 150µg per gram mouse bodyweight in 5 doses at 24‐
hour intervals starting at P28. Doses were provided via oral gavage following brief nasal
anaesthetization of mice with Isoflurane. Following each gavage, mice were monitored until
anaesthetization had fully dissipated. For these strains, an additional round of 5 doses of Tamoxifen
was provided starting the following week. Unless otherwise indicated, the analysis and dissections of
these animals occurred at P56. To account for differences in allele ablation efficiency, the Tamoxifen
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administration schedule was adjusted for the Isl1L/L; Rosa26LsLeYFP/ LsLeYFP; MIPCreERTm, Isl1L/L; MIP
CreERTm, and Isl1L/L mice. These mice only received one round of 5 doses of Tamoxifen at 100µg per
gram mouse bodyweight. The Isl1L/L; MIPCreERTm, and Isl1L/L mice were analyzed and dissected at
P49, whereas, islets were isolated from Isl1L/L; Rosa26LsLeYFP/ LsLeYFP; MIPCreERTm at P42 for the RNA‐
Seq. In all cases, Tamoxifen was dissolved at 50mg/ml in a 90% Sunflower Seed Oil v/v, 10% EtOH
v/v solution. Primary pancreatic islets for the ChIP‐Seq were isolated from 8‐ to 10‐week‐old, male
CD1 mice. The Children’s Hospital of Philadelphia’s as well as the University of Pennsylvania’s
Institutional Use and Care Committees approved all of the experimental methods involving animals.
Immunohistochemical (IHC) and immunofluorescence (IF) analysis‐
Pancreata were quickly dissected; fixed in 10% formalin solution, neutral buffered pH 7.0
(Sigma‐Aldrich, HT501128) for 17h at 4°C; and embedded in paraffin. Following sectioning, tissue
was blocked using CAS‐Block (Invitrogen, 008120) and primary antibodies were applied overnight at
4°C. Signal was detected using multiple methods. Fluorophore‐conjugated and biotinylated
secondary antibodies were applied for 60m and 40m at 37°C, respectively. In the case of IF,
Vectashield mounting medium for fluorescence with DAPI (Vector, H‐1200) was used to counterstain
nuclei. For IHC, signal was detected using VECTASTAIN Elite ABC Kit (Standard) (Vector, PK‐6100)
with Peroxidase Substrate Kit DAB (Vector, SK‐4100) and VECTASTAIN ABC‐AP Kit (Vector, AK‐
5000) with BCIP/NBT AP Substrate Kit (Vector, SK‐5400), and nuclei were counterstained with
haematoxylin or nuclear fast red. In the cases where antigens were difficult to detect with traditional
IF, Tyramide Signal Amplification (TSA) was used. HRP‐conjugated secondaries were applied for 40m
at 37°C and then the TSA Plus Cyanine 3 System (PerkinElmer, NEL744001KT) was used at 1:250 for
a 10m incubation. When employing TSA, no other primaries were applied until TSA signal had been
developed and slides were re‐blocked. In the case of Neurog3 IF, dissected pancreata were only fixed
for 2hr at 4°C, cyroprotected overnight in 30% sucrose v/v 1xPBS, and embedded in Optimal Cutting
Temperature (OCT) Compound (Tissue‐Tek, 4583). Heat‐induced epitope retrieval using a NaCitrate
Buffer (pH 6.0) and pressure cooker was performed for all IHC and IF.

81

Antibodies used with IHC: Rabbit anti‐chromograninA, Guinea Pig anti‐insulin, Rabbit anti‐
glucagon, and mouse anti‐Islet‐1. Antibodies used with TSA: Rabbit anti‐Ldb1, Mouse anti‐Nkx6.1,
Rabbit anti‐gastrin, Mouse anti‐MafA. Antibodies used with IF: Rabbit anti‐chromograninA, Guinea
Pig anti‐insulin, Goat anti‐somatostatin, Rabbit anti‐glucagon, Guinea Pig anti‐glucagon, Rabbit anti‐
Slc2a2, Goat anti‐Pdx1, Guinea Pig anti Neurog3, Goat anti‐GFP, Chicken anti‐GFP.
Signal was visualized using either a Lieca DM6000 B or Nikon Eclipse E6000 microscope and
images were captured using Lieca LAS AF software and Lieca DFC300 FX digital camera or Aperio
Scanscope CS2 software and a Qimaging qclick digital camera. To quantify IHC staining, slides were
digitally scanned using an Aperio Scanscope CS2 and analyzed using Aperio’s ImageScope. To
quantify IF staining, the Metamorph software suite was used to scan and analyze. Antigen+ cell mass
(Insulin+ and ChgA+) was calculated as antigen+ area over total pancreatic tissue area multiplied by
pancreatic mass. Pancreatic mass was determined immediately after dissection. Islet area was an
average of ChgA+ islet size over a single tissue section. Islet density is the reciprocal of the number of
islets per tissue section pancreatic tissue area. Glucagon+ and somatostatin+ cell frequency
normalized the number of each respective cell type to the total ChgA+ area of each tissue section.
Glucose and Insulin Metabolic Assays‐
Plasma insulin and glucose measurements were taken as described previously (Ediger, et al.
2014). Insulin concentration was measured using Ultrasensitive Mouse Insulin ELISA (CrystalChem,
90080). For consistency, random‐fed plasma glucose was assessed between 10:00 AM and 11:00 AM.
Animal glucose tolerance and glucose stimulated plasma insulin levels were assessed as described
previously (Ediger, et al. 2014). Insulin tolerance of animals was measured following a 6‐hour fast.
Insulin, Novolin R (Novo Nordisk, 183311) was administered via intraperitoneal bolus at 0.75U/kg
mouse bodyweight. Total pancreatic insulin and glucagon content was measured as described
previously (Ediger, et al. 2014).
Static Incubation of Isolated Islets‐
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Islets were isolated as described previously (Ediger, et al. 2014). Isolated islets were
cultured for 2 days with islet culture media (RPMI 1640, 10% FBS v/v, 1x penicillin/streptomycin, 1x
glutamine, 5mM HEPES, and 5mM glucose) at 37°C and 5% CO2. Islets were washed with Krebs
Buffer and allowed to equilibrate for 2h in Krebs buffer. Islets were then incubated in batch at 2.0,
5.0, 8.0, 16.0 mM Glucose ± 50nm Exendin‐4 (Ex‐4). Each individual condition was performed in
triplicates consisting of 5 similarly sized islets. Another set of islets was incubated with 0.0, 1.0, 5.0
10.0 mM α‐ketoisocaproate (KIC) all in triplicates consisting of 5 islets for every condition. Following
a 30‐minute incubation period, the culture media was collected and insulin levels were measured as
described above.
Cell sorting, RNA isolation, library synthesis construction and sequencing‐
Islets from induced lineage‐tracing animals were isolated as described (Ediger, et al. 2014).
Islets were then dispersed into single cells using 0.05 Trypsin‐EDTA (Gibco, 25300‐054). MoFlo
Astrios was used to enrich for single, eYFP+ cells. Cells were sorted directly into Trizol (Ambion,
15596018). Each sort reflected an individual mouse. When extracting RNA, sorts with low cell
recovery were pooled in entirety so that a minimum of 25,000‐30,000 cells was achieved; 25,000‐
30,000 cells was an empirically determined threshold that generated sufficient RNA for downstream
applications. Total RNA was extracted using RNAeasy Micro columns (Qiagen, 74004) then DNAse‐
treated with TURBO DNA‐free Kit (Ambion, AM1907) and then cleaned with another RNAeasy Micro
column. Total RNA‐Seq libraries were generated using ScriptSeq Complete Gold – Low Input
(Illumina, SCL6G) and multiplexed using with Illumina barcodes. Sequencing and alignment were
performed by the University of Pennsylvania’s Diabetes Research Center Functional Genomics Core.
Clustering analysis was performed by Hee‐Woong Lim.
Chromatin Immunoprecipitation‐Sequence (ChIP‐Seq)‐
Primary islets were isolated from CD1 mice as previously described (Ediger, et al. 2014).
Immediately following isolation and hand‐picking, islets were cross‐linked with 1.1% formaldehyde
v/v PBS (Fisher Scientific, F79). The nuclear‐lysate chromatin preparation and ChIP were performed
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as described previously (Ediger, et al. 2014). For the Ldb1 ChIP, the CLIM‐2 Antibody (N‐18)‐X (Santa
Cruz, sc11198 X) was used. For the Isl‐1 ChIP, the Anti‐Islet 1 antibody [EP4182] (Abcam, ab109517)
was used. ChIP‐Seq libaries were prepared using NEBNext Ultra DNA Libray Prep Kit for Illumina
(NEB, E7370S) and their low input ChIP‐Seq protocol. Sequencing and alignment was performed by
the University of Pennsylvania’s Diabetes Research Center Functional Genomics Core. Quality control,
peak‐calling, de novo motif analysis was performed by Hee‐Woong Lim.
RESULTS
A. Specifically ablating Ldb1 in mature β‐cells impaired glucose homeostasis.
To determine the functional requirement for Ldb1 in mature β‐cells, we crossed a Ldb1 allele
where the first nine exons were flanked by LoxP elements (Ldb1L) with the inducible, β‐cell‐specific
MIPCreERTm deleter strain to generate Ldb1L/L; MIPCreERTm mice. At P28, tamoxifen was
administered via oral gavage following a two‐week schedule (Figure 15A). During the two‐weeks of
tamoxifen administration, control, Ldb1L/L, and Ldb1 loss‐of‐function, Ldb1L/L, MIPCreERTm, mice did
not gain weight (Figure 15B). After the two‐weeks of tamoxifen administration, both Ldb1L/L and
Ldb1L/L, MIPCreERTm mice began to gain weight at approximately the same rate (Figure 15B). Based
on personal communications and our experience with recombining the Ldb1L allele, we were not
surprised to see a mosaic recombination pattern when we examined Ldb1 ablation efficiency at P56
(Figure 15C‐D). Despite the high dosage of tamoxifen supplied to the animals the recombination
efficiency of the Ldb1L/L, MIPCreERTm mice varied from animal to animal as well as from islet to islet.
Overall, Ldb1 was completely depleted from approximately 40‐60% of β‐cells in the Ldb1L/L, MIP
CreERTm mice, and the cells in the interior of the islets that retained Ldb1 expression appeared to
fluoresce at lower intensities than the similar population in Ldb1L/L mice (Figure 15C‐D).
Upon administering tamoxifen, we tracked the random blood glucose levels of the
experimental mice. Similar to weight gain, the random blood glucose levels of both Ldb1L/L and
Ldb1L/L, MIPCreERTm mice decreased over the two‐week period where tamoxifen was administered
orally (Figure 15E). In the two‐week‐chase period following tamoxifen administration, the random
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Figure 15. Ablating Ldb1 in the mature βcell results in impaired glucose homeostasis and
insulin secretion. A. An infographic depicting the tamoxifen administration schedule for the Ldb1L/L
and Ldb1L/L; MIPCreERTm mice. The red hashes indicate when tamoxifen was administered by
gavage. The yellow hash indicates when animals were experimentally analyzed. B. Weight gain as a
percentage of initial animal weight at P28 tracked following initial tamoxifen gavage (Ldb1L/L, n = 9
and Ldb1L/L; MIPCreERTm, n = 11). C‐D Co‐immunostaining demonstrating Ldb1 ablation with repsect
to Nkx6.1 and insulin from ~P56 pancreata. E. Weekly random blood glucose monitoring tracked
following initial tamoxifen gavage at P28 (Ldb1L/L, n = 9 and Ldb1L/L; MIPCreERTm, n = 11). F.
Comparing baseline IPGTT performed at P28 prior to tamoxifen administration (Ldb1L/L, n = 9 and
Ldb1L/L; MIPCreERTm, n = 11) and at P56 following completion of tamoxifen pulse‐chase (Ldb1L/L, n =
14 and Ldb1L/L; MIPCreERTm, n = 15). G. IPGSIS performed at P56 following completion of tamoxifen
pulse‐chase (Ldb1L/L, n = 9 and Ldb1L/L; MIPCreERTm, n = 10). H. Insulin tolerance test performed at
P56 following completion of tamoxifen pulse‐chase (Ldb1L/L, n = 9 and Ldb1L/L; MIPCreERTm, n = 10).
I. Static glucose islet incubations displayed as raw insulin secretion and (I.’) raw insulin secretion
normalized to baseline secretion at 2.0mM glucose. Tamoxifen induction schedule was adjusted for
the animals that provided islets for static incubations. The initial gavage was at 5.5 weeks‐of‐age. The
same tamoxifen dosage was administered, however, the total pulse‐chase was 9 and 7 weeks
respectively for these Ldb1L/L and Ldb1L/L; MIPCreERTm mice. All images taken at 20x zoom.
Statistical significance codex: repeated measures, two‐way ANOVA with Bonferroni correction: † = P
< 0.05 / †† = P < 0.01 / ††† = P < 0.001 / †††† = P < 0.0001.
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blood glucose levels of the Ldb1L/L mice appeared to stabilize. However, the random blood glucose
levels of the Ldb1L/L, MIPCreERTm mice were slightly elevated in comparison to the Ldb1L/L
littermates by 21 and 28 days after the initial tamoxifen gavage. Even though the trending elevation
in the random blood glucose of the Ldb1L/L, MIPCreERTm mice did not achieving statistical
significance, we performed an intraperitoneal glucose tolerance test (IPGTT), a more sensitive assay
of animal glucose homeostasis, on the P56 mice. The IPGTT demonstrated that Ldb1L/L, MIPCreERTm
mice were indeed glucose intolerant (Figure 15F). Using the same cohort of animals, we also
measured the in vivo glucose‐stimulated insulin response. When compared to Ldb1L/L mice, the
Ldb1L/L, MIPCreERTm mice displayed a significantly blunted glucose‐stimulated insulin response
(Figure 15G). To control for any differences in peripheral tissue insulin sensitivity in the Ldb1L/L, MIP
CreERTm mice, we also performed an insulin tolerance test on the same cohort of animals. We
observed almost identical insulin tolerances between the Ldb1L/L and Ldb1L/L, MIPCreERTm
littermates (Figure 15H). To exclude any baseline glucose homeostatic differences between the
Ldb1L/L and Ldb1L/L, MIPCreERTm mice, we also performed the IPGTT assay on Ldb1L/L, MIPCreERTm
and Ldb1L/L littermates at P28 prior to any tamoxifen administration. At this time point, the two
genotypes displayed almost identical glucose tolerance (Figure 15F). Taken together this in vivo
physiologic analysis demonstrates that Ldb1 expression in the mature β‐cell is required for
maintaining whole animal glucose homeostasis.
B. Ablating Isl‐1 in the mature β‐cells phenocopies Ldb1 ablation and recapitulates previous observations.
Given the well‐characterized mechanistic relationship between Ldb1 and Isl‐1 in directing
cholinergic neuronal fate and the reported functional requirement for Isl‐1 in the developing and
adult endocrine pancreas (Chen, et al. 2014a; Cho, et al. 2014; Du, et al. 2009; Ediger, et al. 2014), we
aimed to analyze our β‐cell‐specific Ldb1 ablation mouse model in parallel with a β‐cell‐specific Isl1
ablation mouse model. To do this, we engineered Isl1L/L; MIPCreERTm mice. Compared to previous
Isl1 loss‐of‐function mouse models (Isl1L/L; Pdx1CreERTm and Isl1mERCremER/L) that have been
utilized to characterize the role of Isl1 in the adult β‐cell, the Isl1L/L, MIPCreERTm mice provided true
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Figure 16. Ablating Isl1 in the mature βcell phenocopies Ldb1 ablation. A. An infographic
depicting the tamoxifen administration schedule for the Isl1L/L and Isl1L/L; MIPCreERTm mice. The
red hashes indicate when tamoxifen was administered by gavage. The yellow hash indicates when
animals were experimentally analyzed. B. Post‐tamoxifen weight gain as a percentage of the pre‐
tamoxifen weight at P28 (Isl1L/L, n = 7 and Isl1L/L; MIPCreERTm, n = 7). C‐D. Dual
immunohistochemistry demonstrating Isl‐1 ablation with respect to glucagon from ~P49 pancreata.
E. Weekly random blood glucose monitoring tracked following initial tamoxifen gavage at P28 (Isl
1L/L, n = 7 and Isl1L/L; MIPCreERTm, n = 7). F. Comparing baseline IPGTT performed at P28 prior to
tamoxifen administration (Isl1L/L, n = 6 and Isl1L/L; MIPCreERTm, n = 8) and at P49 following
completion of tamoxifen pulse‐chase (Isl1L/L, n = 7 and Isl1L/L; MIPCreERTm, n = 7). G. IPGSIS
performed at P49 following completion of the tamoxifen pulse‐chase (Isl1L/L, n = 7 and Isl1L/L; MIP
CreERTm, n = 7). H. Insulin tolerance test performed at P49 following completion of the tamoxifen
pulse‐chase (Isl1L/L, n = 5 and Isl1L/L; MIPCreERTm, n = 5). I. Static glucose islet incubations
displayed as raw insulin secretion and (I.’) raw insulin secretion normalized to baseline secretion at
2.0mM glucose using ~P49 islets. J. Static glucose islet incubations + 50nM Ex‐4 displaying as raw
insulin secretion and (J.’) raw insulin secretion normalized to baseline secretion at 2.0mM glucose
using ~P49 islets. All images taken at 20x zoom. Statistical significance codex: repeated measures,
two‐way ANOVA with Bonferroni correction: † = P < 0.05 / †† = P < 0.01 / ††† = P < 0.001 / †††† = P <
0.0001.
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β‐cell‐specific Isl1 ablation (Chen, et al. 2013; Chen, et al. 2014a; Ediger, et al. 2014). Nonetheless,
analyzing the Isl1L/L; MIPCreERTm model exactly in parallel to Ldb1L/L; MIPCreERTm models was
complicated by the relative recombination efficiencies of the Isl1L and Ldb1L alleles. As with the
Ldb1L/L; MIPCreERTm model, we administered tamoxifen starting at P28 via oral gavage, however, far
less tamoxifen was required to achieve maximal ablation of Isl1 (Figure 16A‐C). Three weeks after
the first gavage, the interior of Isl1L/L; MIPCreERTm islets were consistently depleted of almost all Isl‐
1+ cells (Figure 16C). The random blood glucose levels of the Isl1L/L; MIPCreERTm mice began to
elevate above the levels of their littermate controls as early as 14 days after the first oral tamoxifen
administration (Figure 16E). A week later, the random blood glucose levels of the Isl1L/L; MIP
CreERTm mice were dramatically elevated compared to controls. Nonetheless, the Isl1L/L; MIP
CreERTm mice and their littermate controls gained weight at approximately the same pace (Figure
16D). Despite receiving significantly less tamoxifen than the Ldb1L/L and the Ldb1L/L; MIPCreERTm
mice, the one‐week period of oral tamoxifen administration correlated with a reduced rate of weight
gain and a slight reduction in random blood glucose levels in the Isl1L/L and Isl1L/L; MIPCreERTm
mice, an observation similar to what was observed in the Ldb1L/L and the Ldb1L/L; MIPCreERTm mice
during oral tamoxifen administeration.
Consistent with the elevated random blood glucose levels, the induced Isl1L/L; MIPCreERTm
mice were significantly glucose intolerant and displayed almost no in vivo glucose‐stimulated insulin
secretion response (Figure 16F‐G). Like the Ldb1L/L; MIPCreERTm mice, the Isl1L/L; MIPCreERTm mice
displayed peripheral tissue insulin sensitivity commensurate to their littermate controls (Figure
16H). Overall, this physiologic analysis closely recapitulates what was observed in the previously
characterized Isl1L/L; Pdx1CreERTm and Isl1mERCremER/L mouse models (Chen, et al. 2014a; Ediger, et
al. 2014). Unlike the Isl1L/L; Pdx1CreERTm model, we did not observe any baseline glucose
homeostasis phenotype in the P28 Isl1L/L; MIPCreERTm prior to tamoxifen administration (Figure
16E‐F) (Ediger, et al. 2014). Overall, the glucose homeostasis phenotypes of the Ldb1L/L; MIPCreERTm
and Isl1L/L; MIPCreERTm mice are very similar, albeit there was a notable difference between the
relative severities of the glucose homeostasis defects. However, based on the positive correlation
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Figure 17. Static incubations of Ldb1depleted islets. A. Static glucose islet incubations + 50nM
Exendin‐4 (Ex‐4) displayed as raw insulin secretion and (A.’) raw insulin secretion normalized to
baseline secretion at 2.0mM glucose. B. Static KIC islet incubations displayed as raw insulin secretion
and (B.’) raw insulin secretion normalized to baseline secretion at 0.0mM KIC. Tamoxifen induction
schedule was adjusted for animals providing islets for static incubations. Initial gavage was at 5.5
weeks‐of‐age. The same dosage was administered, however, the total pulse‐chase was 9 and 7 weeks
respectively for these Ldb1L/L and Ldb1L/L; MIPCreERTm mice. Statistical significance codex: repeated
measures, two‐way ANOVA with Bonferroni correction: † = P < 0.05 / ††† = P < 0.001 / †††† = P <
0.0001.
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between the respective ablation efficiencies and the impaired glucose homeostasis phenotypes
(Figure 15 and 16), we believe the difference in glucose homeostatic severity likely reflects the
respective ablation efficiencies of the two models rather than any distinct biological differences.
C. Functional Analysis of Ldb1‐ and Isl‐1‐depleted isolated islets indicates a primary deficit in insulin levels.
To more directly analyze how depleting Ldb1 and Isl1 in the adult β‐cell affects islet
physiology, we performed static incubations on isolated islets. With the islets isolated from the
Ldb1L/L; MIPCreERTm mice and littermate controls, we performed static glucose incubations with and
without the Glp1R agonist exendin‐4 (Ex‐4). With respect to raw insulin secretion, the islets from the
Ldb1L/L; MIPCreERTm mice were refractory to increasingly stimulatory glucose concentrations
(Figure 15J and 17A). However, these differences in raw insulin secretion values could reflect a
global reduction in insulin content instead of an impaired glucose‐stimulated insulin mechanism. To
account for this, we normalized the raw insulin secretion values to the baseline insulin secretion at
2.0 mM glucose. With respect to the static glucose incubations, it appeared that islets from the
Ldb1L/L; MIPCreERTm mice displayed a trending impairment in glucose‐stimulated insulin at both 5.0
and 8.0 mM glucose, but statistical significance was only achieved at 16.0 mM glucose (Figure 15J’).
Following normalization of the static incubations performed with Ex‐4, statistical significance was
only retained at 16.0 mM glucose (Figure 17A’). To further analyze the integrity of the glucose‐
stimulated insulin secretion mechanism, islet static incubations using α‐ketoisocaproate (KIC) were
performed with islets from Ldb1L/L and Ldb1L/L; MIPCreERTm mice. KIC is a presumed substrate for
ATP synthesis and should interrogate the functionality of the glucose‐stimulated insulin secretion
mechanism downstream of glycolysis (Gao, et al. 2003). Similar to the static glucose incubations, the
raw islet insulin secretion values were significantly blunted at the higher concentrations of KIC
(Figure 17B). Nonetheless, normalizing the raw insulin secretion to baseline KIC‐stimulated insulin
secretion did not reveal significant differences between islets from Ldb1L/L and Ldb1L/L; MIPCreERTm
mice (Figure 17B’). Taken together these experiments indicate that decreased islet insulin levels
account for the majority of differences in raw insulin secretion values, however, elements of the
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Figure 18. Ldb1βcells persist, retain ChgA signal, and are insulin depleted. A. Quantified
chromograninA+ cell mass. B. Quantified insulin+ cell mass. C. Quantified average islet size. D.
Quantified pancreatic islet density. E. Frequency of glucagon+ and somatostatin+ cells within
chromograninA+ cell mass. F. Total pancreatic insulin content. G. Total pancreatic glucagon content.
H‐I. Co‐immunostaining for Ldb1, Insulin, and eYFP at P56. J‐K. Co‐immunostaining for Ldb1,
glucagon, and somatostatin at P56. L‐M. Co‐immunostaining for ChgA, insulin, and eYFP at P56. All
images taken at 20x zoom. Statistical significance codex: Student’s two‐way t‐test, ** = p < 0.01 / ****
= p < 0.0001.
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glucose‐stimulated insulin secretion and incretin potentiation mechanisms are noticeably
dysfunctional at high stimulatory concentrations of glucose. The KIC incubations indicate that the
defects in the glucose‐stimulated insulin secretion mechanism are most likely upstream of citric‐acid
cycle ATP generation.
We performed parallel experiments using islets isolated from the Isl1L/L and Isl1L/L; MIP
CreERTm mice (Figure 16I‐J). Similar to the islets from the Ldb1L/L; MIPCreERTm mice, islets from the
Isl1L/L; MIPCreERTm mice, when compared to those from Isl1L/L controls, displayed blunted raw
insulin secretion values with and without Ex‐4. When the raw insulin secretion values were
normalized to the baseline insulin secretion at 2.0mM glucose, the results were slightly different than
those observed with the Ldb1L/L; MIPCreERTm islets. First, there was no difference between the
normalized glucose‐stimulated insulin secretion between the Isl1L/L; MIPCreERTm and Isl1L/L islets,
even at high stimulatory glucose concentrations (Figure 16I’). Second, the ability of Ex‐4 to potentiate
glucose‐stimulate insulin secretion was more acutely blunted in the Isl1L/L; MIPCreERTm islets than
in the Ldb1L/L; MIPCreERTm islets (Figure 16J’ and 17A’). Despite these minor discrepancies between
the two β‐cell‐specific loss‐of‐function models, the static incubation experiments in both models
universally implicated a global deficit in islet insulin content as the primary cause of attenuated raw
insulin secretion in response to glucose.
D. Ablating Ldb1 correlates with insulin paucity but retention of chromograninA.
Upon closer examination of Ldb1 ablation in the pancreatic islets, we observed that the vast
majority of the remaining Ldb1+ cells were insulin+ and there was a smaller population of Ldb1+,
insulin‐ cells (Figure 15C‐D), an expression pattern that would be expected for a pan‐endocrine factor
like Ldb1. Yet, the typical homogenous insulin‐staining pattern observed in the islets of control mice
(Figure 15C’) was visibly disrupted in the Ldb1L/L, MIPCreERTm mice (Figure 15D’). Pancreatic islets
within the Ldb1L/L, MIPCreERTm mice exhibited significant areas of insulin paucity that correlated
with Ldb1 negative nuclei. To indicate if these Ldb1‐, insulin‐ cells were derived from β‐cells we
stained for Nkx6.1, a β‐cell‐specific marker that was previously demonstrated to remain expressed
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Figure 19. Efficiency of Isl1 ablation is reflected by almost complete loss of insulin. A‐B. Co‐
immunostaining for ChgA, Nkx6.1, and insulin at P49. C. Quantified chromograninA+ cell mass. D.
Quantified insulin+ cell mass. E. Quantified average islet size. F. Quantified pancreatic islet density. G‐
H. Co‐immunostaining for insulin, somatostatin, and glucagon at P49. I. Frequency of glucagon+ and
somatostatin+ cells within chromograninA+ cell mass. J. Total pancreatic insulin content. K. Total
pancreatic glucagon content. All images taken at 20x zoom. Statistical significance codex: Student’s
two‐way t‐test, * = p < 0.05 / *** = p < 0.001.
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following β‐cell‐specific ablation of Isl1 (Ediger, et al. 2014). Interestingly, the nuclei of Ldb1‐ cells
remained Nkx6.1+ and accounted for the areas of insulin paucity, an observation consistent with the
global insulin deficit indicated by the static islet incubations. Given the stark insulin phenotype we
quantified pancreatic ChromograninA+ (ChgA) cell mass, a marker of endocrine cell identity, and
insulin+ cell mass (Figure 18A‐B). While there was no significant change in ChgA+ cell mass, there was
an approximate 33% reduction in insulin+ cell mass. Average islet size and pancreatic islet density
were almost indistinguishable between Ldb1L/L, MIPCreERTm mice and littermate controls (Figure
18C‐D). We also did not observe any significant changes in the frequency of α‐ and δ‐cells between
the islets of Ldb1L/L and Ldb1L/L, MIPCreERTm mice (Figure 18E). Further supporting a role for Ldb1
in maintaining insulin levels, total pancreatic insulin content was reduced by 51% in the Ldb1L/L,
MIPCreERTm mice (Figure 18F). Whereas, the total pancreatic glucagon levels in the Ldb1L/L, MIP
CreERTm mice were essentially the same as controls (Figure 18G).
L/L

E. Severity of Isl‐1 ; MIP‐CreER

Tm

glucohomeostatic phenotype reflects Isl‐1 ablation efficiency.

Parallel analysis was performed on the Isl1L/L; MIPCreERTm mice. Like the Ldb1L/L, MIP
CreERTm mice, there were significant areas of insulin paucity, and the insulin‐ cells retained nuclear
Nkx6.1 signal (Figure 19A‐B). The ChgA+ cell mass in the Isl1L/L; MIPCreERTm mice and controls was
similar, however, the insulin+ cell mass of the Isl1L/L; MIPCreERTm mice was reduced by 74% (Figure
19C‐D). Morphometric analysis of Isl1L/L and Isl1L/L; MIPCreERTm mice pancreata revealed that the
average islet size was unchanged between the two genotypes (Figure 19E). As for pancreatic islet
density, there was slightly higher islet density in the Isl1L/L; MIPCreERTm mice compared to controls,
but the trend did not achieve statistical significance (Figure 19F). Interestingly, it also appeared as if
there were slightly more α‐ and δ‐cells in the islets of Isl1L/L; MIPCreERTm mice compared to
littermate controls (Figure 19G‐H). While quantification of both populations did not statistically
support an increase in α‐cell nor δ‐cell frequency, it did appear that both populations were trending
upwards, especially the δ‐cells (Figure 19I). As expected, total pancreatic insulin content was almost
completely depleted in the Isl1L/L; MIPCreERTm mice (Figure 19J). Despite the possible trend for
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Figure 20. The Ldb1 and Isl1 βcell transcriptomes are highly correlated but not identical. A.
Representative populations obtained using FACS to enrich eYFP+ cells. Red histograms of side‐scatter
area represent the respective loss‐of‐function, eYFP+ populations and the blue histograms of side‐
scatter area represent the control, eYFP+ population for comparison. B. Quantification of the mode
and geometric mean of side‐scatter area of enriched Ldb1β‐cells (n=8), Isl1β‐cells (n=5), and
control β‐cells (n=5). C. Clustered heat map representing average differential expression across the
enriched Ldb1β‐cells (n=8), Isl1β‐cells (n=5), and control β‐cells (n=5). D. Gene ontology analysis
and (D.’) KEGG pathway analysis for individual clusters. Histogram color in D. and D.’ reflect cluster
coloring from C. Brown and Cyan as well as Red and Yellow were combined based on high similarity
of initial individual analyses. E. Mini‐table comparing two previous microarray analyses of Isl‐1 in the
mature β‐cell with the datasets of the current study. E’ Venn diagram comparing all differentially
regulated genes, independent of activation or repression, within the three respective datasets. E’’.
Venn diagram comparing the set of genes that were identified as increased in expression in their
respective datasets. E’’’. Venn diagram comparing the set of genes that were identified as reduced in
expression in their respective datasets. Statistical significance codex: repeated measures, two‐way
ANOVA with Bonferroni correction: † = P < 0.05 / †††† = P < 0.0001.
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increased α‐cells, total pancreatic glucagon content was almost identical between Isl1L/L and Isl1L/L;
MIPCreERTm mice (Figure 19K). Largely, the parallel analysis of the Isl1L/L; MIPCreERTm mice closely
phenocopied what was observed in the Ldb1L/L, MIPCreERTm mice. Again, the major difference
between the two loss‐of‐function models is the relative severity of the phenotype. Collectively, our
analyses indicate the difference in phenotype severity most likely reflects the relative ablation
efficiencies of the LdbL and Isl1L alleles.
‐

F. Generating lineage‐tracing mice to track the fate of insulin , Ldb1‐ablated β‐cells.
Given that the quintessential marker of β‐cell fate, insulin, was significantly depleted in our
Ldb1L/L; MIPCreERTm loss‐of‐function model, we crossed the Rosa26LSLeYFP lineage‐tracing allele onto
our Ldb1L/L; MIPCreERTm loss‐of‐function models to track the fate of the Ldb1‐depleted β‐cells. The
resulting Ldb1L/L, Rosa26LSLeYFP/ LSLeYFP; MIPCreERTm strain was compared to a control lineage tracing
strain: Rosa26LSLeYFP/ LSLeYFP; MIPCreERTm. From here on, the homozygous Rosa26LSLeYFP/ LSLeYFP
genotype will be abbreviated as R26LSLeYFP. After tamoxifen induction, eYFP signal in R26LSLeYFP; MIP
CreERTm mice was exclusively detected in Ldb1+, insulin+ cells; no eYFP signal was detected in Ldb1+,
insulin‐ negative cells (Figure 18H). In the Ldb1L/L; R26LSLeYFP; MIPCreERTm mice, eYFP signal was
almost exclusively detected in Ldb1‐, insulin‐ cells (Figure 18I). However, there was a small fraction
of eYFP+, Ldb1Lo, insulin+ cells (Figure 18I’’’), but strong insulin signal and eYFP signal were almost
mutually exclusive (Figure 18I’’). Notably, all Ldb1+, insulin‐ cells were eYFP‐ as seen in the R26LSLeYFP;
MIPCreERTm mice (Figure 18H’’’ and I’’’). Moreover, Ldb1 signal was maintained in the somatostatin
and glucagon positive cells of islets in both the R26LSLeYFP; MIPCreERTm and Ldb1L/L; R26LSLeYFP; MIP
CreERTm mice (Figure 18J‐K). We also performed ChgA staining to assess the accuracy of our lineage‐
tracing model. In the R26LSLeYFP; MIPCreERTm, mice we obtained the expected result where eYFP
signal was only detected in ChgA+, insulin+ cells and no eYFP signal was detect in ChgA+, insulin‐ cells
(Figure 18L). In islets from Ldb1L/L; R26LSLeYFP; MIPCreERTm mice, eYFP signal was almost exclusively
detected in ChgA+, insulin‐ cells (Figure 18M). While there was still a population of eYFP‐, ChgA+,
insulin‐ cells representing the non‐β‐cell endocrine cells, ChgA was replete throughout the islet with
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Table 5. Differentially regulated genes with relevance to βcell biology. Table demonstrating
relative fold changes in each loss‐of‐function enriched β‐cell population with respect to the enriched
control β‐cells presented with P‐value and False Discovery Rate (FDR). The table also compares
differential regulation between loss‐of‐function populations. The table also indicates whether the
gene was identified in the microarray from Chapter 2 and whether it is miss‐regulated in the same
direction (‐ = not identified, $ = identified in same direction, and * = identified in a different
direction). The table also indicates whether peaks from the Ldb1/Isl‐1 common and Isl‐1‐alone peak
sets are within a ± 200kb TSS for the respective gene († = same peak).
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noticeably higher signal intensity in eYFP+ cells compared to the remaining insulin+ cells (Figure
18M). Interestingly, a similar ChgA versus insulin staining pattern was also observed in the Isl1L/L;
MIPCreERTm islets (Figure 19B). Taken together these results confirm the utility of our lineage‐
tracing model, and confirm ablating Ldb1 results in insulin‐ cells that retain the endocrine cell marker
ChgA.
G. The Ldb1 and Isl‐1 mature β‐cell transcriptomes encompass key cell biology.
To determine the comprehensive transcriptional requirement for Ldb1 in relation to Isl‐1 in
mature pancreatic β‐cells we performed RNA‐Seq. We crossed the R26LSLeYFP onto the Isl1L/L; MIP
CreERTm strain to generate a commensurate lineage tracing line for the Isl1 β‐cell‐specific, loss‐of‐
function mice. Instead of using isolated islets, we dispersed the islets and used FACS to enrich for
eYFP+ cells. By using FACs, we aimed to enrich (90% or greater) for β‐cells while excluding as much
of the non‐β‐cell contamination that is inevitably incorporated using isolated islets. Simultaneously,
we employed FACS as a means to enrich for cells where successful recombination had occurred, an
issue particularly relevant to the mosaic ablation pattern of Ldb1L/L; R26LSLeYFP; MIPCreERTm mice.
With respect to the Isl1L/L; R26LSLeYFP; MIPCreERTm mice, we harvested the islets a week earlier than
the age at which we performed the physiological analysis (Figure 16A). This alteration in protocol
was made to better sync the glucose homeostasis phenotypes of the respective loss‐of‐function
models. Cells sorted from the R26LSLeYFP; MIPCreERTm animals were used as a common control and
underwent the same tamoxifen schedule as the Ldb1L/L; R26LSLeYFP; MIPCreERTm animals (Figure
15A). When we sorted the dissociated islets we observed clear eYFP signal in all strains (Figure 20A).
Unexpectedly, we also observed that sorted eYFP+ populations from the Isl1L/L; R26LSLeYFP; MIP
CreERTm and Ldb1L/L; R26LSLeYFP; MIPCreERTm islets displayed similar forward‐scatter, side‐scatter
profiles that were distinct from cells isolated from R26LSLeYFP; MIPCreERTm islets. Both eYFP+
populations extracted from the loss‐of‐function models had noticeably reduced side‐scatter, an
indicator of cellular granularity (Figure 20A‐B). The reduced cellular granularity observation in the

101

Figure 21. eYFP contamination in the transcriptome reveals novel paracrine effect of Ldb1
ablation. A‐B. Co‐immunostaining for eYFP, Insulin, and glucagon (Gcg) at P56. C‐D. Co‐
immunostaining for eYFP, Insulin, and somatostatin (Sst) at P56. E‐F. Co‐immunostaining for eYFP,
Insulin, and Gastrin at P56. All images taken at 20x zoom.
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enriched Ldb1‐ and Isl1‐β‐cell populations is consistent with the reduced insulin content in both
loss‐of‐function models.
Given that the function of Isl‐1 is thought to be completely dependent on Ldb1, we were
surprised that the cluster analysis of the enriched Ldb1‐β‐cells and Isl1‐β‐cells transcriptomes
appeared visibly different (Figure 20C). Upon closer examination, the majority of differentially
expressed genes identified in the cluster analysis actually behaved similarly between the enriched
Ldb1‐β‐cells and Isl1‐β‐cells, however, it was the magnitude of misexpression that accounted for
the major differences between the enriched Ldb1‐β‐cells and Isl1‐β‐cells transcriptomes. In fact,
only three small clusters (Brown, Cyan, and Orange) were distinguished by inverse gene expression
behavior between the enriched populations of loss‐of‐function β‐cells. To appreciate the functional
significance of the Isl‐1 and Ldb1 β‐cell transcriptomes, we performed Gene Ontology and KEGG
Pathway analysis on each of eight clusters. The Brown and Cyan cluster analysis was combined
because their individual Gene Ontology and KEGG Pathway analysis were similar, an observation
supported by the dendrogram; the same was true for the Red and Yellow clusters. Overall some very
interesting terms and pathways were generated; the most statistically significant findings for each
cluster are displayed (Figure 20D). We were encouraged to see the MODY and Type 2 Diabetes KEGG
pathways enriched in the Blue cluster, a set of genes generally down‐regulated in both loss‐of‐
function models (Figure 20D’). The Green cluster, another consisting of genes that were grossly
repressed in both loss‐of‐function models, also yielded terms related to mitochondrial function, an
important component of the glucose‐stimulated insulin secretion mechanism, as well as organelle
membranes, a finding that may also be related to the reduced granularity observed in the sorted cell
populations. Both the cyan and brown clusters, genes exclusively up‐regulated in the enriched Isl1‐‐
β‐cells and repressed in the enriched Ldb1‐‐β‐cells, were significantly enriched for genes related to
the cell‐cycle and M‐phase. Given that the enriched Isl1‐‐β‐cells were isolated from younger mice, it
is unclear whether these cyan and brown clusters reflect real Isl‐1 biology or are an artifact of
isolating islets from younger mice. Collectively, both the Isl‐1 and Ldb1 β‐cell transcriptomes reflect
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Figure 22. Ldb1 ablation results in loss of Mafa and Pdx1 and the simultaneous expression of
Neurog3. A‐B. Co‐immunostaining for eYFP, Insulin, and Slc2a2 at P56. C‐D. Co‐immunostaining for
eYFP, Insulin, and MafA at P56. E‐F. Co‐immunostaining for eYFP, Insulin, and Pdx1. G‐H.
Immunostaining on littermates for Neurog3 at P56. For sections from Ldb1L/L; R26LsLeYFP; MIPCreERTm
mice, eYFP was used as counter‐stain. Multiple islets are presented that represent at least two
animals from each genotype to provide broader representation of staining. All images taken at 20x
zoom.
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the integral and largely overlapping role both proteins play in multiple aspects of mature β‐cell cell
biology.
To validate and contextualize the transcriptional data sets of the current study with past
investigations characterizing the role of Isl‐1 in the adult β‐cells, we compared our RNA‐Seq datasets
to two previously generated microarray datasets (Figure 20E)(Ediger, et al. 2014; Liu, et al. 2012).
The set of differentially expressed genes from a microarray generated using isolated islets from a
mouse modestly over‐expressing Isl1 (Pdx1PBIsl1Myc) had almost no overlap with our current data
sets (Figure 20E’). We were even more surprised to see the limited overlap between our recently
published microarray that was generated with islets from the Isl1; Pdx1CreERTm strain (Figure 20E’’
and E’’’). While we expected the RNA‐Seq to be more sensitive than the microarray, i. e. detect more
genes, we also expected that the Isl1; Pdx1CreERTm microarray would more faithfully overlap with
the RNA‐seq generated from the enriched Isl1‐‐β‐cells. Instead, only 21.3% and 20.7% of the genes
that were respectively increased and reduced in the Isl1; Pdx1CreERTm microarray overlapped with
the genes that were respectively increased and reduced in the enriched Isl1‐‐β‐cell RNA‐Seq (Figure
20E’’ and E’’’). We believe these observations reflect the improved specificity of our current methods
the employ a more accurate mouse model and more precise methods of tissue isolation. But, we
acknowledge the lack of overlap between the two data sets could also be due to the different genetic
background, gender, and experimental design used to generate the Isl1; Pdx1CreERTm microarray.
H. Targeted analysis of RNA‐Seq datasets for genes with relevance to β‐cell biology.
While the Gene ontology and KEGG Pathway analysis strongly argues that Ldb1 and Isl‐1
play important roles in regulating numerous aspects of cell biology, we also took a more detailed look
at our data set for genes related to β‐cell biology, the endocrine pancreas, and pancreatic
development (Table 5). Notably, the set of genes we identified through this meta‐analysis generally
behaved the same way in both enriched β‐cell loss‐of‐function populations. With that said, the
respective gene expression changes in the enriched Ldb1‐β‐cells were almost always more acute
than in the enriched Isl1‐β‐cells (Table 5). Focusing on the hormones of the adult endocrine
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Figure 23. Ldb1 and Isl1 are coenriched throughout the βcell genome. A. Expression profile of
potential LIM‐HD and LMO binding partners for Ldb1 identified in the respective enriched β‐cell
populations. B. Peak signal (reads per million) correlation between Isl‐1 and Ldb1 primary islet ChIP‐
Seqs. The blue dots represent peaks in the Ldb1/Isl‐1 common set. The red dots represent peaks in
the Isl‐1‐alone set. Delineation of sets based on log2(Isl‐1 ChIP‐Seq RPM/Ldb1 ChIP‐Seq RPM) = 2.0.
C. Genome annotation by individual ChIP and by self‐defined peak‐set prioritized as follows: NcRNA
= Non‐coding RNA, pTSS = proximal promoter (‐1.0kb to +0.1kb), TTS = transcription termination
site (‐0.1kb to +1.0kb), Exon = Coding sequence that is Exons, 5UTR = 5’ UTR, 3UTR = 3’ UTR, Intron
= Introns, dTSS = distal promoter (‐10kb to +1.0kb), and Intergenic = all other regions. D. Genes with
at least one Ldb1/Isl‐1 common peak within a ±100kb window of the TSS that were differentially
expressed in either of the enriched Ldb1‐β‐cells or Isl1‐β‐cells grouped by reduced or elevated
expression and depicted as a percent of the totality of genes within the respective categories. E.
Genes with at least one Ldb1/Isl‐1 common peak within a ±100kb window of the TSS that were
identified in the RNA‐Seq gene clustering analysis organized by gene cluster and depicted as a
percent of the totality of genes within the respective cluster. The ‘All’ group reflects the totality of
genes identified by the gene clustering analysis. F. De Novo motif analysis of the Ldb1/Isl‐1 common
peak set. The de novo motif is presented with the percent of Ldb1/Isl‐1 common peaks containing it
and the P‐value. Below the respective de novo motifs are the matched consensus sequence/s. G.
Density of motifs with respect to identified peaks. Colors in upper, right‐hand corner of individual
plots correspond to the respective curve in the overlay. H. Incidence of consensus motif (Isl‐1,
Nkx6.1, Nkx3.1, Foxa, or bHLH) with respect to (w. r. t.) the first nucleotide of an anchoring Isl‐1
consensus motif.
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pancreas, we were not surprised to see the expression of Ins1 and Ins2 were significantly reduced in
both models. Interestingly, there was also a modest but significant increase in the respective levels of
Sst and Gcg expression, whereas, Ghr expression was modestly decreased. There was no change
detected in Ppy expression. Interestingly, Gast, the gene encoding the hormone Gastrin, was among
the top three up‐regulated genes in both models. In the adult animal Gastrin expression is normally
found in the stomach and intestine, however, a population of pancreatic endocrine cells expressing
Gastrin during development has been described (Suissa, et al. 2013).
Key elements of the murine insulin secretion pathways were also reduced. With respect to
the glucose‐stimulated mechanism, the expression of Slc2a2, the gene encoding the Glut2 glucose
transporter, and Abcc8 and Kcnj11, the two genes encoding the respective subunits of the ATP‐
dependent potassium channel, were significantly down‐regulated (Ashcroft, et al. 1984; Cook and
Hales 1984; Meissner and Schmelz 1974). As for the incretin signaling pathway, the gene encoding
the Glp1R, the receptor through which incretin signaling potentiates insulin secretion, was also
significantly down‐regulated. The gene encoding Urocortin 3, a β‐cell‐specific factor that helps
promote insulin secretion (van der Meulen, et al. 2012), was also significantly down‐regulated,
whereas, expression of ChgA, as our staining indicated, was increased. We also noted that Gjd2 was
down‐regulated; Gjd2 encodes connexin‐36 which is the major connexin used in the functionally
important gap‐junctions that interlink β‐cells (Pizarro‐Delgado, et al. 2014).
More interestingly, the network of genes that establishes and directs pancreatic endocrine
and, more‐specifically, β‐cell‐fate was significantly altered. The genes encoding the β‐cell maturation
factors MafA and Tshz1 were decreased (Tshz1 reduction was specific to the enriched Ldb1‐‐β‐cells)
(Raum, et al. 2015). Additionally, the genes encoding the transcription factors Pdx1 and Nkx6.1 that
specify β‐cell‐fate were both decreased in expression (Nkx61 reduction was specific to the enriched
Ldb1‐‐β‐cells) (Henseleit, et al. 2005; Schaffer, et al. 2013). We also observed that Insm1, Mnx1, and
Rfx6 were differently regulated; these three genes are key factors expressed in the endocrine
precursors that remain expressed in mature β‐cells. Possibly the most interesting observation was
that the gene encoding Neurogenin3, the primary transcription factor that specifies pancreatic
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Figure 24. The Isl1alone peak set and the lack of evidence for an Ldb1alone set. A. Genes
with at least one Isl‐1‐alone peak within a ± 100kb window of the TSS that were differentially
expressed in either of the enriched Ldb1‐β‐cells or Isl1‐β‐cells grouped by reduced or elevated
expression and depicted as a percent of the totality of genes within the respective categories. B.
Genes with at least one Isl‐1‐alone peak within a ± 100kb window of the TSS that were identified in
the RNA‐Seq gene clustering analysis organized by gene cluster and depicted as a percent of the
totality of genes within the respective cluster. The ‘All’ group reflects the totality of genes identified
by the gene clustering analysis. C. De Novo motif analysis of the Isl‐1‐alone peak set. The de novo
motif is presented with the percent of Isl‐1‐alone peaks containing it and the P‐value. Below the
respective de novo motifs are the matched consensus sequence. D. Analysis of motif enrichment with
regard to the ratio of Ldb1 to Isl‐1 peak strengths. Purple lines are the group delimiters defined by
the equation log2(Isl‐1 ChIP‐Seq RPM/Ldb1 ChIP‐Seq RPM). The relative frequency of motifs within
the groups are plotted in two ways. The first is with respect to the raw number of peaks in a
particular group. The second attempts to normalize for the variability of peak density between
groups.
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endocrine fate, was up‐regulated 7.8 and 22.8 fold in the respective enriched Isl1‐‐ and Ldb1‐‐β‐cell
populations. Triaging against the list of important development transcription factors tabulated
in (Pan and Wright 2011), we did not observe any significant expression changes in the NeuroD1,
Nkx2.2, Pax4, FoxA1, and FoxA2. Nor did we observe any changes in the genes encoding the mature
alpha‐cell‐specific factors Arx, MafB, and Brn4; the mature ductal factors Hnf6, Hnf1β, and Sox9; nor
the mature acinar factors Ptf1a, Gata4, Mist1, and Nr5a2. Likewise transcriptional changes in other
pancreatic development transcription factors were not observed; this includes Myt1, Snail2, and
Gata6.
I. Increased Gcg, Sst, and Gast expression reflects non‐β‐cell paracrine signaling.
We were intrigued to see ectopic hormone expression in the respective enriched loss‐of‐
function populations, however, our earlier work establishing the Ldb1L/L; R26LSLeYFP; MIPCreERTm
lineage‐tracing suggested that all Sst and Glucagon expressing cells were also Ldb1+ (Figure 18J‐K).
Given the limited number of eYFP+ cells were able to obtain per mouse via sorting we were only able
to perform enriching selection for eYFP+ cells. In contrast to performing a purifying selection, it is
likely that a small fraction (~ ≤ 10%) of non‐β‐cells were included in our enriched eYFP+ populations.
To investigate whether the increase non‐β‐cell transcripts like Gcg and Sst reflected contamination or
real biology, we returned to our Ldb1L/L; R26LSLeYFP; MIPCreERTm lineage‐tracing model. Co‐
immunofluorescence staining for glucagon, insulin, and eYFP did not yield any distinct co‐localization
of glucagon with either insulin or eYFP+ (Figure 21A‐B). For instances that were difficult to
distinguish on the epifluorescent microscrope, we employed confocal microscopy to confirm or deny
colocalization. Even with confocal microscopy convincing evidence of colocalization was not
detected (Data not shown). If glucagon is activated in the enriched Ldb1β‐cells, it is either a very
rare event or a visually undetectable level of activation. More likely, the detected Gcg reflects α‐cell
contamination. The same conclusion was reached with regards to the Sst representing δ‐cell
contamination (Figure 21C‐D).
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Figure 25. Differences in Isl1 chromatin occupancy in βTC3 and αTC6 cells are validated by
primary isletcistromes. IGV browser tracks with the primary islet‐based tracks (IP’s, input and
peak calls) colored red, the βTC3 tracks labeled blue, and the αTC‐6 tracks are labeled green. The
RefSeq track is also labeled blue. A. Slc2a2 locus. B. Pdx1 locus. C. MafA locus. D. Arx locus. Peaks
within each respective locus that have been previously characterized are labeled. Differences in the
αTC‐6 track compared to one or both of the other ChIP‐seq data sets are indicated by the black
arrowheads.
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Given our findings regarding glucagon and somatostatin, we were more cautious in
approaching transcripts such as gastrin that were identified in the RNA‐Seq but are not normally
expressed in mature β‐cells. While the relationship between gastrin and the developing endocrine
pancreas made it an interesting target, it is predominantly co‐expressed in glucagon+ not insulin+
cells in the developing pancreas (Suissa, et al. 2013). Using the Ldb1L/L; R26LSLeYFP; MIPCreERTm mice
we performed immunofluorescence staining for gastrin, insulin, and eYFP (Figure 21E‐F). Like
glucagon and somatostatin, we did not detect any colocalization of gastrin with either eYFP or
insulin. Unlike glucagon and somatostatin, it was clear that the expression of gastrin was increased in
the Ldb1L/L; R26LSLeYFP; MIPCreERTm islets. While we were able to detect a very minimal level of
gastrin staining in the R26LSLeYFP; MIPCreERTm mice (Figure 21E), gastrin staining was strikingly
elevated at the periphery of the islets in the Ldb1L/L; R26LSLeYFP; MIPCreERTm animals (Figure 21F).
Notably, the level of gastrin in the islets of the Ldb1L/L; R26LSLeYFP; MIPCreERTm was orders of
magnitude less than that observed in the G‐cells that populate the stomach and gastrointestinal tract
of wildtype mice (Data not shown). Taken together this result indicates that there are clear paracrine
effects that result from ablating Ldb1 in β‐cells. The gastrin staining also suggests that the increases
in Gcg and Sst expression may also reflect paracrine biology.
J. Ldb1 ablation in β‐cells decreased Slc2a2, MafA, and Pdx1 while increasing Neurog3.
We were also interested in validating the expression changes of some of the key β‐cell
factors identified in the RNA‐Seq. Despite the RNA‐seq data set indicating an approximate two‐fold
decrease in Nkx6.1 transcript in the Ldb1L/L; R26LSLeYFP; MIPCreERTm mice, we already observed that
Nkx6.1 protein expression was retained at some level in the Ldb‐, insulin‐ cells (Figure 15D). We
focused on validating Slc2a2, MafA, and Pdx1 because all three of these factors had been previously
validated as direct transcriptional targets of Isl1 in the adult pancreatic β‐cell (Du, et al. 2009;
Ediger, et al. 2014). Employing the Ldb1L/L; R26LSLeYFP; MIPCreERTm mice, we saw that Slc2a2, MafA,
and Pdx1 were all depleted in the islets of the Ldb1L/L; R26LSLeYFP; MIPCreERTm mice (Figure 22A‐F). In
the Ldb1L/L; R26LSLeYFP; MIPCreERTm islets, eYFP signal was almost exclusively in the cells depleted for
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Slc2a2, MafA, and Pdx1 (Figure 22B’’, D’’’, F’’’). In contrast, insulin signal was almost exclusively
detected in the cells that retained Slc2a2, MafA, and Pdx1 expression (Figure 22B’, D’’, F’’). No such
exclusive patterns between insulin, eYFP, and the factor of interest were observed in the islets of
R26LSLeYFP; MIPCreERTm animals (Figure 22A, C, E).
Observing that the key factor that specifies β‐cell fate, Pdx1, as well as the factor that directs
β‐cell maturation were both significantly repressed in the Ldb1‐‐β‐cells, the significant increase in
Neurog3 expression suggested that the Ldb1‐‐β‐cells may be dedifferentiating to towards an
endocrine progenitor state. While the Neurog3 transcript is recognized as being expressed in adult β‐
cells (Wang, et al. 2009a), translation of the message into protein in adult β‐cells is more
controversial (Courtney, et al. 2013; Wang, et al. 2009b; Xiao, et al. 2013). Therefore, like gastrin, we
sought to demonstrate whether an increased level of Neurog3 protein was expressed in the Ldb1‐‐β‐
cells. Like previous studies investigating Neurog3 expression in adult β‐cells we observed a faint but
nuclear signal in a fraction of the cells populating the islets of Ldb1L/L; R26LSLeYFP animals (Figure
22G). In islets from Ldb1L/L; R26LSLeYFP; MIPCreERTm mice the Neurog3 signal was noticeably stronger
and expressed in more cells (Figure 22H). When we overlaid the Neurog3 with the eYFP lineage
tracer, there was a very high correlation between eYFP signal and Neurog3 signal (Figure 22H’’).
Notably, the most intense Nuerog3+ cells were almost always eYFP+. Nonetheless, there was also a
small population Neurog3+ cells that were eYFP‐ in the Ldb1L/L; R26LSLeYFP; MIPCreERTm, however, this
population was mostly comprised of cells with lower intensity Neurog3 signal that was comparable
to what was observed in the controls. In both mutant and control islets there was substantial islet‐to‐
islet variability of Neurog3 staining. Therefore, multiple islets from different control and mutant mice
were provided for a better representation of the immunofluorescence staining. Taken together these
results would suggest that ablating Ldb1 in the mature β‐cell collapses its terminal differentiated
state.
K. Ldb1 and Isl‐1 enrichment across the β‐cell genome is highly correlated.
Given the significant role Ldb1 appears to play in maintaining β‐cell identity we wanted to
more thoroughly interrogate the mechanistic relationship between Ldb1 and its potential binding
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partners in the adult β‐cell. Our work and previous studies point to Isl‐1 acting as the major partner
in the adult β‐cell. Our RNA‐Seq analysis also demonstrated that Isl1 followed by Mnx1 are by far the
most expressed species of LIM‐HD or LMO proteins in the enriched β‐cell population (Figure 23A).
However, we also detected the expression of the genes encoding the LIM‐HD proteins Lhx1, Lmx1a,
and Lhx6 as well as LMO1, 2, and 4. With the potential variety of LIM‐HD and LMO transcripts
expressed in the enriched β‐cells, Ldb1 could possibly act independently of Isl‐1.
To determine if Ldb1 exclusively interacts with Isl‐1 in mature β‐cells, we performed ChIP‐
Seq for both Ldb1 and Isl‐1 using chromatin extracted from primary islets. Following peak calling, we
plotted each identified peak based on its respective signal strength (reads per million) from the Ldb1
and Isl‐1 ChIP‐Seqs (Figure 23B). From this analysis, two distinct groups of peaks arose. One group,
comprised of approximately 795 peaks, displayed strong Isl‐1 ChIP signal and no Ldb1 ChIP signal;
we labeled this group the Isl‐1‐alone peaks. The second and much larger group of 3928 peaks
displayed a high correlation between Ldb1 and Isl‐1 ChIP‐Seq signal, a pattern consistent with co‐
enrichment; we labeled this set of peaks as Ldb1/Isl‐1 common peaks. We then performed genome
annotation for the peaks identified in the respective ChIP‐Seqs as well as the self‐defined groups of
peaks (Figure 23C). Notably, the Isl‐1 ChIP‐Seq had a greater proportion of peaks located proximal to
the transcription start site, i.e. ‐1kb to +100bp, than the Ldb1 ChIP‐Seq. When we performed the
same genome annotation analysis on our self‐defined peak groups, the Ldb1/Isl‐1 common peaks
were distributed across the genome similar to the Ldb1 ChIP‐Seq genome annotation. However, the
Isl‐1‐alone set of peaks displayed a high proportion of its peaks enriched proximal to the
transcription start site. Likely, the Isl‐1‐alone set of peak accounts for the increased proportion of
peaks observed in proximal promoter region within the Isl‐1 ChIP‐Seq. Collectively this analysis
suggests that Isl‐1 is the most robust partner of Ldb1 in the mature islets. Due to the open nature of
the chromatin at the proximal promoter, the high enrichment of the Isl‐1‐alone peaks in the proximal
promoter also indicates that this set of peaks likely reflects non‐specific antibody binding.
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To identify whether our self‐defined peak sets had any functional relevance we cross‐
referenced the peak sets with our transcriptome analysis. For each peak set, we identified peaks that
were within a ± 100kb window of the transcription start site (TSS) of differentially expressed genes.
For both the enriched Isl1‐‐ and Ldb1‐‐β‐cell transcriptomes, the Ldb1/Isl‐1 common peaks were
slightly more enriched in proximity to genes with reduced expression (Figure 23D). Whereas, there
was little enrichment of the Isl‐1‐alone peak set in proximity of either reduced or elevated genes in
either transcriptome (Figure 24A). The same analysis was repeated with respect to the RNA‐Seq gene
clusters. The Ldb1/Isl‐1 common peaks were enriched in the purple, blue, green clusters; all three of
these clusters represent genes that are generally reduced in both loss‐function models (Figure 23E),
consistent with the analysis based on categorical assignment of gene behavior. Again, the Isl‐1‐alone
peaks were in proximity to a much smaller proportion (9.5%) of differentially regulated genes
compared to Ldb1/Isl‐1 common peaks (31.8%) (Figure 24B). With respect to specific gene clusters,
the Isl‐1‐alone peaks were more enriched in the brown, red, purple, blue, and green (Figure 24B).
While the purple, blue, and green clusters represent genes that were activated in both models, the
red cluster is enriched in genes that were repressed in both models and the brown cluster reflects
genes that were repressed in the enriched Ldb1‐‐β‐cells but activated in the enriched Isl1‐‐β‐cells.
Taken together this analysis suggests that a putative Ldb1, Isl‐1 complex preferentially but not
exclusively functions as an activator in the mature β‐cell. Whereas, the low and random enrichment
of Isl‐1‐alone peaks in proximity to differentially regulated genes, again, indicates these peaks set
may be artifactual.
Finally we performed de novo motif analysis for both sets of peaks. Starting with Isl‐1‐alone
peaks, de novo motif analysis was not successful in identifying any significantly enriched motifs
(Figure 24C). The three de novo motifs that were identified most frequently closely matched the
MED‐1, Elk1, and Hnf4α consensus sequences but were only identified at 2.4%, 4.8%, and 2.3% of the
Isl‐1‐alone peaks, respectively. Again, another line of evidence indicating the questionable biology of
this peak set. Unlike the Isl‐1‐alone peak set, the Ldb1/Isl‐1‐common set was highly enriched for a de
novo motif matching the Isl‐1 consensus sequence, a consensus sequence almost identical to that of
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Nkx6.1 and Pdx1 (Figure 23F). In addition to the Isl‐1 motif, de novo motifs matching FoxA2, Nkx3.1,
NeuroD1, and Phox2a were also identified (Figure 23F). The density of the Isl‐1, Nkx6.1 and Nkx3.1
motifs with respect to the Ldb1/Isl‐1 common peaks were all centered on the peak (Figure 23G). The
FoxA2 motif was mostly centered at the peak with a small density downstream. Interestingly, the
NeuroD1 motif density was highest flanking the center of the peak, suggesting that NeuroD1 may be
a recruited co‐factor. In light of this motif analysis, we were still surprised that our ChIP‐Seq analysis
had not yielded a clear subset of Isl‐1‐independent, Ldb1‐alone peaks. Given that the variability in
the Isl‐1 ChIP‐Seq signal could possibly be obscuring an Ldb1‐alone group, we went back to the Isl‐1
and Ldb1 ChIP‐seq correlation plot and divided it into eight groups defined by log2(Isl‐1 RPM/Ldb1
RPM) = ±1.5, ±1.0, ±0.5, and 0. We then looked to see if any of our identified motifs (Isl‐1, Nkx6.1,
FoxA2, Nkx3.1, NeuroD1) were uniquely enriched in any of the 8 groups (Figure 24D). Besides the
paucity of motif enrichment in the groups defined by higher Isl‐1 RPM (the Isl‐1‐alone peaks), no
distinct enrichment pattern was identified. Even with this method, we were unable to generate clear
evidence of an Isl‐1‐independent, Ldb1‐only peak set.
Additionally we wanted to use our ChIP‐Seq data to place the requirement for Ldb1 in β‐cells
in the greater context of the Ldb1‐mediated transcriptional paradigms that have been observed in
other cell types. In hematopoiesis, Ldb1 plays an essential role in a multimeric transcription factor
complex that, among other things, directs differentiation by mediating promoter‐enhancer looping
(Love, et al. 2013). This transcriptional paradigm places Ldb1 in a pentameric complex directly
binding Lmo2 that is bridging an E‐box heterodimer and Gata factor (Love, et al. 2013). Another
transcriptional, paradigm implicates Ldb1 homodimers driving cell fate by mediating multimeric
transcription factor complexes containing LIM‐HD proteins. This paradigm has been demonstrated to
be important for as somatic motor and striatal neuron differentiation (Cho, et al. 2014). In these
contexts, a hexameric complex with Isl‐1 bridging a non‐Isl‐1/2 LIM‐HD species with Ldb1 is
predicted (Bhati, et al. 2008). With respect to the former Ldb1‐LMO paradigm our current analysis
would argue against that mechanism functioning in the same fashion in β‐cells. 1) We did not identify
a distinct population of Ldb1‐specific peaks and, maybe more importantly, 2) the de novo motif
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search did not identify any motifs that match the GATA consensus sequence (Li, et al. 2010a). As for
the Ldb1‐LIM‐HD paradigm, this seems to be the strongest possibility. According to the LIM‐HD
paradigm, Isl‐1 would be interacting with another LIM‐HD protein, but no other LIM‐HD motif was
identified. To see if there was any positional relationship between the different de novo motifs, we
performed a bipartite motif analysis. To accomplish this analysis, we chose the Isl‐1 motif to be our
anchor and the Isl‐1 or another motif to be our query. We then scanned 30bp upstream and
downstream of our anchoring motif on the sense strand for our query motif. This scanning was
repeated for every incidence of where the anchor motif was identified in proximity to a called peak.
The analysis using the Isl‐1 motif as the anchor is presented (Figure 23H). We did observe an
increased frequency of sequential Isl‐1 motifs spaced approximately 8 to 12 base pairs apart.
Considering the similarity between Isl‐1 motifs and other LIM‐HD proteins, this would suggest a
multimeric LIM‐HD complex may be forming at a subset of peaks.
L. Analysis of islet‐ and cell‐line‐based cistromes suggest cell‐type‐specific roles for a Ldb1, Isl‐1
complex.
Finally we reconciled our ChIP‐Seq data with the list of pancreatic endocrine‐related genes
that we had identified as differentially expressed in our transcriptome analysis (Table 5). Almost all
the genes that we had identified were in close proximity to at least 1 and often 2+ peaks (200kb
upstream and downstream from the TSS) (Table1). Interestingly, we did not observe any clear peaks
within close proximity to Ins1 nor Ins2, suggesting that in adult islets Ldb1 and Isl‐1 may not be
directly activating insulin expression. Similarly, we did not observe any clear peaks within close
proximity to Neurog3, an indication that Ldb1 and Isl‐1 do not work directly to repress Neurog3
expression. However, we did find multiple Ldb1/Isl‐1 common peaks in proximity to the Slc2a2,
Pdx1, and MafA loci. All three loci had been previously interrogated in an Isl‐1 ChIP‐Seq performed
using chromatin extracted from the βTC‐3 insulinoma line (Ediger, et al. 2014). To provide additional
validation to our peak calling in the islet ChIP‐Seqs, we took a more detailed look at each of those
three loci in direct comparison with the βTC‐3 Isl‐1 ChIP‐Seq that originally described direct
functional role for Isl‐1 at these loci.
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Given that the isolated islets used to perform our Isl‐1 and Ldb1 ChIP‐Seqs are a hetergenous
tissue source, we also incorporated data from an Isl‐1 ChIP‐Seq performed using αTC‐6 glucagonoma
cells to aid in distinguishing signal contributions from α‐ and β‐cells (Liu, et al. 2011). At the three
loci, the signals for the ChIP‐Seqs performed with islet and βTC‐3 chromatin were very similar
(Figure 25A‐C). However, some minor differences existed. For instance, the relative signal strength at
the upstream enhancer elements in the Pdx1 locus were different between the islet and βTC‐3 ChIPs
(Figure 25B) (Gerrish, et al. 2000; Gerrish, et al. 2004). For both the Isl‐1 and Ldb1 ChIP‐Seqs from
islets, the signal intensity at Area I was much more intense than the peaks at Area II and IV. Whereas,
the signal strength of those three peaks in the Isl‐1 βTC‐3 ChIP‐Seq were more evenly enriched. With
respect to MafA, a novel 2nd peak significantly downstream from the characterized Region 3 (Reg. 3)
was observed in both ChIP‐Seqs performed with islets, but there was not corresponding peak in the
Isl‐1 βTC‐3 ChIP‐Seq (Figure 25C) (Raum, et al. 2006). Interestingly, for the very same peak down
stream of MafA, there is a corresponding peak in the αTC‐6 Isl‐1 ChIP‐Seq, whereas, there was no
enrichment for Isl‐1 in the αTC‐6 Isl‐1 ChIP‐Seq at the previously characterized Reg. 3. In fact,
notable differences at the other two loci were observed between the αTC‐6 Isl‐1 ChIP‐Seq and those
ChIP‐Seqs performed with islet and/or βTC‐3 chromatin. These differences would suggest that the
enrichment of Isl‐1 and Ldb1 at these loci are distinct between β‐ and α‐cells and these differences
may have a functional role in directing the distinct expression profiles of these two cell types. To
investigate this further we looked at the Arx locus, a known target of Isl‐1 in α‐cells (Figure 25D). In
the αTC‐6 Isl‐1 ChIP‐Seq, Isl‐1 was enriched in the 3rd intron of Arx and at a second region
downstream of Arx within the last intron of Pola1, as was been described (Liu, et al. 2011). When
examining the Arx locus in both the Ldb1 and Isl‐1 ChIP‐Seq using islets we did not observe a peak
within the last exon of Pola1, but we were surprised to see a very strong peak within the 3rd intron of
Arx. The same pattern of enrichment was observed in the Isl‐1 βTC‐3 ChIP‐Seq, however the peak
within the 3rd intron of Arx was less distinguished. Given the role we have demonstrated for Ldb1
and Isl‐1 in maintaining the cell identity of mature β‐cells, this would suggest a similar role for these
factors in distinguishing and maintaining α‐cell fate.
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DISCUSSION
In this study, we employed an inducible, β‐cell‐specific, loss‐of‐function mouse model to
determine the functional requirement for Ldb1 in the mature β‐cell. Ablating Ldb1, even in
approximately 50% of the β‐cell population, resulted in glucose homeostasis defects predominantly
caused by reduced insulin levels. We complemented the analysis of Ldb1 in the mature β‐cell, with
parallel characterization of a β‐cell‐specific, Isl1 loss‐of‐function mouse model. The physiologic and
morphometric analysis of both mouse models were grossly identical. By performing comparative
high‐throughput analysis of the Ldb1 and Isl‐1 transcriptomes using FACS enriched β‐cells, we were
able to determine the global role that Ldb1 and Isl‐1 play in mature β‐cell biology. From this analysis,
it was evident that both factors were essential for maintaining the functional identity of the mature
β‐cell (Figure 26A). Finally we investigated the mechanistic relationship between Ldb1 and Isl‐1 in
primary mouse islets. Consistent with described mechanistic relationship of Ldb1 and Isl‐1, the two
factors were almost exclusively co‐enriched throughout the genome. Analysis of specific loci,
demonstrated that Ldb1 and Isl‐1 were co‐enriched at previously described cis‐regulatory elements
for Slc2a2, Pdx1, and MafA. (Ediger, et al. 2014; Gerrish, et al. 2000; Gerrish, et al. 2004; Hunter, et al.
2013; Raum, et al. 2006). Finally meta‐analysis of our islet‐based ChIP‐Seq data with cell line‐based
ChIP‐Seq data indicated that common sites of Ldb1, Isl‐1 enrichment are distinct between α‐ and β‐
cells.
Resolved to have comparable physiologic results between the two mouse models, the largest
challenge we faced was synchronizing the induction protocols of both mouse strains. Due to the
relative difficulty of ablating the Ldb1L allele versus the relative ease of ablating the Isl1L allele, the
task was technically challenging. Given that we had previously characterized the Isl1L/L; Pdx1‐
CreERTm mice (Ediger, et al. 2014), we focused on optimizing the induction protocol for the Ldb1L/L;
MIP‐CreERTm mice. Subsequently, we developed a milder protocol for the Isl1L/L; MIP‐CreERTm mice
that would ensure those animals were glucose intolerant but not hyperglycemic at the time of
analysis. While the phenotypes displayed by the inducible, β‐cell‐specific Ldb1 and Isl1 loss‐of‐
function models were grossly similar, we acknowledge that detailed comparison of the two models
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Figure 26. Impairing Ldb1mediated complex formation in βcells collapses the terminally
differentiated state. A. Comparison of key β‐cell factors expressed in mature wildtype β‐cells versus
Ldb1/Isl1 β‐cells. Red font indicates previously identified Ldb1/Isl‐1 direct targets. Green font
indicates putative Ldb1/Isl‐1 direct targets. B. Diagram indicating fate of Ldb1 β‐cells. Black arrows
indicate normal developmental progression from endocrine progenitor (light purple) to endocrine
precursor (dark purple) to immature β‐cell (light blue) to mature β‐cell (dark blue). Red arrows
indicate collapse of mature β‐cell identity following loss of Ldb1. Key expression changes associated
with Ldb1 loss indicated in red with  symbolizing increased expression and  symbolizing
decreased expression. Paracrine effects for α‐ and δ‐cells also presented. C. Ldb1‐mediated
complexes in mature WT, Isl1‐, and Ldb1 β‐cells with Ldb1 (blue), Mnx1 (orange), and Isl‐1 (green).
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revealed minor discrepancies that, in most cases, reflected the relative severities of the glucose
homeostatic phenotypes. The Isl1L/L; MIP‐CreERTm mice consistently displayed more efficient
ablation that correlated with increased glucose homeostatic dysfunction.
We argue that the differences in gene ablation rather than biological differences reflecting
the requirement for Isl‐1 and Ldb1 account for the more sever phenotype in the Isl1L/L; MIP‐CreERTm
mice. In support of this argument, key genes regulating β‐cell function were more acutely miss‐
expressed in the enriched Ldb1β‐cells than the enriched Isl1β‐cells. The levels of Ins1 and Ins2
expression in the enriched Ldb1β‐cells were respectively 5.6 and 6.5 fold less than in the enriched
Isl1β‐cells. The mosaic ablation of Ldb1 may also account for the lack of phenotypic penetrance in
the Ex‐4 and KIC static incubations. The Glp1R levels in the enriched Ldb1β‐cells was 2.5 fold less
than in the enriched Isl1β‐cells, however the Isl1L/L; MIP‐CreERTm islets displayed severely
impaired Ex‐4 potentiated insulin signaling. Likewise, the Ldb1L/L; MIP‐CreERTm islets did not exhibit
an impaired KIC response despite a 3.0 and 2.7 fold decrease in the respective expression of Kcnj11
and Abcc8, the genes encoding the two subunits of the ATP‐dependent potassium channel. Ultimately,
the physiological defects of Ldb1 β‐cells were likely masked at the whole animal and islet levels due
to Ldb1L ablation efficiency.
With regard to the methodology employed in the RNA‐Seq experiment, we also acknowledge
that the differences in the experimental design makes direct comparison of the datasets more
complicated. With that in mind, we expected that some differences between the two transcriptomes
would arise, but we were surprised at just how disparate they were. The Brown, Cyan, and Orange
clusters, where differential gene expression behavior was in disagreement between the enriched
Ldb1 and Isl1β‐cells, were unexpected. Coincidentally, gene ontology analysis of the Brown and
Cyan clusters, the clusters where expression was elevated in the enriched Isl1β‐cells and reduced
in the enriched Ldb1β‐cells, returned terms relating to mitosis. Given that the enriched Isl1β‐cells
were isolated from mice approximately two‐weeks younger than those of from the Ldb1L/L; R26LSLeYFP;
MIPCreERTm and R26LSLeYFP; MIPCreERTm mice, it is possible that both of these clusters reflect the
youth of the islets as opposed to a biological consequence of ablating Isl1. Moreover, the timing of
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enriched Isl1β‐cells isolation corresponds with the waning of a postnatal period of β‐cell expansion
(Jiang, et al. 2008).
When interpreting the RNA‐Seq data, we found that it detected highly expressed genes from
contaminating cell‐types as was observed with Sst and Gcg. The RNA‐Seq analysis was also sensitive
enough to detect robust expression changes in contaminating cell populations as seen with the 50+
fold upregulation of Gast in both the enriched Isl1β‐cells and Ldb1β‐cells. Our
immunofluorescence results indicate the Sst, Gcg, and Gast signals are derived from non‐β‐cell, eYFP‐
sources in the Ldb1L/L; R26LSLeYFP; MIPCreERTm mice. Due to the small cell populations we were
sorting, the technical limitations of the FACS instrument and the downstream RNA‐library protocols
prevented us from performing purifying selections. Purifying our populations would have
significantly reduced our already low yields, and would have almost certainly forced us to prepare
our RNA‐Seq libraries using amplification methods, a means of introducing unnecessary bias due to
preferential sequence amplification. Despite this limitation, the transcriptome results achieved with
the enriched Ldb1β‐cells vindicate our selection of methodology over isolated islets. If our co‐
immunofluorescence analysis of the Ldb1L/L; R26LSLeYFP; MIP‐CreERTm islets is representative of the
enriched Ldb1β‐cells, our sorting protocol was able to exclude the majority of noise resulting from
the population of non‐recombined β‐cells. We were also surprised by the lack of overlap between the
microarray from isolated islets using Isl1L/L; Pdx1‐CreERTm mice described in Chapter 2 and our Isl‐1
transcriptome data. Despite the differences between the experiments, we believe the lack of overlap
represents the increased sensitivity and specificity we achieved by enriching for β‐cells with FACS
and performing RNA‐Seq instead of microarray.
With the cistromic datasets that we generated using primary islets, we want to exercise
caution in categorically excluding biology that we were not able to detect in our experiments. This is
especially true in the case of our analysis where the read depth for both the Ldb1 and Isl‐1 ChIP‐Seqs
was low. Therefore, we believe our cistromic data should be interpreted as reflecting the most robust
functional Ldb1 and Isl‐1 targets. Additionally, the isolated islets represent a heterogeneous tissue
population. Given that Ldb1 and Isl‐1 are expressed in all mature pancreatic endocrine cells, it is
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difficult to exclusively claim enrichment of any factor at any particular locus as β‐cell‐specific, and it
is simultaneously difficult to dismiss less robust patterns as they may reflect non‐β‐cell biology. To
better indicate the cell‐type specificity of the peaks identified at triaged loci, we included the βTC‐3
and αTC‐6 Isl‐1 ChIP‐Seqs in our locus‐specific analysis.
Our current study places Ldb1, a factor with no DNA‐binding nor enzymatic activity
(Matthews and Visvader 2003), at the center of regulating mature β‐cell‐function. More detailed
analysis of the Ldb1 transcriptome and cistrome data indicates a putative role in regulating genes
that have been attributed to directing β‐cell‐identity (Figure 26A). These genes include MafA, the
gene encoding the β‐cell terminal maturation factor, and Pdx1, the gene encoding the factor that
specifies the β‐cell fate of pancreatic endocrine progenitors. Additionally, ablating Ldb1 in mature β‐
cells leads to the cell‐autonomous up‐regulation of Neurog3, the factor that specifies pancreatic
endocrine fate. The importance of these three factors in pancreatic endocrine and β‐cell development
has been well established. Misexpression of MafA, Pdx1, and Neurog3 in various combinations has
been sufficient to induce β‐cell‐like phenotypes in numerous mature cell‐types (Hang and Stein 2011;
Nomura, et al. 2006; Zhou, et al. 2008). For instance, misexpression of all three factors converted
epithelial intestinal cells to functional insulin‐producing cells that were capable of ameliorating mice
with induced hyperglycemia (Chen, et al. 2014b). Given the importance both MafA and Pdx1 have in
relation to establishing and maintaining β‐cell identity, ablating Ldb1 in mature β‐cells effectively
collapsed their terminally differentiated status (Figure 26B). Interestingly, the phenotypes observed
in both the Ldb1‐β‐cells closely resembles the recently described functional senescence and
dedifferentiation displayed by FoxO1‐β‐cells that are exposed to prolonged metabolic stress (Pajvani
and Accili 2015a; Talchai, et al. 2012). Similar to the Ldb1‐β‐cells, the metabolically stressed FoxO1‐
β‐cells are functionally defective, retain ChgA expression, display reduced MafA and Pdx1, and
upregulate Neurog3. Despite these similarities, the Ldb1‐β‐cells do not activate the pluripotency
markers Oct4 and Nanog as described in the metabolically stressed FoxO1‐β‐cells. In light of these
observations, it is possible that Ldb1‐β‐cells have not dedifferentiated as extensively as the stressed
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FoxO1‐β‐cells. In support of this, other factors associated with β‐cell and endocrine identity remain
expressed in the Ldb1‐β‐cells such as Pax4 and Nkx2.2.
The metabolically stressed FoxO1‐β‐cells were also reported to activate glucagon, pancreatic
polypeptide, and somatostatin (Talchai, et al. 2012). Based on the detection of increased Gcg, Sst, and
Gast transcript in the Ldb1‐ and Isl1‐β‐cell transcriptomes, we were intrigued that a population of
the Ldb1‐ and Isl1‐β‐cells may have also been expressing ectopic hormones. However, we were
unable to find any evidence supporting expression of Gcg, Sst, and Gast in the lineage‐traced Ldb1‐β‐
cells. Instead, the increased expression of Gcg, Sst, and Gast was most likely due to paracrine
activation in non‐β‐cells. While these findings further distinguish the dedifferentiation phenotypes
between the Ldb1‐β‐cells and the metabolically stressed FoxO1‐β‐cells, these findings are also
consistent with the requirement for both Ldb1 and Isl‐1 in the developing endocrine pancreas (Du, et
al. 2009; Hunter, et al. 2013). Both Ldb1 and Isl‐1 are required for the differentiation and hormone
activation of the α‐, β‐, δ‐, and PP‐cell populations. Therefore, the lack of trans‐differentiation
following Ldb1 ablation in the mature β‐cell adds support to a continuous role for Ldb1‐mediated
complexes in establishing and maintaining β‐cell fate in the prenatal, postnatal, and mature animal.
Moreover, Ldb1‐mediated complexes may have a broader role in establishing and maintaining the
identities of the non‐β‐cells in the adult endocrine pancreas. It was previously demonstrated that the
somatostatin+ population of the Pdx1+ δ‐cells was significantly decreased in Isl1L/L; Pdx1CreERTm
mice (Ediger, et al. 2014). Now, our current Isl‐1 cistromic analysis indicates that Isl‐1 is
differentially enriched at the Arx and MafA loci between insulinoma and glucagonoma cells.
Our data strongly argue that Ldb1 interacts almost exclusively with Isl‐1 in the mature β‐cell.
Consequently, the predominant Ldb1 transcriptional paradigm in the mature β‐cell is most likely the
LIM‐HD paradigm. The Ldb1‐mediated LIM‐HD transcriptional paradigm plays a crucial role in
directing neuronal fate in both the central and peripheral nervous systems; the terminal identity of
many neuronal progenitors is largely determined by the varying LIM‐HD species that are
incorporated into Ldb1‐mediated complexes (Cho, et al. 2014; Hunter and Rhodes 2005). In the
biological contexts where Isl‐1 is the direct Ldb1 binding partner, a second species of LIM‐HD factor
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is incorporated into the functional complex. (Bhati, et al. 2008). For example, in the somatic motor
neuron progenitor population, an Lhx3:Isl‐1:Ldb1:Ldb1:Isl‐1:Lhx3 hexamer drives differentiation
(Thaler, et al. 2002). Thus, the relationship between Isl‐1 and Ldb1 in the mature β‐cell is likely to
involve additional layers of complexity and other LIM‐HD factors. It is very likely that the functional
Ldb1‐mediated complex in the mature β‐cells contains both Mnx1 and Isl‐1 (Figure 26C). Mnx1 is
highly enriched in mature β‐cells (Harrison, et al. 1999; Li, et al. 1999) and our RNA‐Seq data
demonstrates that Mnx1 is the second most enriched LIM‐HD and LMO species in β‐cells after Isl1.
The abundance of Mnx1 may also reconcile the highly correlated Ldb1 and Isl‐1 primary islet
cistromes with the dissimilar Ldb1‐ and Isl1‐β‐cell transcriptomes. While ablating Ldb1 in mature
β‐cells eliminates the capacity to form any Ldb1‐mediated complexes, singularly ablating Isl1 in
mature β‐cells only removes the predominant Ldb1 binding partner (Figure 26C). Therefore, Ldb1 is
still capable of aggregating other LIM‐HD and LMO factors into multimeric complexes in the Isl1‐β‐
cells.
While we have demonstrated that Ldb1 is required for maintaining the terminal
differentiation status of pancreatic β‐cells, moving forward it will be necessary to fully elucidate the
mechanism by which Ldb1 and Isl‐1 maintain the identity of pancreatic β‐cells. Intriguingly, Ldb1‐
mediated complexes are required for the promoter‐enhancer looping interactions that drive
hematopoiesis and erythropoiesis (Krivega, et al. 2014). However, this function of Ldb1 had only
been observed in the context of Ldb1 interacting directly with LMO factors (Love, et al. 2013).
Recently, Ldb1‐dependent looping was also demonstrated to be required for cardiomyocyte
progenitor differentiation (Caputo, et al. 2015a). Importantly, Ldb1‐dependent looping in the
cardiomyocytes was dependent on an Ldb1, Isl‐1 complex. Given this finding, it is very likely Ldb1
and Isl‐1 are required for directing promoter‐enhancer looping in the mature β‐cells.
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CHAPTER 4
CONCLUDING REMARKS
Ldb1 and its evolutionary orthologs are the cornerstone of a dynamic, multifaceted
transcriptional paradigm that facilitates cellular complexity throughout biology (Love, et al. 2013;
Matthews and Visvader 2003). The LIM‐HD transcription factor Isl‐1 is one of the essential partners
through which Ldb1 directs the cell‐fate of progenitor populations within the developing organism
(Hunter and Rhodes 2005). Both Ldb1 and Isl‐1 are enriched in the pancreatic endocrine progenitors
where they are required for the terminal differentiation of the cell types that populate the mature
endocrine pancreas (Du, et al. 2009; Hunter, et al. 2013). In the terminally differentiated cell‐types of
the mature pancreas, these two developmental partners, Isl‐1 and Ldb1, remain expressed. In
Chapter 2, I combined physiologic characterization of an inducible, β‐cell‐specific Isl1 loss‐of‐
function mouse with meta‐analysis of high‐throughput cistromic and transcriptomic data to
demonstrate that Isl‐1 directly regulates β‐cell function in the adult mouse. In Chapter 3, I utilized
high‐throughput transcriptome and cistrome analysis in combination with inducible loss‐of‐function
and lineage‐tracing mouse models to demonstrate an Ldb1, Isl‐1 complex coordinates the
maintenance of β‐cell‐fate in the mature pancreas (Figure 26).
While the work presented in Chapters 2 and 3 focuses on mature β‐cell biology, these β‐cell‐
specific findings also have broader implications with respect to all of the cell‐types that populate the
mature endocrine pancreas. As mentioned in Chapter 1, the terminally differentiated, functionally
distinct cell‐types that comprise the mature pancreatic endocrine compartment 1) originate from a
common progenitor population and 2) retain Isl‐1 and Ldb1 expression in the adult animal (Gu, et al.
2002; Hunter, et al. 2013; Thor, et al. 1991). Based on these two established observations, my
findings that Isl‐1 and Ldb1 are required for maintaining mature β‐cell function and identity suggest
that one of two axioms broadly encompass the functional requirement for Isl‐1 and Ldb1 in the β‐
and non‐β‐cells in the mature endocrine pancreas. Ldb1 and Isl‐1 must either have identical
functional requirements in every cell‐type within the endocrine pancreas, or some biological
mechanism must delineate the distinct functional requirement for Isl‐1 and Ldb1 on a cell‐type by
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cell‐type basis. Given the well‐characterized mechanistic role that Ldb1‐mediated complexes play in
directing cell‐fate decisions (Hunter and Rhodes 2005; Love, et al. 2013), it is quite possible that a
mechanism similar to the ‘LIM Code’ that defines motor neuron differentiation and sub‐type
specification directs endocrine pancreas differentiation and reinforces the cellular identity of all
mature pancreatic endocrine cell‐types (Alaynick, et al. 2011).
A. BROAD GOALS FOR FUTURE INVESTIGATION OF LDB1 AND ISL‐1 IN THE PANCREAS.
Given the findings presented in Chapters 2 and 3, many future directions of investigation can
and should be pursued. These future lines of investigation can be encompassed into three distinct but
interconnected aims. The first aim would be to characterize, mechanistically, how Ldb1 and Isl‐1
maintain the identity of the terminally differentiated β‐cells. The second aim would be to determine
the functional role of Ldb1 and Isl‐1 in the non‐β‐cell endocrine cells and connect these findings to
the known mechanisms that specify the mature pancreatic endocrine lineages. The third aim would
be to characterize the β‐cell Isl‐1 and Ldb1 cistrome throughout development and physiologically
interesting postnatal time points.
Overarching all three aims would be the desire to perform these experiments using human
tissue when appropriate and justified. It is well‐established that there are many biological differences
between the mouse and human endocrine pancreas (Nair and Hebrok 2015). In humans, unlike mice,
the endocrine progenitors are specified in a single wave and a large fraction of the early endocrine
cells are polyhormonal (Bocian‐Sobkowska, et al. 1999; Salisbury, et al. 2014). While the
transcriptional networks that direct endocrine cell fate seem to be mostly conserved between
humans and mice (Pan and Wright 2011), the cytoarchitecture of the developing islets in humans
undergoes dynamic changes that are not observed in mice (Nair and Hebrok 2015). Initially human
islets are organized similar to that of mice, but they rearrange so that the α‐ and β‐cells are almost
completely separated into homogenous clusters (Jeon, et al. 2009). The cells within islets rearrange
themselves one final time so that all cell types appear mixed together with no apparent organization
(Cabrera, et al. 2006). Additionally, the proportion of the mature cell‐types is different in humans
than mice. In humans, there is a more equivalent ratio of β‐cells (50%) to α‐cells (40%), a
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significantly larger portion of δ‐cells (10%), and very few PP cells (Brissova, et al. 2005). In the
mature human islets, GLUT2 (SLC2A2) is not the essential glucose transporter nor is MAFB
expression down‐regulated in the post‐natal β‐cells (McCulloch, et al. 2011). Even the cis‐regulatoy
elements for orthologous loci can be significantly different between mice and humans as illustrated
with the insulin promoter (Hay and Docherty 2006).
While the data generated from human tissue are clearly more medically relevant, technical
tradeoffs do exist when performing experiments with human islets. The pros are that cadaveric islets
provide significantly greater experimental material, the non β‐cells populations are more abundant,
and characterized surface markers enable isolation of specific cell populations (Dorrell, et al. 2008).
Nonetheless, the level of experimental control is complicated by genetic diversity of humans and the
lifestyle of individual donors. Ethically, any human tissue sample that is donated for scientific
research should be considered very precious material and used judiciously and respectfully. This is
especially true for human islets because the process of isolating human islets almost exclusively
requires that they be obtained from deceased donors.
B. INTEROGATING THE MECHANISM OF ACTION BETWEEN LDB1 AND ISL1 AND POTENTIAL PARTNERS IN
THE β‐CELL: TRANSCRIPTIONAL SCAFFOLDING
Considering the cistromic analysis performed in Chapter 3, the potential mechanistic
function for Ldb1 and Isl‐1 in the mature β‐cells likely reflects the LIM‐HD domain paradigm
introduced in Chapter 1. In the context of that transcriptional paradigm, the current consensus is that
Isl‐1, for biochemical reasons, cannot interact with Ldb1 in the absence of another LIM‐HD factor
(Bhati, et al. 2008). Instead, Isl‐1 incorporates itself into a trimeric complex by bridging an Ldb1 and
a LIM‐HD factor (Bhati, et al. 2008). For instance, a trimeric complex directs the cholinergic fate of
the somatic motor neurons and striatal interneurons (Cho, et al. 2014). Our bipartite motif analysis in
Chapter 3 suggests a similar trimeric complex may occur in islets. It is clear from the enriched β‐cell
RNA‐Seq data that Mnx1 was by far the second most abundant transcript encoding a LIM‐HD or LMO
factor identified. Furthermore, Mnx1 expression is known to be restricted to the β‐cell in the mature
endocrine pancreas (Harrison, et al. 1999; Li, et al. 1999). If a biochemically stable Isl‐1, Ldb1

130

complex requires incorporation of another LIM‐HD factor, then it would seem Mnx1 would be the
most likely candidate in mature β‐cells (Figure 26C). Nevertheless, our enriched β‐cell RNA‐Seq data
also identified other putative LIM‐HD and LMO species are expressed at lower levels in the enriched
β‐cell population. Are these other LIM‐HD and LMO transcripts expressed in β‐cells, or are they
signal from non‐β‐cells similar to what was observed with gastrin, glucagon, and somatostatin in the
Ldb1L/L; R26LsLeYFP; MIPCreERTm animals? To conclusively determine which Ldb, LIM‐HD, and LMO
factors are expressed in mature β‐cells, single‐cell RNA‐Seq of dispersed islets could be used, coupled
with immunofluorescence if appropriate detection tools are available. In those cDNA libraries that
we are certain represent single cells, transcriptomes could be assigned cell‐identities based on
hormone expression. Additionally, this type of analysis could determine if distinct splice variants of
Isl‐1, like the one that disrupts the Isl‐1LID and is enriched in a portion of developing retinal ganglion,
is indeed enriched in mature β‐cells (Ando, et al. 2003; Whitney, et al. 2015). Moreover, the single‐
cell RNA‐Seq analysis could generate the Ldb, LIM‐HD, LMO expression profiles for all the endocrine
and exocrine cell types in the mature pancreas.
Our cistromic analysis from Chapter 3 also identified multiple de novo motifs corresponding
to consensus sequences of transcription factors with known function in the mature β‐cell including
Nkx6.1, Pdx1, FoxA2, and NeuroD1. Notably, a recent and thorough study comparing the cistromes of
PDX1, FOXA2, NKX2.2, NKX6.1, and MAFB to the epigenomic landscape of human islets found that
active enhancers were significantly more likely to be enriched for multiple (2, 3, 4, and even all 5)
transcriptions factors (Pasquali, et al. 2014). Moreover, they demonstrated these active enhancer
regions bound by transcription factors are more likely to be incorporated into higher‐level chromatin
structures. Given these findings, aggregation of multiple transcription factors at Ldb1/Isl‐1 common
sites of enrichment may not be that unexpected. In regards to general Ldb1 function, transcriptional
activation and repression appears largely regulated by recruited cofactors especially in the Ldb1‐
LMO paradigm that was introduced in Chapter 1. In the context of the SCL‐complex, incorporation of
Gata2 versus Gata1 is associated with transcriptional repression versus activation, respectively
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(Bresnick, et al. 2010). Mechanistically, Gata2 containing complexes recruit Eto2 a co‐repressor
protein that in turn recruits NCor, Sin3, and HDACs (Goardon, et al. 2006; Meier, et al. 2006).
In regards to the LIM‐HD paradigm, a role for recruited cofactors has not been significantly
investigated. As discussed before, there is evidence that Nkx6.1 occupancy at an intronic cis‐
regulatory element in Arx represses Arx in β‐cells, whereas, Isl‐1 occupancy at the same site activates
Arx expression in α‐cells (Schaffer, et al. 2013). Interestingly, we identified both Ldb1 and Isl‐1 as
significantly enriched at the intronic cis‐regulatory element of Arx in islets, suggesting Nkx6.1 might
directly interact with Isl‐1 in a repressive manner. The prevalence of NeuroD1 is also interesting
because it is a bHLH factor and its motif enrichment is densest flanking the peak center, a pattern
associated with co‐factor binding. In motor neurons the proneural bHLH factors act synergistically
with LIM‐HD factors (Lee and Pfaff 2003). NeuroD1 has been demonstrated to interact with Isl‐1
when exogenously expressed in 293T as well as HIT‐T15 cells (Huang, et al. 2000; Peng, et al. 2005);
however, no endogenous interaction was detected in βTC3 cells (Hunter, et al. 2013). Recently, even
a functional Pdx1, Isl‐1, Set7/9 complex was detected in HIT‐T15 and NIT‐1 cells, where Set7/9 acts
as a bridge for Isl‐1 and Pdx1 as well as a methyltransferase (Yang, et al. 2015). However, in the case
of FoxA2, there is no precedent for its involvement with Ldb1‐mediated transcriptional paradigms.
Therefore, continued in silico analysis of our cistromic datasets from Chapter 3 that
incorporates available NeuroD1, Pdx1, Nkx6.1, and FoxA2 cistromic mouse islet data and the
epigenomic landscape, e.g. histone methylation, histone acetylation, CTCF enrichment and DNA
methylation will be insightful. Unlike the previously mentioned human islet analysis, we will be able
to overlay our transcriptional analysis from Chapter 3 to indicate the functional significance of
putative transcription factor complexes. This analysis may prove useful in distinguishing whether an
Ldb1, Isl‐1 complex is functioning in an activating or repressive manner. While meta‐analysis of our
transcriptomic and cistromic datasets suggests that an Ldb1, Isl‐1 complex preferentially activates its
targets, the Ldb1, Isl‐1 peaks were also enriched in proximity to genes that were activated in our
loss‐of‐function mouse models suggesting the possibility that Ldb1, Isl‐1 complexes can also mediate
transcriptional repression.
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C. INTEROGATING THE MECHANISM OF ACTION BETWEEN LDB1 AND ISL1 AND POTENTIAL PARTNERS IN
THE β‐CELL: PROMOTER‐ENHANCER LOOPING
The current mechanistic understanding of the Ldb/LIM‐HD paradigm has been significantly
influenced by early work performed in Drosophila and chicken embryos investigating wing and
motor neuron development, respectively (Thaler, et al. 2002; van Meyel, et al. 1999). While clever
use of conjugated proteins has strongly supported the functional role of Ldb1, LIM‐HD dimers and
trimers in these developmental contexts (Lee, et al. 2012; Lee and Pfaff 2003; Thaler, et al. 2002), the
LIM‐HD mechanism, broadly speaking, remains under‐characterized with respect to both today’s
experimental standards and implementation of current experimental techniques. Possibly one
reason why this field has lagged behind others is the difficulty of isolating enough biological material
from progenitor populations to perform certain experiments and the simultaneous lack of relevant
cell lines to use as a substitute. In light of the work presented in Chapters 2 and 3, the pancreatic
islets (mouse and humans), the associated relevant immortalized cell lines, and iPSC β‐cell directed‐
differentiation protocols, collectively, could be an integral biological context for expanding the
frontier of knowledge regarding the Ldb1, LIM‐HD transcription paradigm in a similar fashion to
SCL‐complex in models of hematopoiesis and erythropoiesis. Thus, to fully characterize the
mechanism of Ldb1, Isl‐1 complexes in the mature β‐cell, it is important to acknowledge the
unsupported presumptions and heuristics of the Ldb‐mediated LIM‐HD paradigm. The following are
three important examples: Ldb factors dimerize in a 1:1 ratio; Ldb factors self‐associate into
homologous multimers; and the 2 or 4 homeodomains within the tetrameric or hexameric
complexes, respectively, recognize and interact with sequential homeobox elements that are in close
proximity. While there may be truth to these mechanistic presumptions in certain biological contexts,
they have never been rigorously tested.
With that in mind, one tantalizing aspect of the Ldb1/Isl‐1 mechanism in β‐cells that would
be interesting to investigate is the possibility that these complexes mediate chromatin looping. While
looping runs counter to the presumed role of Ldb‐mediated LIM‐HD complexes, it is one of the major
roles Ldb1 plays as a component of the SCL‐complex in hematopoiesis and erythropoiesis (Kim and
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Dean 2012; Krivega, et al. 2015; Krivega, et al. 2014). Similar to the lack of investigation of promoter‐
enhancer looping in the Ldb‐mediated LIM‐HD looping, promoter‐enhancer looping has not been
extensively investigated in the context of endocrine pancreas biology. However, promoter‐enhancer
looping has become an almost de facto component of the molecular mechanisms by which distal cis‐
regulatory elements mediate gene expression (Cavalli and Misteli 2013). Our targeted analysis of loci
with biological relevance to β‐cells and the endocrine pancreas performed in Chapter 3
demonstrated that multiple peaks were often enriched in proximity to a specific locus, and these
peaks were often spaced from each other and the TSS by at least 10 to 20kb. To investigate whether
Ldb1‐mediated looping is occurring in β‐cells, I would first want to perform chromatin conformation
capture (3C) at loci like Slc2a2 and Nkx6.1 that contain multiple peaks. Due to the large amount of
chromatin needed to perform these experiments and the significant similarity between the peaks
identified in the islet and βTC‐3 Isl‐1 ChIP‐Seqs, I would perform the experiments in βTC‐3
insulinoma cells instead of primary mouse islets. If the initial 3C experiments are successful,
knockdown and exogenous expression of dominant negative Ldb1 could be used to specifically
implicate a functional role for Ldb1 in mediating chromatin looping. From there, I could think of
expanding investigations into more relevant cell‐types and/implementing more powerful techniques
such as ChIP‐loop or ChIA‐PET. In support of this line of investigation, a recent study demonstrated
that the Ldb1, Isl‐1 complex mediates looping that is required cardiomyocyte differentiation (Caputo,
et al. 2015b).
Admittedly, in asserting the hypothesis that an Ldb1, Isl‐1 complex mediates promoter‐
enhancer looping, it should be noted that a low percentage of our called Ldb1/Isl‐1 common peaks
occupied the distal and proximal promoter region (‐10kb to +1kb). Interestingly, this observation is
in contrast to previous studies arguing that Isl‐1 is enriched at the proximal promoter of putative
targets such as Ins1, Ins2, Iapp, Sst, Gcg, Ccnd1, and Myc (Guo, et al. 2011; Karlsson, et al. 1990;
Leonard, et al. 1992; Wang and Drucker 1995; Wang and Drucker 1996). Granted, most of these
studies proposed a regulatory relationship between Isl‐1 and a particular gene based on reporter
assays using constructs containing fragments of the respective proximal promoters. ChIP was only
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employed to demonstrate Isl‐1 enrichment in the proximal promoters of Ccnd1 and Myc in HIT‐T15
cells (Guo, et al. 2011). Nevertheless, neither of our ChIP‐Seq datasets from islet chromatin
corroborate Isl‐1 enrichment at any of these putative cis‐elements in the proximal promoters.
Notably, peaks at significantly greater distances from the transcription start site were identified for
Iapp, Sst, and Gcg. But, there were no robust peaks in a 200kb window of the TSS of either Ins1 or
Ins2. Historically, this is significant because Isl‐1 was originally identified because it bound to a DNA
probe that was composed of a homeobox‐rich portion of rat Ins1 proximal promoter (Karlsson, et al.
1990). Overall, standalone use of reporter assays no longer meet today’s standard for confirming a
direct functional requirement for a cis‐regulatory element. If I were to confirm any novel cis
elements identified in my cistromic analysis, I can now use CRISPR technology to selectively disrupt
putative cis‐regulatory elements in biologically relevant cell lines.
Given the paucity of Ldb1/Isl‐1 common peaks in the distal promoter region, it is interesting
to speculate whether there is any biological function associated with the Isl‐1‐alone peak set
described in Chapter 3. Unlike the Ldb1/Isl‐1 common set of peaks, almost a third of the Isl‐1‐alone
peaks are proximal to the transcription start site, however, the de novo motif enrichment associated
with the entire set of peaks did not yield robust results. Taken together this would suggest the
majority of those peaks are due to non‐specific binding or DNA‐independent binding. Additionally,
only about 9% of the Isl‐1‐alone peaks were in a ±100kb proximity to any TSS for a gene that was
identified in the RNA‐Seq clustering analysis; the absence of association with functional gene
regulation further supports the contention that these peaks are artifactual. To conclusively
demonstrate whether these Isl‐1‐alone peaks are real or not, a ChIP‐Seq using islets from the Isl1
loss‐of‐function mouse could be performed. Likewise a similar experiment using islets from the Ldb1
loss‐of‐function mouse could be performed to validate Ldb1 peaks.
If the 3C experiments do establish that Ldb1 mediates looping in the β‐cell, that could lead to
a very interesting line of experimentation. A number of interesting studies have been performed in
erythrocytes characterizing the role for Ldb1‐mediated chromatin looping in erythropoiesis. As
introduced in Chapter 1, Ldb1‐mediated looping is responsible for localizing the chromatin to the
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transcriptionally active areas of the nucleus (Krivega, et al. 2014; Song, et al. 2010). In fact, detailed
study of the β‐globin locus has revealed Ldb1‐mediated looping coordinates the temporal expression
of the different β‐globin isoforms (Kim and Dean 2012). Now, researchers have successfully forced
Ldb1‐mediated looping and consequently gene expression by conjugating the Ldb1SAD to designer
zinc‐finger proteins (Deng, et al. 2012; Deng, et al. 2014b). If Ldb1 mediates looping in β‐cells, a
similar experimental path could be followed with the goal of utilizing designer Ldb1‐zinc‐finger
proteins to force expression of important developmental/therapeutic genes. In the context of
generating functional β‐cells from iPSCs, forced Ldb1‐mediated looping could potentially be used to
increase the efficiency of protocols as well as improve the cell‐type purity of the resulting cell
populations.
D. INTEROGATING THE BROADER REQUIREMENT FOR ISL1 AND LDB1 IN THE ENDOCRINE PANCREAS.
Another important observation to come from our cistromic analysis in Chapter 3 was made by
collectively comparing our islet‐based ChIP‐Seq data against βTC‐3‐ and αTC‐6‐based ChIP‐Seq data
for Isl‐1 (Ediger, et al. 2014; Liu, et al. 2011). By comparing all four datasets, we were able to use
primary tissue data to judge the validity and biological relevance of the data generated in the
immortalized cell lines. Excitingly, we identified peaks in both islet‐based cistromes that were unique
to either the βTC‐3 or αTC‐6 Isl‐1 ChIP‐Seqs. Often the putative α‐cell‐specific signal identified in the
αTC‐6 Isl‐1 ChIP‐Seqs was observed in the islet‐based ChIP‐Seqs but at a lower intensity, an
observation that may reflect the lower ratio of α‐cells to β‐cells in mouse islets. Broadly, these
observations would signify that the sets of Ldb1, Isl‐1 common peaks in mature α‐ and β‐cells are
distinct. This observation is even more interesting considering differential enrichment was observed
at Arx and MafA the respective factors involved in α‐ and β‐cell differentiation and maturation.
Moreover, work we performed in Chapter 2 indicates that Isl‐1 was required for somatostatin
expression in the subset of Pdx1+ δ‐cells. Collectively, these observations have justified exploring the
functional role of Ldb1 and Isl‐1 in the non‐β‐cell endocrine cells and hopefully connecting it to
mechanisms of pancreatic endocrine progenitor fate‐determination.
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Experimentally, I think the single‐cell RNA‐Seq analysis, suggested above, will be important
for this endeavor. It will aid in understanding whether distinct Ldb1, Isl‐1 binding partners are
expressed in the non‐β‐cells versus the β‐cells. Given the characterized relationship between POU‐
domain containing factors and Isl‐1 in the retina and other biological contexts (Deng, et al. 2014a; Li,
et al. 2014), the α‐cell enriched Pou3f4 (Brn4) is of distinct interest. More targeted in silico analysis of
the cistromic datasets analyzed in Chapter 3 may be required with respect to the αTC‐6 dataset;
almost no analysis besides alignment has been performed on it. Following peak‐calling, de novo motif
analysis, and a correlative analysis with the peaks in the βTC‐3‐ and islet‐based Isl‐1 ChIP‐Seqs, there
will be a more stable foundation of knowledge to decide the best direction of investigation. It would
be especially interesting to determine if the less enriched de novo motifs in the islet‐based ChIP‐Seqs
correlate with the αTC‐6 peaks.
Given the heterogeneity of primary islets, do the less‐enriched de novo motifs indicate
background noise or real biology in the non‐β‐cells? For instance, the de novo motif matching the
consensus sequence for the paired‐like homeobox factor Phox2a was lowly enriched in the Ldb1, Isl‐
1 common peak set. While there is no clear connection between Phox2a and the endocrine pancreas
biology in the literature, paired‐like homeobox factors, including Phox2a, are known partners of Isl‐1
and Ldb1 in multiple biological contexts (Bach, et al. 1997; Mazzoni, et al. 2013). It may be possible
that a paired‐like homeobox factor is also interacting with Ldb1 and Isl‐1 in α‐, δ‐, and PP‐cells. Given
the lack of reliable non‐β‐cell mouse models and the relatively small fraction these respective cell‐
types represent of the mouse endocrine pancreas, further investigating the function of Isl‐1 and Lbd1
in the non‐β‐cells will need to be performed using human tissue. As mentioned above, sorting
strategies for the mature cell types of the human pancreas exist (Dorrell, et al. 2008). Additionally,
the α‐ and δ‐cell populations are significantly more abundant in human islets (Brissova, et al. 2005).
In this context it would be possible to generate human cell‐type‐specific cistromes for Isl‐1 and Ldb1
in almost all mature human endocrine cell‐types. Analysis of the Ldb1 cistromes could also be
extended to the ductal and acinar cells where Ldb1 is also expressed. To test the functional
properties of potential cell‐type specific Isl‐1, Ldb1 targets, CRISPR technology could be used to
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disrupt cis‐elements and then the resulting effect on human iPCS directed differentiation of
endocrine cells could be characterized.
E. INTEROGATING AND QUANTIZING THE TEMPORAL REQUIREMENT FOR ISL1 AND LDB1 IN THE β‐CELL.
Returning to mouse β‐cell biology, Ldb1 is ubiquitously expressed in the developing
pancreas prior to pancreatic endocrine specification (Hunter, et al. 2013), and Isl‐1 is activated
shortly after specification of the endocrine progenitor (Du, et al. 2009). As has been repeatedly
mentioned, both Isl‐1 and Ldb1 remain expressed in the terminally differentiated β‐cells (Hunter, et
al. 2013; Thor, et al. 1991). The findings in Chapter 2 and 3 illustrate that both of these factors are
required for the function of the mature β‐cell. Chapter 3 indicates that ablating either of these factors
in the mature β‐cell actually results in loss of mature cell identity and the reactivation of the
endocrine progenitor factor Neurog3. While these Ldb1 and Isl1 cells do not faithfully recapitulate
an endocrine progenitor, the results clearly demonstrate that these two factors are intrinsically
linked to the maintenance of terminal β‐cell identity. In line with this important role and extended
expression pattern, it follows that the functional role for these two factors would faithfully reflect the
cell biology of the β‐cells throughout the lifetime of the animal. For instance, aging is correlated with
reduced β‐cell functionality and regenerative capacity (Rankin and Kushner 2010). Likewise, the
same study correlated aging with reduced Isl1 expression in islets. In the developing endocrine
pancreas, expression levels of Slc2a2, a direct target of Ldb1 and Isl‐1 in the mature β‐cells, appeared
to be unaffected by Isl1 ablation in the pancreatic epithelium (Ediger, et al. 2014; Hunter, et al.
2013). A similar example of a temporal role for Isl‐1 expression levels in pancreatic progenitors has
been linked to the process of epithelial delamination. Driving Cdc42 expression with the Rat Insulin
Promoter inhibits delamination from the pancreatic epithelium by enforcing apical polarity (Kesavan,
et al. 2014). In these mice, Isl‐1 expression was reduced at E15.5. Moreover, MafA, a direct target of
Isl‐1, was undetectable. Together this would suggest the process of epithelial delamination also
influences the expression level of Isl‐1.

138

Currently, defining the distinct stages in the life of a β‐cell from specification, maturation,
and terminal‐maturation is receiving more attention. This refocus is partly due to directed
differentiation protocols generating insulin+ cells that are physiologically and transcriptionally
similar to immature β‐cells (Hrvatin, et al. 2014). Given the above examples indicating that Isl‐1 has
temporal requirements in the β‐cell, it would be of importance to characterize the β‐cell Isl‐1 and
Ldb1 cistrome throughout development and the postnatal maturation period. For this particular
investigation, embryonic and post‐natal human islets would provide the most translatable data set
for informing iPSC directed differentiation protocols.
In conclusion, the work presented in Chapters 2 and 3 demonstrate a clear functional
requirement for Ldb1 and Isl‐1 in the mature pancreatic β‐cell. Moreover, the reduction of the β‐cell
maturation factor MafA and β‐cell specification factor Pdx1 and the simultaneous activation of the
pancreatic endocrine specification factor Neurog3 indicate that both Ldb1 and Isl‐1 are required for
maintaining the mature identity of the pancreatic β‐cells. High‐throughput transcriptomic and
cistromic analysis of primary tissue identified that Ldb1 and Isl‐1 are co‐enriched at putative cis‐
regulatory elements. More focused analysis at key β‐cell loci demonstrated that Ldb1 and Isl‐1
directly regulate Slc2a2, MafA, and Pdx1. Overall, these findings clearly demonstrated the continued
requirement for these two developmentally essential, pan‐endocrine factors in the mature β‐cell.
Simultaneously, they hint at a broader, dynamic role in establishing and maintaining the respective
cell‐identities that comprise the mature endocrine pancreas, possibly a mechanism involving Ldb1‐
mediated looping.
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